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Abstract 
The natriuretic peptides, atrial natriuretic peptide (ANP), brain natriuretic               
peptide (BNP) and C-type natriuretic peptide (CNP) are members of a family of             
hormones that play an important role in mammalian fluid and electrolyte balance. In               
the periphery, natriuretic peptides reduce blood volume and subsequently blood               
pressure by increasing renal natriuresis and diuresis and relaxation of vascular smooth 
muscle. The actions of natriuretic peptides are mediated via two membrane-linked 
guanylate cyclase receptors (NPR-GC); natriuretic peptide receptor-A (NPR-A) which            
has a high affinity for ANP and BNP; and natriuretic peptide receptor-B (NPR-B)                 
which has the greatest affinity for CNP. A third receptor not linked to guanylate                
cyclase, natriuretic peptide receptor-C (NPR-C) also exists, which binds to ANP, BNP             
and CNP with a relatively equal affinity, and is involved with clearance of the peptides 
from the circulation and tissues. The natriuretic peptides are present in the brain and                
are particularly predominant in cardiovascular and fluid and electrolyte regulating areas 
such as the anteroventral third ventricle (AV3V) region. This distribution has led to the 
suggestion natriuretic peptides play a neuromodulatory role in the central control of               
fluid homeostasis. Natriuretic peptides in the brain have been observed to inhibit the 
release of other fluid and electrolyte regulating hormones such as arginine vasopressin 
(AVP) and angiotensin II (All). 
Natriuretic peptides have also been identified in the non-mammalian vertebrates 
although information regarding the distribution of the peptides and their receptors in the 
non-mammalian brain is limited. In amphibians, immunohistochemical studies have              
shown that natriuretic peptides are highly concentrated in the preoptic region of the              
brain, an area believed to be analogous to the A\T3\ region in mammals, which                
suggests that natriuretic peptides may also be involved in central fluid and electrolyte 
regulation in amphibians. To date, CNP is the only natriuretic peptide that has been      
isolated and cloned from the lower vertebrate brain, although studies on the distribution            
of CNP binding sites in the brain have only been performed in one fish species. Studies             
on the distribution of ANP binding sites in the lower vertebrate brain are similarly              
limited and have only been performed in one fish and two amphibian species.               
Moreover, the nature and distribution of the natriuretic peptide receptors has not been 
characterised.   The  current  study  therefore,  used  several  approaches  to  investigate  the 
  
XVI
distribution of natriuretic peptides and their receptors in the brain of the amphibian Bufo 
marinus. The topographical relationship of natriuretic peptides and the fluid and            
electrolyte regulating hormone arginine vasotocin was also investigated, in order to gain            
a greater understanding of the role of the natriuretic peptide system in the lower              
vertebrate brain. 
Immunohistochemical studies showed natriuretic peptides were distributed 
throughout the brain and were highly concentrated in the preoptic region and 
interpeduncular nucleus. No natriuretic peptide-like immunoreactivity (NP-IR) was 
observed in the pituitary gland. Arginine vasotocin-like immunoreactivity (AvT-IR)                 
was confined to distinct regions, particularly in the preoptic/hypothalamic region and 
pituitary gland. Double labelling studies of NP-JR and AvT-IR showed the peptides                
are not colocalised in the same neural pathways. 
The distribution of natriuretic peptide binding sites using the ligands 125I-rat              
ANP (125I-rANP) and 125I-porcine CNP (125I-pCNP) showed different distributions in                
the brain of B. marinus. The specificity of binding was determined by displacement                
with unlabelled rat ANP, porcine CNP and C-ANF, an NPR-C specific ligand. 125I-             
rANP binding sites were broadly distributed throughout the brain with the highest 
concentration in pituitary gland, habenular, medial pallium and olfactory region.             
Minimal 125I-rANP binding was observed in the preoptic region. Residual 125I-rANP 
binding in the presence of C-ANF was observed in the olfactory region, habenular and 
pituitary gland indicating the presence of both NPR-GC and NPR-C in these regions.             
125I-pCNP binding was limited to the olfactory region, pallium and posterior pituitary 
gland. All 125I-pCNP binding was displaced by C-ANF which suggests that CNP in the 
brain of B. marinus binds only to NPR-C. 
Affinity cross-linking and SDS-PAGB demonstrated two binding sites at 136             
kDa and 65 kDa under reducing conditions. Guanylate cyclase assays showed 0.1 µM ANP 
increased cGMP levels 50% above basal whilst a 10-fold higher concentration of                 
CNP was required to produce the same result. Molecular cloning studies revealed a 669 
base pair fragment showing 91% homology with human and rat NPR-A and 89% 
homology with human, rat and eel NPR-B. A 432 base pair fragment showing 67% 
homology to the mammalian NPR-C and 58% homology with eel NPR-D was also 
obtained. 
The results show natriuretic peptides and their receptors are distributed               
throughout   the   brain   of B.   marinus   which   indicates   that   natriuretic  peptides  may 
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participate in a range of regulatory functions throughout the brain. The potential for 
natriuretic peptides to regulate the release of the fluid and electrolyte regulating          
hormone AVT also exists due to the high number of natriuretic peptide binding sites in            
the posterior pituitary gland. At least two populations of natriuretic peptide receptors              
are present in the brain of B. marinus, one linked to guanylate cyclase and one              
resembling the mammalian clearance receptor. Furthermore, autoradiography and 
guanylate cyclase studies suggest ANP may be the major ligand in the brain of B.               
marinus, even though CNP is the only natriuretic peptide that has been isolated from              
the lower vertebrate brain to date. 
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SUMMARY OF THESIS SUBMITTED FOR THE DEGREE OF 
 
DOCTOR OF PHILOSOPHY 
 
Title of thesis:  The natriuretic peptides and their receptors in the brain                       
of the amphibian, Bufo marinus. 
 
The natriuretic peptides are a family of hormones that reduce hypervolaemia                 
and hypertension by increasing renal diuresis and natriuresis and vasodilation. In the 
mammalian brain, natriuretic peptides and their receptors have been identified in key                 
areas involved in the regulation of cardiovascular control and osmoregulation, and there              
is evidence to suggest natriuretic peptides have an important neuromodulatory role in                
this system. For example, natriuretic peptides in the brain can modulate the activity of               
the water-conserving molecule arginine vasopressin and are linked to the release of 
natriuretic peptides from the heart. In contrast to mammals, there are few studies on the 
natriuretic peptide system of the non-mammalian brain. Several studies have used 
immunohistochemistry and autoradiography to describe the distribution of natriuretic 
peptides and their binding sites in the brain of representative species of fish and 
amphibians. However, there are no studies describing the potential for interaction                
between natriuretic peptides and other brain peptides such as arginine vasotocin, nor                
have the natriuretic peptide receptors in the brain been characterised. 
This thesis examines the brain natriuretic peptide system of the toad, Bufo               
marinus, and describes i) the distribution of natriuretic peptides and their relationship             
with arginine vasotocin, ii) the distribution of natriuretic peptide receptors and iii) the                
types of natriuretic peptide receptors present in the brain. The data show that the toad             
brain contains an extensive natriuretic peptide system that could possibly interact with 
peptides such as arginine vasotocin. Whilst natriuretic peptides are not colocalised with 
arginine vasotocin in neurons, high levels of natriuretic peptide receptors in both the 
anterior and posterior pituitary gland suggest possible interactions with not only               
arginine vasotocin but several hormones involved in a number of different functions.                 
The data also indicate natriuretic peptides in the toad brain may exert their effects via            
both guanylate cyclase and non-guanylate cyclase containing receptors. 
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The maintenance of a constant internal environment is critical for cellular 
processes including enzymatic activity, muscle function and transmission within the 
nervous system (Strange 1993). Processes such as respiration, perspiration, food and 
water ingestion and renal regulation, continually alter the osmotic concentration of the 
extracellular fluid and, therefore, the composition and distribution of fluid and 
electrolytes must be monitored and effector systems activated, in order to maintain a 
stable environment. 
In mammals, it is well established that a complex integrative system consisting 
of a number of neural, hormonal and behavioural mechanisms is involved in the 
maintenance of fluid and electrolyte homeostasis. This is a co-ordinated response with 
the brain as the key control centre receiving neural and sensory input from central and 
peripheral sources, that in turn activate effector systems such as the kidneys, heart and 
vasculature, which are the major organs responsible for fluid and electrolyte regulation. 
Indeed, the mechanisms involved in the control of dehydration in mammals have been 
well known for a number of years. 
In the mammalian brain, specialised osmoreceptors of the hypothalamus detect 
increases in osmotic pressure and send signals via neural pathways to other 
hypothalamic nuclei which are responsible for the production of the posterior pituitary 
gland hormone arginine vasopressin (AVP) (Bourque et al 1994). Arginine vasopressin 
has been recognised as one of the major hormones regulating the physiological 
mechanisms that counter dehydration (Bentley 1974). Arginine vasopressin is 
synthesised in neurons of the supraoptic and paraventricular nuclei of the 
hypothalamus, and is transported in axons of the hypothalamo-pituitary tract to the 
posterior pituitary gland in which it is stored in secretory granules (Berecek 1992). 
Osmoreceptors in the hypothalamus, sensitive to changes in the osmotic pressure of the 
cerebrospinal fluid, stimulate the release of AVP into the circulation to promote the 
retention of salt and water (Leng et al 1982). Arginine vasopressin acts on the renal 
collecting ducts to increase water reabsorption and thus prevent dehydration (Acher & 
Chauvet 1995; Howl & Wheatly 1995). Arginine vasopressin also exhibits a strong 
vasopressor effect on blood vessels, which maintains blood pressure in the face of blood 
volume depletion. These combined actions of AVP contribute to the conservation and 
redistribution of body fluids. The osmoreceptors can also evoke behavioural 
mechanisms  such as drinking (Bourque et al 1994; Quan & Cogan 1993), and sodium 
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sensitive osmoreceptors can induce salt appetite (Bourque et al 1 994) in response to 
osmotic stimulation from the circumventricular fluid that surrounds them. 
In the periphery, changes in blood pressure are detected by sensory 
baroreceptors that provide neural input to cardiovascular control centres in the brain. 
When blood pressure is raised, the baroreceptors increase their input to these control 
centres that in turn decrease the sympathetic activity to the heart and vasculature. The 
reduction in sympathetic activity to the cardiovascular system slows the heart rate and 
dilates the blood vessels to restore levels to a balanced state (Martini 1995). 
Alternatively, when blood pressure is lowered, the baroreceptor input to the brain 
decreases, and the brain initiates an increase in sympathetic activity to the heart and 
vasculature to increase pressure to maintain homeostasis (Martini 1995). 
In addition to AVP, other powerful effectors act on the kidneys and vasculature  
in response to dehydration. The renin-angiotensin system plays an important role when 
blood pressure drops and osmolarity is increased. Renin is released from the renal 
juxtaglomerular apparatus when sensory baroreceptors in this region detect a fall in 
blood pressure and volume (Guyton 1987). A series of enzymatic reactions involving 
renin as the initial substrate, results in the production of angiotensin II (AII), a powerful 
hormone that acts to increase salt and water reabsorption. Angiotensin II stimulates the 
release of aldosterone from the adrenal gland, which promotes sodium ion retention and 
subsequently increases water reabsorption by osmosis in the kidney (Ganten et al 1991). 
In addition, All initiates the sensory and behavioural responses such as thirst and 
drinking to increase fluid volume (Sernia 1995). It also stimulates a neuroendocrine 
reflex to release AVP, and is a potent vasoconstrictor that acts to increase blood 
pressure and volume (Ganten et al 1991; Sernia 1995). 
The complexity of the mammalian system is such that there are numerous 
peptides in addition to AVP and All, which are involved in fluid and electrolyte 
homeostasis and in the control of dehydration. Peptides, including neuropeptide Y 
(NPY) and endothelins are potent vasoconstrictors (Ganten et al 1991), and contribute 
to the distribution of body fluids and cardiovascular homeostasis. Neuropeptide Y is 
abundant in both the central and peripheral nervous systems and induces a rise in blood 
pressure due to a long-lasting constrictor effect on the vasculature (Ganten et al 1991). 
The endothelins are a group of peptides produced in the endothelium of blood vessels 
and the heart (Inagami et al 1995), and are believed to be one of the most potent group 
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of vasoconstrictors identified (Ruskoaho et al 1997). These peptides along with others 
all contribute to protect against increases in osmotic pressure and dehydration. 
Whilst the hormonal elements that participate to combat dehydration in the 
mammalian system have been extensively investigated, it was not until the 1980’s that a 
circulating peptide responsive to increases in blood pressure and volume, was 
identified. The presence of a natriuretic factor was suspected for some time, as a 
number of studies that involved the injection of hypertonic saline in goats and lesions of 
the hypothalamic region in dogs, not only altered the drinking response, but induced a 
marked natriuresis (Andersson & McCan 1955a; Andersson & McCann 1955b; 
Andersson & McCann 1955c). This natriuresis was also observed following blood 
volume expansion (Bahlmann et al 1967), and evidence for a circulating natriuretic 
factor was confirmed when blood from a volume-expanded dog was perfused through a 
second animal in which a natriuresis was observed (Davis & Freeman 1976). The 
observation by de Bold et al. (1981) that the injection of atrial extracts into rats induced          
a rapid diuresis and natriuresis, marked the beginning of a new focus of study into 
mammalian fluid and electrolyte regulation. Subsequently, the natriuretic peptides, a 
group of peptide hormones that act to lower fluid and electrolyte levels and 
subsequently blood pressure, were discovered. 
 
The Natriuretic Peptides 
 
The natriuretic peptide family consists of several members, of which the most 
recognised are the three main forms; atrial natriuretic peptide (ANP), brain natriuretic 
peptide (BNP) and C-type natriuretic peptide (CNP) (Espiner 1994). Other members of 
the family also exist, including urodilatin that is present in the kidney (Schulz-Knappe 
et al 1988), and ventricular natriuretic peptide (VNP) that was identified in eel 
ventricles (Takei et al 1991). All natriuretic peptides exhibit a characteristic seventeen 
amino acid ring structure due to disulphide bonds between cysteine residues that are 
essential for biological activity (Inagami 1989; Rosenweig & Seidman 1991) (see 
Figure 1.1). 
The biological actions of natriuretic peptides are to decrease blood pressure and 
blood volume, by stimulating salt and water loss and promoting vasorelaxation (Espiner 
1994). These actions are mediated in a number of ways. In the kidneys, natriuretic 
peptides  increase  salt  and water excretion by increasing the glomerular filtration rate 
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(GFR) through vasodilation of the afferent arteriole (Kenyon & Jardine 1989). In 
addition, it is thought that natriuretic peptides may inhibit the All-stimulated sodium 
and water reabsorption in the renal tubules (Chamienia & Johns 1991). Moreover, the 
natriuretic peptides are believed to have a direct action on the renal tubules to increase 
sodium excretion (Awazu & Ichikawa 1993). Natriuretic peptides reduce peripheral 
resistance in the vascular bed through actions at the vascular smooth muscle, which 
result in dilation of the blood vessels (Rosenweig & Seidman 1991). These actions are 
also enhanced by the natriuretic peptide-stimulated inhibition of the renin-angiotensin 
pathway (Espiner 1994; Rosenweig & Seidman 1991). 
The atria are the major site of ANP gene expression and contain the highest 
levels of natriuretic peptides in the body (Needleman et al 1989). Atrial natriuretic 
peptide is released into the circulation following mechanical stretch of the atria as a 
result of increased venous return due to a rise in blood volume (Lang et al 1985). 
Although it is primarily found in the atria, ANP mRNA has been identified in a number 
of organs including the kidneys, vasculature and lungs (Espiner et al 1995), which 
indicates the potential for widespread actions of ANP. Brain natriuretic peptide was 
originally identified in porcine brain, (Sudoh et al 1988), but it is now predominantly 
recognised as a heart natriuretic peptide, and occurs at the highest concentration in the 
ventricles (Yandle 1994). The role that BNP plays in cardiovascular homeostasis is 
probably the least well-understood of the natriuretic peptides (Suga et al 1992). 
However, it is interesting to note that BNP levels are raised in humans presenting with 
chronic heart failure and that this is possibly due to an increase in the tension in the 
ventricular walls under these conditions (Espiner 1994). C-type natriuretic peptide was 
also discovered in the brain (Sudoh et al 1990) and, due to its limited distribution, but 
high concentration in neural tissue, it was thought to be the main natriuretic peptide of 
the central nervous system. The subsequent identification of CNP in the endothelium 
of blood vessels (Barr et al 1 996; Stingo et al 1 992b) has suggested that CNP may also 
perform a paracrine role as a regulator of vascular smooth muscle and the endothelium 
(Inagami et al 1995). 
The diuretic, natriuretic and vasorelaxant activities of natriuretic peptides are 
mediated through two receptors, natriuretic peptide receptor-A (NPR-A) and natriuretic 
peptide receptor-B (NPR-B), which contain an intracellular guanylate cyclase domain 
(collectively termed, NPR-GC) (Maack 1992). Binding of the natriuretic peptides to 
NPR-GC  results  in  the  conversion  of  GTP  to  cGMP which initiates the biological 
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actions of the peptides. The NPR-GC exhibit preferential binding of the natriuretic 
peptide family members. Natriuretic peptide receptor-A binds ANP with greatest 
affinity followed by BNP, and has a lower affinity for CNP. C-type natriuretic peptide,  
on the other hand, binds almost exclusively to NPR-B, whilst ANP and BNP are only 
observed to bind to NPR-B at physiologically extreme levels (Suga et al 1992). A third 
natriuretic peptide receptor lacking an intracellular guanylate cyclase domain, called 
NPR-C, has also been identified. The NPR-C has been observed to bind ANP, BNP and 
CNP with a relatively equal affinity (Suga et al 1992). Upon binding to NPR-C, the 
natriuretic peptide/NPR-C complex is internalised and transported to lysosomes within 
the cell in which the peptides are hydrolysed. The uncoupled receptor is then recycled 
back to the cell membrane (Levin 1993; Nussenzveig et al 1990). This function is 
consistent with the suggestion that the NPR-C do not mediate the cardiovascular effects 
of the natriuretic peptides (Maack et al 1996), and instead, are primarily concerned with 
the clearance of the natriuretic peptides from the circulation. However, NPR-C has 
been implicated in pathways linked to second messenger systems other than the cGMP 
pathway. There is evidence to suggest that NPR-C may mediate natriuretic peptide 
functions other than those involved in fluid and electrolyte regulation. For example, C- 
type natriuretic peptide acting via the NPR-C has been observed to suppress dopamine 
release from PC12 cells (Trachte et al 1995). The cell signaling pathways through 
which the NPR-C are thought to mediate the actions of natriuretic peptides are via G 
inhibitory proteins in the adenylate cyclase/cAMP transduction pathway, or by 
increasing the production of 1P (Anand-Srivastava & Trachte 1993; Levin 1993), 
although this has only been reported in isolated and cultured cells. 
There is a great deal of literature detailing the role of natriuretic peptides in the 
heart, kidneys and other peripheral organs, see (Hagiwara et al 1995; Rosenweig & 
Seidman 1991; Ruskoaho 1992). However, it is the purpose of this review to discuss 
natriuretic peptides in the brain, and their role in central fluid and electrolyte regulation 
only. 
 7
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 The amino acid sequence and structure of the mature forms of ANP, BNP, 
CNP, and Urodilatin showing the characteristic seventeen amino acid ring which is 
essential for biological activity. 
 8
 
 
 9
The Brain and Cardiovascular Regulation 
 
The brain is an important centre for recognising changes in fluid and electrolyte 
homeostasis (Johnson et al 1 992). A number of key hormones including AVP and AII 
are synthesised within the hypothalamus, a region critical to the regulation of salt and 
water balance (Brody & Johnson 1980). Several areas within the hypothalamus, in 
particular in the anteroventral third ventricle (AV3V) region, lie outside the blood brain 
barrier and are believed to be the site of the osmoreceptors (Leng et al 1982). Several 
nuclei make up the AV3V region including the median preoptic nucleus, organum 
vasculosum of the lamina terminalis (OVLT) and the supraoptic nucleus (Bourque et al 
1994; McKinley et al 1996). The significance of the AV3V region was recognised 
when experiments involving saline injections into this part of the brain altered drinking 
behaviour in goats (Andersson & McCann 1955b), and electrical stimulation of this 
area also produced similar results (Andersson & McCann 1955c). Subsequent studies 
have shown that lesions of the AV3V region not only altered drinking, but affect blood 
pressure levels, the release of AVP and sodium excretion (Johnson 1985). A number of 
connecting neural pathways have been identified between the nuclei within the AV3V 
region, indicating an important communication circuit in the central control of 
osmoregulation (McKinley et al 1996). It is within this circuit that changes in 
osmolarity initiate the release of neural and hormonal elements such as All, AVP and 
others, in order to maintain a homeostatic medium for basic cell function. 
 
Natriuretic Peptides in the Mammalian Brain 
 
Whilst natriuretic peptides and their receptors have been identified in the heart, 
kidneys and vasculature, which are key organs involved in fluid and electrolyte 
regulation, a natriuretic peptide system encompassing all three peptides and their 
receptors is also present in the brain. There is significant evidence that indicates a role 
for natriuretic peptides in the central control of cardiovascular and fluid and electrolyte 
homeostasis (Gutkowska et al 1997a). It was not long after its discovery in the heart 
that the presence of ANP was shown in the brain. Radioimmunoassays indicated a high 
concentration of ANP in the hypothalamic nuclei (Kawata et al 1985; Morii et al 1985), 
an observation that was also confirmed by immunohistochemistry (Kawata et al 1985; 
Standaert  et  al  1986).    In  rat,  ANP-immunoreactive  (ANP-IR)  cell  bodies  were 
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observed in the supra optic and paraventricular nuclei (Palkovits 1984), and in the 
median preoptic nucleus, periventricular hypothalamic nucleus and dorsal and ventral 
hypothalamic nuclei, which are located adjacent to the third ventricle (Kawata et al 
1985). High concentrations of ANP-IR fibres were also noted in the preoptic region 
and lateral hypothalamus (Saper et al 1985). As has been previously mentioned, the 
AV3V region is an important region in the control of cardiovascular and fluid and 
electrolyte homeostasis (Johnson 1985; Johnson et al 1992). The presence of ANP in 
this key region indicates the potential for ANP to be involved in central fluid and 
electrolyte regulation. However, the distribution of ANP-IR was not confined to the 
AV3V region, since ANP-IR was identified in the habenular nucleus, amygdala, median 
eminence, olfactory bulb and interpeduncular nucleus (Standaert et al 1986; Zamir et al 
1986). These observations suggested that natriuretic peptides in the brain may have 
other regulatory roles in addition to those related to fluid and electrolyte homeostasis. 
Subsequent immunohistochemical studies have indicated that the distribution of ANP- 
JR in the brain appears to differ between species, but, in all species the largest 
accumulation of cells and fibres is in the critical fluid and electrolyte regulating centre, 
the AV3V region (Gutkowska et al 1997a). 
A number of techniques have shown that ANP, BNP and CNP have distinct 
distributions in the brain. Brain natriuretic peptide-immunoreactivity has been 
observed to be more widespread than ANP-JR. Specifically, BNP-JR is present in the 
sensory part of the cerebral cortex, brainstem and spinal cord (Saper et al 1989), regions 
in which ANP-JR is absent. Minimal BNP-IR is present in the olfactory, amygdala and 
preoptic regions, locations in which high levels of ANP-JR have also been reported. 
Interestingly, in the anteroventral periventricular nucleus adjacent to the third ventricle, 
high levels of ANP-JR are present and BNP-JR is essentially absent (Saper et al 1989). 
However, significant overlap of the two peptides has been observed in other 
hypothalamic areas including the supraoptic nucleus and lateral hypothalamus. In 
mammals, CNP has only been detected in the brain by radioimmunoassays. In the 
human central nervous system, CNP-JR is present in the cerebral cortex, thalamus, 
hypothalamus, pons, cerebellum and spinal cord (Totsune et al 1994). This distribution          
is similar to that found in porcine and rat brain in which CNP-IR was also observed in 
the medulla and the anterior pituitary gland, which contains the highest concentration of 
CNP (Komatsu et al 1991; Ueda et al 1991). 
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In situ hybridisation techniques have revealed the distribution of mRNA for 
ANP and CNP in rat brain. The distribution of ANP mRNA shares a general similarity 
with ANP detected immunohistochemically (Kawata et al 1985; Ryan et al 1997; Zamir 
et al 1986). Both the peptide and its mRNA are present in areas including the olfactory 
region, habenular nucleus and some regions of the hypothalamus (Kawata et al 1985; 
Langub et al 1995b). However, some differences were observed in regions, such as the 
paraventricular nucleus, in which high concentrations of ANP-IR cell bodies were 
observed but little ANP mRNA was detected (Langub et al 1995b; Standaert et al 
1986). It is suggested that this discrepancy may be due to a number of factors such as 
antibody cross-reactivity with other peptides containing similar ring structures, or 
because of a high rate of ANP mRNA turnover in this nucleus (Langub et al 1995b). 
The expression of CNP mRNA in the rat brain has also been investigated and has been 
shown to share a similar topographical distribution to that of ANP mRNA (Herman et 
al 1 993). C-type natriuretic peptide mRNA, like ANP mRNA, is present in the 
olfactory region and hypothalamus; however, only low levels of CNP mRNA are 
expressed in the amygdala, and CNP mRNA is absent in the habenular region (Herman  
et al 1993; Langub et al 1995b). In the hypothalamus, CNP mRNA and ANP mRNA 
are present in the same regions with the exception of the supraoptic nucleus in which 
ANP mRNA is absent (Herman et al 1993; Langub et al 1995b). B-type natriuretic 
peptide mRNA was not detected in rat brain (Herman et al 1 993). The absence of BNP 
mRNA expression is interesting considering BNP-IR has been reported in rat brain. It 
is possible that the antibody used in these early immunohistochemical studies had some 
cross-reactivity with either ANP or CNP in these brain regions or perhaps with another 
peptide that shares a similar ring structure. The similarity of the ANP and CNP mRNA 
distributions in the brain suggests a combined role for ANP and CNP in 
neuromodulation and cardiovascular control. 
The natriuretic peptide receptors, NPR-A, NPR-B and NPR-C, are distributed 
throughout the brain. Autoradiographic techniques, competitive binding and in situ 
hybridization studies have been used to demonstrate the location of natriuretic peptide 
receptors in the brain. Autoradiography has shown substantial ANP binding in the 
olfactory bulb, choroid plexus, area postrema, subfornical organ and interpeduncular 
nucleus (Konrad et al 1990; Mantyh et al 1987; Quirion et al 1984). In addition, 
medium levels of ANP binding sites are present in the median preoptic nucleus, 
habenular  nucleus,  median  eminence  and dorsomedial hypothalamic nucleus, whilst 
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only low levels of binding are observed in the pineal gland, suprachiasmatic nucleus 
and pituitary gland (Konrad et al 1990; Mantyh et al 1987). This binding is displaced 
using unlabelled ANP and BNP which would suggest that both peptides share conmon 
receptor sites (Brown & Czarnecki 1990). Indeed, ANP and BNP binding sites in the 
rat brain share a common distribution, with the exception of the locus ceruleus, 
periventricular nucleus and medial preoptic nucleus, in which ANP binding is absent 
(Konrad et al 1990). This is an unusual observation considering both ANP and BNP 
bind preferentially to the NPR-A. The differences in binding patterns observed may be 
due to differences in experimental techniques (Konrad et al 1 990), or may indicate 
preferential binding of NPR-A for BNP over ANP in these regions. 
It is also interesting to note that high levels of receptors for ANP and BNP are 
not only present in the AV3V region, but in other extrahypothalamic regions of the 
brain, which suggests that the actions of natriuretic peptides in the brain are widespread. 
To characterise the types of natriuretic peptide receptor populations in the mammalian 
brain, displacement studies using rat des [Gln18, Ser19, Gly20, Leu21 Gly22]ANP-(4-
23)NH2 (C-ANF), an NPR-C specific ligand, have been performed. In the choroid 
plexus and pia araclmoid, ANP binding was displaced by C-ANF (Konrad et al 1990), 
which suggests that NPR-C is the only natriuretic peptide receptor present in these brain 
regions. Binding of ANP to NPR-GC in the presence of C-ANF was still visible in the 
olfactory bulb, anteroventral periventricular region and subfomical organ (Konrad et al 
1990). Grove and colleagues (1997) observed no displacement of ANP binding by C- 
ANF in the subfornical organ, cortex and habenular nucleus, which suggests that all 
binding was to NPR-A. In contrast to Konrad et al. (1991), this study also showed ANP 
binding was not displaced by C-ANF in the choroid plexus, which indicates that NPR-C 
is not present in this region. In situ hybridisation studies of NPR-A mRNA expression, 
have confirmed the high levels of receptors observed with autoradiography in the 
subfornical organ and habenular regions of the brain (Langub et al 1995a). Lower 
levels of NPR-A mRNA were also observed in the pituitary gland. Interestingly, the 
distribution of NPR-A mRNA expression was predominant in regions outside the 
hypothalamus (Langub et al 1995a), which suggests that the actions of ANP and. BNP 
in the brain occur in regions other than those involved in cardiovascular control and 
fluid and electrolyte regulation. 
More recently, autoradiographical studies using CNP have been perfromed. C- 
type  natriuretic  peptide,  like  other members of the natriuretic peptide family, contains a 
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seventeen amino acid ring essential for biological activity (see Figure 1.1), although 
unlike other natriuretic peptides, CNP lacks a carboxy-terminal extension following the 
second cysteine residue (Yandle 1994). The lack of this C-terminal extension from the 
amino acid ring is thought to be related to the specificity of CNP for its receptor, NPR-          
B (Gardner 1994). The findings from these autoradiographical studies have indicated            
that there is not a uniform agreement to the distribution of CNP binding sites in the           
brain. In rat, CNP binding is present in the olfactory bulb, cerebral cortex, lateral septal 
nucleus and choroid plexus (Brown & Zuo 1993), and is displaced by unlabelled CNP 
and C-ANF, which indicates that NPR-C is the only natriuretic peptide receptor present  
in these regions. This is an interesting finding considering CNP is believed to be the 
predominant natriuretic peptide in the brain and suggests that its biologically active 
receptor, NPR-B, is absent in these brain regions. In contrast, Grove and colleagues 
(1997) reported that NPR-C was not detected in the choroid plexus and cortex or in the 
subfomical organ and habenular nucleus, as C-ANF did not compete with ANP for 
binding sites. The authors suggested that NPR-A is the predominant receptor in these 
brain regions. It has been determined that iodination of CNP may reduce the affinity of 
the peptide for NPR-B (Thibault et al 1995), which may account for the lack of specific 
binding observed by Brown and Zub (1993). In contrast to NPR-A mRNA, the        
expression of NPR-B mRNA in the brain is predominant in the hypothalamus and has 
been observed in the paraventricular, supraoptic and median preoptic nuclei (Langub et           
al 1995a). This observation implies that CNP is a key natriuretic peptide involved in 
central cardiovascular control. Therefore, the presence of ANP in these regions (as 
observed in initial immunohistochemical studies) suggests ANP synthesised in neurons  
in the hypothalamus may be released to initiate actions in other brain regions, or that the 
ANP-IR observed in the hypothalamic nuclei may have been due to cross-reactivity            
with CNP. 
It appears, therefore, that an extensive natriuretic peptide system is present in             
the mammalian brain with the peptides and their receptors generally showing a similar 
distribution throughout the brain. The concentration of natriuretic peptides and their 
receptors in the circumventricular organs lends support to their role in influencing 
cardiovascular homeostasis. What must not be overlooked, however, is the presence of 
the peptides and their receptors in regions such as the olfactory bulb and habenular 
nucleus, which indicates that the peptides may also participate in a wide range of 
neuromodulatory  functions.  However,  as  for  many  neurotransmitters,  some mismatch 
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in distribution between natriuretic peptides and their receptors is observed (Kuhar et al 
1986). This is particularly relevant in the brain, which is often considered an endocrine 
organ in which neurotransmitters can be released to act at a distant (receptor) site              
(Kuhar et al 1 986). In the case of the natriuretic peptides, this has been observed in the 
subfornical organ in which evidence for the peptides is lacking, although a high number 
of natriuretic peptide receptors are present (Konrad et al 1990; Quirion et al 1984). It is 
possible natriuretic peptide receptors in the subfornical organ receive input from 
natriuretic peptides released in other brain regions. 
 
Physiological Actions of Natriuretic Peptides in the Brain 
 
The significance of natriuretic peptides in the AV3V region and their potential          
to play a role in blood volume and electrolyte regulation has been identified through a 
number of physiological investigations, most of which have used the ligand ANP.              
Early studies showed that the application of ANP to neurons in the    
preoptic/hypothalamic region of the rat brain altered their firing activity (Wong et al 
1986). Of the neurons tested in the lateral septal nucleus, anterior commissure and           
medial preoptic nucleus, one third v inhibited by ANP, only two were excited, and               
the rest exhibited no response (Wong et al 1986). Moreover, application of ANP to 
neurons of the paraventricular nucleus inhibited firing in approximately half of the 
neurons examined (Haskins et al 1986). In regions surrounding the paraventricular 
nucleus, 27% of neurons exposed to ANP were also inhibited (Haskins et al 1986). The 
inhibitory response of ANP on neurons in the hypothalamic/AV3V region is consistent 
with the idea that ANP influences the release of other hormones, in particular the 
inhibition of AVP release, as has previously been suggested by Samson (1985a). This 
observation has been further supported by a more recent study that showed that both  
ANP and BNP mediated the inhibition of AVP-producing neurons in the AV3V region 
and supraoptic nucleus (Yamamoto et al 1995). 
Physiological studies have shown that blood volume expansion by intravenous 
injection of isotonic saline (Lang et al 1985) results in an increase in plasma ANP           
levels. The expansion of blood volume induces an increased venous return, which 
subsequently causes mechanical stretch of the atria and release of ANP. The circulating 
ANP then acts at the kidneys and vasculature to increase sodium and water excretion 
which  leads  to  a  reduction  in blood volume. Hypertonic saline injection into the AV3V 
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region of the brain also raises plasma ANP levels (Bealer et al 1983), which suggests           
that ANP release may be influenced by central controls in addition to mechanical           
stretch of the atria. The suggestion that the AV3V region can influence ANP release in 
the periphery is enhanced by the observation that animals with lesions of the AV3V 
region showed a reduction in the circulating ANP levels following blood volume 
expansion (Baldissera et al 1989). Moreover, rats with lesions of the median eminence 
and pituitary gland also showed reduced ANP plasma levels following blood volume 
expansion (Antunes-Rodrigues et al 1991), which suggests that the hypothalamo- 
pituitary pathway exerts an important influence on ANP release from the heart. It is 
thought that brain ANP released from neurons in the AV3V region, contributes little to 
the large increases in plasma ANP observed following stimuli such as blood volume 
expansion (McCann et al 1997), due to the significantly lower content in the brain 
compared with ANP levels in the heart. 
Fluid and electrolyte homeostasis is also monitored by neural pathways such as 
the baroreceptor reflex, which is sensitive to increases in blood volume and pressure,           
and sends signals to the brain to restore imbalances. It has been suggested that the 
parãventricular nucleus, a region containing AVP, AII and natriuretic peptides, receives 
input from the baroreceptors (Badoer 1996). Indeed, animals with lesions of the             
carotid-aortic sinus baroreceptor pathways demonstrate a decrease in elevated plasma 
ANP levels that are normally associated with blood volume expansion (Antunes 
Rodrigues et al 1992). This observation has lent further support to the hypothesis that          
the release of ANP from the heart may require an initial stimulus from the brain           
(McCann et al 1997). 
Although mechanical stretch of the atria due to an increased venous return is 
recognised as the major stimulus for ANP release from the atrial myocytes (Lang et al 
1985), recent evidence suggests that a number of other factors may be involved in 
mediating this response. Peptides such as oxytocin, endothelin and AII have been 
implicated in enhancing the mechanical stretch stimulus, and may be involved in the 
transduction pathway resulting in ANP release (Gutkowska et al 1997b; McCann et al 
1996; Ruskoaho et al 1997). The manner in which these peptides participate in the    
release of cardiac ANP is not fully known at present. Endothelin receptors are located           
on atrial myocytes and endothelin has been observed to augment the stretch-induced  
ANP release from isolated perfused rat hearts (Ruskoaho et al 1997). A role for AII in 
blood  volume  expansion-induced  ANP release is also possible, although whether such a 
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role would result from increases in pressure due to the constrictor effects of AII, or via 
direct receptor action on the atrial myocytes is yet to be clarified (Ruskoaho et al 1997). 
Oxytocin is also a key factor in mediating cardiac ANP release. It is thought that 
pressure-stimulated baroreceptors signal to ANP neurons in the AV3V region which in 
turn initiate the release of oxytocin from the posterior pituitary gland into the              
circulatory system. The peptide is then thought to circulate to the atria and induce the 
release of ANP (McCann et al 1996). This hypothesis is supported by the observation  
that intraperitoneal and intravenous injections of oxytocin were observed to cause 
increases in sodium and water excretion as well as a large increase in plasma ANP          
levels. Moreover, oxytocin receptor inRNA has recently been identified in rat heart 
(Gutkowska et al 1997b), and a dose-related inhibition of oxytocin-induced ANP           
release from perfused hearts was observed using oxytocin antagonists. The vasodilator, 
nitric oxide (NO), is also thought to influence ANP release from the heart; however,            
NO appears to depress rather than augment ANP release (Ruskoaho et al 1997).            
Indeed, the release of ANP from isolated and intact hearts is elevated in the presence of 
NO inhibitors (Ruskoaho et al 1997). It appears, therefore, that the natriuretic peptide 
system of the brain may play a pivotal role in modulating the release of peripheral ANP 
from the heart. The pathway through which this release is enhanced or inhibited may            
also involve a number of factors including oxytocin, AII, NO and endothelin. 
The subsequent discovery of CNP in the brain and its high concentration in the 
AV3V region and pituitary gland indicated the potential for CNP, in addition to ANP          
and BNP, to be involved in central fluid and electrolyte regulation. However, in 
mammals, some of the biological actions of CNP differ from ANP and BNP C-type 
natriuretic peptide is a powerful vasodilator, although it does not appear to stimulate 
natriuresis and causes only a minimal diuretic effect (Espiner 1994). Moreover, in           
many instances, CNP demonstrates opposing actions to those of ANP. For example, 
intravenous infusion of CNP in dogs resulted in a decrease in mean arterial pressure, 
cardiac output and atrial pressure, but, in contrast to the effects of ANP, a decrease in 
sodium excretion was also observed (Stingo et al 1992a). More recently, intravenous 
infusion of CNP in humans did not alter cardiac output or arterial pressure, implying           
that in humans, at least, CNP does not have any great influence as a circulating             
hormone (Barletta et al 1998). Indeed, it has been reported that the levels of CNP 
circulating in the blood are quite low compared to that of ANP and BNP (Lopez et al 
1997).     Studies  on  the  central  actions  of  natriuretic  peptides  in  sheep  have  shown 
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intracerebroventricular administration of ANP reduces the mean arterial pressure and 
decreases water intake (Charles et al 1992). In contrast, intracerebroventricular 
application of CNP also reduces arterial blood pressure but stimulates an increase in 
water intake (Charles et al 1992). A similar effect is seen in rats in which 
intracerebroventricular administration of ANP decreased water intake following water 
deprivation; however, central application of CNP was observed to increase water intake 
under the same conditions (Samson et al 1991). In addition, CNP was also shown to 
augment the response of AII-induced drinking in these rats (Samson et al 1991) in 
contrast to ANP. Thus CNP, unlike other natriuretic peptides, appears to demonstrate 
antinatriuretic/antidiuretic properties. The underlying mechanisms controlling the 
regulation of blood pressure and homeostasis involve a number of hormonal systems 
including AVP and AII, which are released in response to a decrease in blood pressure,  
in order to maintain homeostasis (Acher & Chauvet 1995; Martini 1995). It is not clear 
whether the enhanced drinking and antinatriuretic response seen following 
administration of CNP are as a result of direct actions of the peptide itself, or the 
stimulation of the AVP and AII pathways due to the powerful vasodilatory actions of 
CNP. Although in sheep, intracerebroventricular application of CNP was shown to 
stimulate an initial rise in plasma renin activity and aldosterone and cortisol levels, 
which were observed to decrease beyond basal levels with continued infusion of CNP 
(Charles et al 1992). Therefore, the antinatriuretic/antidiuretic responses observed in 
sheep may be a result of the actions of CNP itself. The significance of the opposing 
actions of CNP to other natriuretic peptides has not yet been clearly defined. 
 
Natriuretic Peptides and Other Fluid and Electrolyte Regulating Hormones in the 
Brain 
 
The significance of the circumventricular organs in the control of fluid and 
electrolyte homeostasis is recognised by the abundance of neurons that synthesise key 
regulating hormones such as AVP, oxytocin and AII. Natriuretic peptides are also 
present in these regions, but, their diuretic, natriuretic and vasorelaxant activities are in 
opposition to those effects promoted by hormones such as AVP and AII (antidiuresis, 
antinatriuresis, vasoconstriction). Thus natriuretic peptides may play a regulatory role 
in neuroendocrine systems, influencing the synthesis and release of AVP and AII 
during osmotic imbalances (McArdle et al 1994). 
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As discussed previously, AVP is synthesised in neurons of the supraoptic and 
paraventricular nuclei of the hypothalamus and stored in the posterior pituitary gland. 
The release of AVP is initiated by decreasing blood volume levels and increasing 
osmolarity of the extracellular fluid (Leng et al 1982). The opposing roles of AVP and 
the natriuretic peptides suggests an antagonistic relationship exists between these 
hormones and there is significant evidence to demonstrate that ANP impedes the release 
of AVP. A dose-related inhibition of AVP levels in rats was observed following 
intravenous injection of ANP (Samson 1985a), and ANP was also found to reduce AVP 
secretion from isolated pituitary glands (Obana et al 1985). Centrally infused ANP 
decreases AVP levels in both hydrated and dehydrated sheep (Lee et al 1987), and a 
similar result is observed with injection of ANP into the AV3V region in rats (Samson 
et al 1987). The intracerebroventricular injection of AVP increases blood pressure and 
heart rate, a response that is attenuated when AVP is injected simultaneously with ANP 
(Stepniakowski et al 1991). Application of ANP, and more recently BNP, to 
hypothalamic neurons has been observed to significantly inhibit the activity of AVP 
neurons in vitro (Standaert et al 1987; Yamamoto et al 1995). Much of the literature 
supports a central action for ANP in the inhibition of AVP synthesis and release, with 
the most likely site of action in the hypothalamus. The hypothesis that ANP inhibits 
AVP at the level of the hypothalamus is further strengthened by the observation that 
AVP levels in the median eminence or pituitary gland are not altered in the presence of 
ANP (Samson 1987). 
The AV3V region is richly invested with AJI-synthesising neurons and binding 
sites, particularly in the OVLT, median preoptic nucleus and subfornical organ (Ganten   
et al 1991; Johnson 1985). This distribution is closely associated with natriuretic 
peptides and their receptors (Imura et al 1992), and natriuretic peptides have been 
observed to antagonise the central actions of AII (Samson 1988). Angiotensin II 
promotes water and salt retention through actions such as vasoconstriction, drinking, 
increased salt appetite and stimulation of the release of AVP (Sernia 1995) (see above). 
The antagonistic relationship between ANP and AII is well-documented (Cargill et al 
1995; Kohno et al 1991; Shimizu et al 1986). In water- and salt-deprived rats, ANP 
inhibits AII-induced water intake as well as salt intake, (Imura et al 1992), and when 
the actions of aldosterone and AII are blocked, there is an increase in ANP-mediated 
natriuresis and vasorelaxation (Chamienia & Johns 1991). The potential also exists for 
a dual modulatory role for the two peptides as the diuretic and natriuretic effects of 
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natnuretic peptides are lowered when AII levels are increased (Chamienia & Johns 
1991). To test the effects of ANP on AII in the brain, Galli and Phillips (1996) used 
antisense oligonucleotides to inhibit translation of ANP from mRNA in rat brain. In 
response to AII, experimental rats showed an enhanced drinking response, which 
suggests that the endogenous inhibitory effects of ANP on AII were blocked due to the 
antagonism of ANP synthesis. 
 
Natriuretic Peptides and Other Hypothalamo - Pituitary Hormones 
 
The presence of natriuretic peptides in the hypothalamus and pituitary gland 
suggests that they not only influence the release of the fluid and electrolyte regulating 
hormone AVP, but also may influence the synthesis and release of other hormones. 
Indeed, ANP has been co-localised with a subpopulation of oxytocin neurons in the 
paraventricular and supraoptic nuclei, which implied a potential for ANP to influence 
oxytocin release (Jirikowski et al 1986). Interactions between ANP and the 
corticotropin pathway have also been reported. Atrial natriuretic peptide neurons 
terminate in the vicinity of corticotropin releasing factor (CRF) cell bodies in the 
paraventricular nucleus (Palkovits et al 1987), and ANP has also been observed to 
inhibit the acetylcholine—induced release of CRF in the isolated perfused rat 
hypothalamus (Takao et al 1988). In addition, intra-arterial administration of ANP 
antiserum to stress-induced rats reduces the levels of adrenocorticotropin hormone 
(ACTH) (Antoni et al 1992), which may be an indirect response due to the inhibitory 
effects of ANP on CRF release from the hypothalamus, or due to the direct actions of 
natriuretic peptides at the level of the pituitary gland. 
The actions of BNP and CNP on hypothalamo-pituitary hormone release have 
also been investigated. In conscious sheep, Charles et al 1992, demonstrated that CNP, 
like ANP, has an inhibitory effect on ACTH secretion, which again may be at the 
hypothalamic or pituitary gland level. In contrast, Gardi et al (1997) showed a decrease  
in CRF-like immunoreactivity in the hypothalamus following intracerebroventricular 
administration of CNP, which suggests that a reduction in CRF levels in the 
hypothalamus was due to an increase in the release of CRF, under the influence of 
CNP. Injection of BNP, on the other hand, as has been observed for ANP, increased 
CRF-like immunoreactivity, which is consistent with a rise in storage levels due to 
inhibition of release by BNP (Gardi et al 1997). 
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It appears that variations in activity between ANP and CNP are not only 
observed in fluid and electrolyte regulating pathways, but in the regulation of other 
pituitary gland hormones as well. Central administration of ANP in rats inhibited the 
secretion of prolactin, whilst intracerebroventricular injection of CNP resulted in a rise          
in plasma prolactin levels (Huang et al 1992b). Using cytotoxin cell-targeting strategies 
to knock out cells expressing either ANP receptors (NPR-A and NPR-C) or CNP 
receptors (NPR-B and NPR-C), it has been determined that the opposing actions of 
ANP and CNP on prolactin secretion occur via different cellular pathways, which have 
yet to be identified (Samson et al 1995). However, it appears that not all of the actions 
of CNP in the brain are in opposition to those of ANP. Indeed, in some instances, the 
effects of CNP and ANP are complementary; for example, intracerebroventricular 
injection of both ANP and CNP has been observed to decrease plasma luteinizing 
hormone levels (Huang et al 1992a; Samson et al 1988a). Cytotoxin cell targeting 
studies to block the ANP or CNP specific receptors, have indicated that ANP and CNP 
may work together in the inhibition of luteinizing hormone release (Samson et al 1993). 
Blockade of ANP receptors results in no change in plasma luteinizing hormone levels 
with ANP, but CNP caused a significant drop in plasma luteinizing hormone levels. In 
contrast, inactivation of CNP receptors resulted in no change in plasma luteinizing 
hormone levels following infusion of both ANP and CNP, which suggests that the role   
of ANP in luteinizing hormone release may be to displace CNP from NPR-C, leaving it 
free to bind to NPR-B to exert its inhibitory effects (Samson et al 1993). This type of 
action suggests that some of the observed effects of natriuretic peptides are a combined, 
co-ordinated response of natriuretic peptide family members, whilst other effects are the 
result of individual natriuretic peptides. 
 
The Mammalian Brain and the Amphibian Brain 
 
The anatomy and physiology of the amphibian brain has long been used as a 
tool for assessing potential functions in the higher vertebrate brain (Jorgensen 1974). 
This section attempts to provide a basic outline of several analogies that have been 
suggested between the amphibian and mammalian brains, and to clarify some of the 
terminology that will be used in the experimental chapters of this thesis. 
Investigations into the arrangement and functions of the amphibian brain have 
been performed over the past two hundred years (Jorgensen 1974). During this time a  
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description of the anatomical structure of the brain of various amphibians has evolved.         
In the course of experimental discovery, the nomenclature given to various structures 
and regions has varied, providing some difficulties in the interpretation of the anatomy. 
The basis of identification of anatomical structures within the brain relies, in part, on 
the arrangement, shape and size of neurons within particular brain areas. In the 
amphibian brain, at least, there appears to be overlap of neighbouring neuronal groups 
within specified areas, and as such, these structures will more commonly be referred to        
as a “region” or “area”, rather than a nucleus (Butler & Hodos 1996). It is also apparent 
that variations exist in anatomical structures between aquatic and terrestrial species and, 
therefore, much of the anatomy discussed in this section refers to mainly terrestrial 
species as the experimental work performed in this thesis is based on a terrestrial 
anuran. 
The amphibian brain consists of a telencephalon and diencephalon which make  
up the forebrain, and the mesencephalon, cerebellum and medulla which constitute the 
hindbrain (Oksche & Ueck 1976) (see Figure 1.2). The mammalian brain contains 
similar structures arranged in a different manner, with a large telencephalon that 
conceals much of the diencephalon and mesencephalon (see Figure 1.2). The 
telencephalic cortex in amphibians is believed to be a more primitive form of the 
mammalian cortex, containing a simple neuronal arrangement in comparison to the 
layered pattern of mammals (Kemali & Braitenberg 1969). The pallial region within 
the telencelphalon of the frog brain is thought to be analagous to the hippocampus in 
mammals (Kemali & Braitenberg 1969; Kicliter & Ebbesson 1976). The frog 
diencephalon consists of three regions, an epithalamus, which contains the habenular 
region, the thalamus in which the neural cell bodies are arranged in streaks, and the 
hypothalamus which contains cell masses concentrated in the infundibular and preoptic 
(Kemali & Braitenberg 1969). An extensive hypothalamo-pituitary system is present in 
the amphibian brain that shows strong similarities to pathways present in higher 
vertebrates (Oksche & Ueck 1976). The hypothalamic region is of particular interest to 
the present study as it is a key region for ANP neurons and receptors and is important in 
osmoregulation (Brody & Johnson 1980; Kawata et al 1985; Quirion et al 1984). As 
has been discussed previously, the hypothalamic/AV3V region in mammals contains 
the supraoptic and median preoptic nuclei and the OVLT (Bourque et al 1994; 
McKinley et al 1996) (see Figure 1.3). In the amphibian brain, osmoreceptors are 
believed to lie in the anterior part of the hypothalamus surrounding the third ventricle, 
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which has been termed the preoptic region (see Figure 1 .4) (Jorgensen 1974; Kemali & 
Braitenberg 1969). The preoptic region is believed to be analogous to the AV3V region  
in mammals (Wada et al 1980). An OVLT and subfornical organ have been reported in 
amphibians (Oksche & Ueck 1976); however, in some amphibians, these structures are 
not considered to be separate (Hanke 1976). An organum vasculosum (OV) has been 
described in a more recent study (Neary & Northcutt 1983), although the differentiation 
of the specific nuclei in the amphibian preoptic region is difficult, and for the purposes         
of this study, the term preoptic region will be used as a blanket term, covering the 
whole of the anterior hypothalamic region. The caudal part of the amphibian 
hypothalamus has been assigned several names, including the infundibular region, tuber 
cinerarium and paraventricular organ (Hanke 1976; Oksche & Ueck 1976). More 
recent literature suggests that this region is now commonly termed the ventral 
hypothalamus (Neary & Northcutt 1983). In the mesencephalon, the amphibian optic 
tectum is also believed to share similarities with the mammalian cerebral cortex 
(Kemali & Braitenberg 1969). 
 
Natriuretic Peptides in the Lower Vertebrate Brain 
 
The natriuretic peptides have been identified in the brain of many vertebrate 
species including birds (Arimura et al 1991) amphibians (Netchitailo et al 1986) and 
elasmobranchs and agnathans (Donald et al 1992). However, in comparison to the 
mammalian brain there is limited knowledge regarding which members of the 
natriuretic peptide family and their receptors are present in the lower vertebrate brain. 
C-type natriuretic peptide-like peptides have been isolated from a number of 
species including the killifish, Fundulus heteroclitus (Price et al 1990) the chicken 
(Arimura et al 1991) and the dogfish, Triakis scyllia (Suzuki et al 1992). The amino 
acid sequences of these peptides show a strong homology to mammalian CNP. In the 
amphibian, Rana catesbeiana, CNP-like peptides have also been cloned and 
characterised (Kojima et al 1994). To date, reverse transcription polymerase chain 
reaction has only indicated the presence of mRNA for an ANP-like peptide in the brain  
of the eel Anguilla japonica (Takei et al 1997a). However, immunohistochemical 
studies using antibodies raised against ANP have suggested this peptide is also present        
in the brain of other species (Donald & Evans 1992; Feuilloley et al 1993; Netchitailo et 
al  1986;  Netchitailo  et  al  1987). As seen in mammals, the distribution of natriuretic 
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peptides in the lower vertebrate brain demonstrates differences between species,    
although, as has been observed in higher vertebrates, the peptides appear concentrated            
in the preoptic/hypothalamic region. 
Medium to high levels of natriuretic peptide-like immunoreactivity (NP-IR) has 
been reported in the preoptic region of several lower vertebrate species (see Table 1.1) 
(Donald & Evans 1992; Donald et al 1992; Feuilloley et al 1993; Netchitailo et al 1986; 
Vallarino et al 1990; Vallarino et al 1996). However, it is interesting to note that the 
presence of NP-JR in the pituitary gland demonstrates variation between species (see 
Table 1.1). Natriuretic peptide-like immunoreactivity is also present in  
extrahypothalamic brain regions of the non-mammalian vertebrates in areas including            
the pallium, habenular region and interpeduncular nucleus. The significance of the 
variations in distribution between species is not well-understood and may reflect 
differences in environmental conditions between species. The use of different            
antibodies and immunohistochemical techniques to investigate the distribution is also a 
potential source of variation. 
Much of the evidence regarding the natriuretic peptide receptor system in the 
brain of lower vertebrates arises from autoradiographical studies using mammalian             
ANP as the ligand. To date, the distributibn of ANP binding in the non-mammalian             
brain has only been demonstrated in three species - the lungfish Protopterus annectens 
(Vallarino et al 1996), the terrestrial amphibian Rana. ridibunda (Tong et al 1989) and  
the aquatic amphibian, Xenopus laevis (Kloas & Hanke 1992a). Atrial natriuretic              
peptide binding sites are distributed across the brain of each of the species examined; 
however, the density of binding sites in the various brain regions in each species,           
appears to differ. For example, the habenular region in R. ridibunda and X laevis,  
contains significant ANP binding whilst it is only minimal in this region in P.             
annectens. Interestingly, in the preoptic region, variation is also apparent with high 
numbers of ANP binding sites in R. ridibunda and P. annectens and low densities in X 
laevis. It is of interest to note that the posterior pituitary gland in all three species 
demonstrates a significant number of ANP binding sites which suggests that the           
posterior pituitary gland may be an important target for natriuretic peptide action. In P. 
annectens and R. ridibunda, the distribution of natriuretic peptides mimics the 
distribution of binding sites in most brain regions. In R. ridibunda, some             
receptor/ligand mismatch distribution is observed in the lateral forebrain bundle,            
median  eminence  and  ventral  hypothalamus,  in which NP-JR is present but no binding 
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sites have been observed, and the anterior pituitary gland and olfactory region in which 
ANP binding sites are found but the presence of the peptide was not observed  
(Netchitailo et al 1986; Tong et al 1989; Vallarino et al 1996). 
There is little information regarding which members of the natriuretic peptide 
receptor family are present in the lower vertebrate brain. A second non-GC linked 
natriuretic peptide receptor has been recently identified in eel gills (NPR-D) (Kashiwagi 
et al 1995), which demonstrates a similar affinity for the three main natriuretic peptides  
as NPR-C. The expression of NPR-B, NPR-C and NPR-D mRNA has only been shown  
in the brain of the eel Anguilla japonica (Kashiwagi et al 1995; Katafuchi et al 1994).  
The ANP binding observed in R. ridibunda, P. annectens and X. laevis only provides us 
with information on the distribution of binding in the lower vertebrate brain for that 
peptide. As ANP binds to both NPR-A and NPR-C, these studies have not indicated 
whether both receptor types are present. The distribution of NPR-A and NPR-C, as         
well as NPR-B and NPR-D in non-mammalian vertebrates other than eel has yet to be 
determined. 
The relationship between ANP and AII binding sites has been investigated in        
the brain of the clawed frog X. laevis (Kloas & Hanke 1992a). Binding of the two 
peptides was densest in the habenular region and both lobes of the pituitary gland,          
which suggests that a potentially antagonistic relationship between the peptides exists in 
these areas, as has been observed in the mammalian brain. To date, no studies have 
investigated any relationship between natriuretic peptides and other fluid and electrolyte 
regulating hormones such as AVT (the non-mammalian equivalent to AVP), in the          
brain of lower vertebrates. 
 
Aims of the Present Study 
 
The amphibians represent a transitional stage in vertebrate evolution between          
the water and the land; however, although they have acquired many adaptations for 
existence in a terrestrial environment, most have retained their fish like characteristics 
and kept water as their primary habitat (Alvarado 1979). Even the more terrestrial 
members of the class depend on an aquatic environment for species survival; for   
example, the need to reproduce in a fluid medium is one such constraint. The high 
permeability of the integuement renders the land-adapted amphibians susceptible to the 
threat  of  dessication  in  a  dry environment.   Many of these species have adapted to this 
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problem by adopting certain behaviours, and through the development of endocrine 
systems to regulate dehydration. Some of the behavioural mechanisms employed by 
amphibians to defend against water and electrolyte loss include avoidance of conditions 
causing dehydration, underground burrowing, water conserving postures and          
anticipatory drinking (Shoemaker et al 1992). Arginine vasotocin (AVT) is the non- 
mammalian equivalent of AVP and plays a major role in preventing dehydration in 
amphibians. High concentrations of AVT are present in terrestrial amphibians, most of 
which is contained in the posterior pituitary gland (Alvarado 1 979). The kidneys, skin 
and bladder are all involved in amphibian water and electrolyte balance and are all 
regulated by AVT (Bentley 1974). In the kidneys, AVT constricts the glomerular 
vasculature decreasing the glomerular filtration rate and also increases the permeability 
ofthe renal tubules, skin and bladder to water and sodium (Alvarado 1979; Cree 1988). 
The significance of the posterior pituitary gland and AVT in the control of amphibian 
dehydration was demonstrated when the response of neurohypohysectomised toads to 
dehydration  was  much  slower than that observed in intact controls (Bakker & Bradshaw 
1977). 
The nature of the permeable integument is such that amphibians are not only 
subject to water loss on land, but also hypervolaemia (volume loading) when they enter        
a freshwater environment. The physiological mechanisms through which this problem         
is regulated have not yet clearly been identified. In addition to AVT, the amphibian 
posterior pituitary gland contains two other hormones, oxytocin and mesotocin. The          
role of oxytocin, like AVT, is involved with the uptake of water (Warburg 1995); 
however the effects of mesotocin appear to be somewhat controversial. In some 
amphibians, mesotocin produces a diuretic effect, while in others it causes antidiuresis 
(Nouwen & Kuhn 1984). High doses of mesotocin produce the same effect as AVT, 
whilst lower doses increase the glomerlular filtration rate, resulting in a diuretic 
(Alvarado 1979). Blood volume expansion by intravenous injection of hypertonic           
saline in R. ridibunda produced a diuretic and natriuretic effect; however, no change in 
the mesotocin levels were observed (Nouwen & Kuhn 1984). The opposing responses 
observed for mesotocin suggests its role in amphibian fluid and electrolyte balance is 
equivocal. The diuresis and natriuresis seen in amphibians in response to         
hypervolaemia may, therefore, be due to the involvement of other hormonal factors,         
such as the natriuretic peptides. In mammals, there is significant evidence to suggest          
that  the  natriuretic  peptides  in  the brain have an important role in regulating peripheral 
 26
fluid and electrolyte levels. Natriuretic peptides are also present in the brain of lower 
vertebrates including several amphibian species, although to date there is only limited 
information on this system. The presence of natriuretic peptides in the lower vertebrate 
brain suggests a significant role of the peptides in fluid and electrolyte regulation 
throughout the vertebrates. It is the intent of the present study to use the simple  
amphibian model Bufo marinus, to investigate the natriuretic peptide system in the          
lower vertebrate brain. 
The aims of this thesis are as follows: First, immunohistochemistry was used to 
compare the distribution of natriuretic peptides with that of AVT in the brain, to 
determine if a potential relationship exists between these two major antagonistic          
systems in the control of amphibian fluid and electrolyte homeostasis. Second, the 
distribution and types of natriuretic peptide receptors in the brain was determined using 
autoradiography and biochemical and molecular analysis. The data increase our 
understanding of the potential role of natriuretic peptides in fluid and electrolyte 
regulation in amphibians, and may contribute to a greater understanding of the general 
role of natriuretic peptides in the brain. 
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Figure 1.2 A. Dorsal view of the amphibian brain. B. Lateral view of the mammalian 
brain. H Hind brain; Cb Cerebellum; OT Optic tectum; D Diencephalon; T 
Telencephalon; OB Olfactory bulb. Adapted from Comparative Vertebrate 
Neuroanatomy, Evolution and Adaptation. A.B. Butler, W. Hodos (Eds), Wiley-Liss, New 
York, 1996. 
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Figure 1.3 Schematic frontal section of the AV3V region of the mammalian brain.           
MPO Medial Preoptic Nucleus; MnPO Median Preoptic Nucleus; PVN Paraventricular 
Nucleus; OC Optic Chiasm; 3V Third Ventricle. Adapted from Standaert and Saper 
(1988), The Journal of Neuroscience 8(6): 1940-1950. 
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Figure 1.4 Schematic frontal section of the preoptic region in the amphibian brain. 
Adapted from Neary and Northcutt (1983), The Journal of Comparative Neurology       
213: 262-278. The dots represent the antatomical location of cell nuclei in this region           
of the brain. MP Medial Pallium; DP Dorsal Pallium; LP Lateral Pallium; POa         
Anterior Preoptic Region; ON Optic Nerve. 
 32
 
 
 
  
 
 
 
 
 
 
 
 
 33
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1 Table of the distribution of ANP-immunoreactivity and binding sites in the 
brain of the lower vertebrate species investigated to date. IR Immunoreactivity; BIND 
Binding sites. + Few; ++ Moderate; +++ High. 
aVallarino et at. 1996; bValla et al. 1990; c,eet al. 1992; dDonald and Evans                      
1992; fKloas and Hanke 1992a; gTong et al. 1989 (BIND) and Netchitailo et al. 1987 (IR) 
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CHAPTER TWO 
 
The Distribution of Natriuretic Peptides in the Brain of Bufo 
marinus: Relationship with Arginine Vasotocin 
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I. The Relationship Between Arginine Vasotocin-like and Natriuretic 
Peptide-Like Immunoreactive Structures in the Brain of Bufo marinus. 
 
INTRODUCTION 
 
As discussed in Chapter 1, the mechanisms to counter the effects of dehydration 
in mammals are well known, with the hypothalamo-pituitaiy hormone arginine 
vasopressin (AVP) playing a significant role in this response. A well developed neuro- 
endocrine pathway is also evident in the non-mammalian brain, which participates in            
the dehydration response in a similar manner to that seen in mammals (Bentley 1974; 
Kemali & Braitenberg 1969). However, in birds, reptiles, amphibians and all fish, 
arginine vasotocin (AVT) is the major hormone that mediates the mechanisms to               
counter dehydration (Bentley 1974). Arginine vasotocin differs only from AVP by the 
replacement of the third amino acid, phenylalanine, with isoleucine (Acher 1993;          
Zoeller & Moore 1986). Similar to AVP in mammals, AVT is synthesised in the 
preoptic/hypothalamic region and transported to the posterior pituitary gland for storage 
(Bentley 1974). The AVT system in amphibians has been extensively investigated, and 
there is substantial evidence showing AVT promotes water retention and prevents 
dehydration in amphibians and, therefore, is a key hormone in amphibian fluid and 
electrolyte regulation (see Chapter 1) also (Bentley 1974; Cree 1988; Jard & Morel            
1963; Middler et al 1967; Warburg 1995). In mammals, the natriuretic peptides are 
recognised for their ability to reduce blood volume and blood pressure by facilitating 
natriuresis, diuresis and vasodilation (Saper 1995) see Chapter 1). Natriuretic peptides  
are also present in amphibians, but their role in amphibian fluid and electrolyte  
regulation is essentially unknown. 
Immunohistochemical studies in the mammalian brain have shown natriuretic 
peptides are present in key hypothalamic cardiovascular regulating regions in which  
AVP neuronal cell bodies are also found (Kawata et al 1985; Needleman et al 1989; 
Saper et al 1985). An antagonistic relationship between natriuretic peptides and AVP            
has been observed in the mammalian brain (see Chapter 1) which suggests that the 
potential for natriuretic peptides to modulate AVP release exists, although the pathways 
through which this occurs have not clearly been identified. In amphibians, natriuretic 
peptide-like- immunoreactivity  has  been  identified  in  the  preoptic  region of the brain, 
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which is thought to be equivalent to the AV3V/hypothalamus in mammals (Feuilloley            
et al 1993; Netchitailo et al 1986). The preoptic region of the amphibian brain is also             
the site of AVT-synthesising neurons (Gonzalez et al 1992a; Zoeller & Moore 1986). 
Because AVT is a key osmoregulatory hormone in the brain of amphibians, it is             
pertinent to examine the anatomical relationship between natriuretic peptides and AVT            
in B. marinus to determine the potential for a similar antagonistic role of the two            
peptides exists in the brain of this species. Indeed, some studies have implied that an 
antagonistic relationship between natriuretic peptides and AVT is also evident in 
amphibians. For example, in the periphery, natriuretic peptides have been observed to 
inhibit the AVT-induced water reabsorption in the toad bladder (Samson & Vanatta  
1986) and skin (Berman et al 1994). However, there have been no investigations 
examining the relationship between natriuretic peptides and AVT in the amphibian             
brain. In Part I of this chapter, the distribution of the natriuretic peptides in the brain of 
the toad, B. marinus, using immunohistochemistry, was examined. The anatomical 
relationship between natriuretic peptides and AVT was also investigated to determine           
the potential for interaction between the AVT and natriuretic peptide systems in the 
amphibian central nervous system. The molecular cloning of natriuretic peptides and 
AVT was attempted in Part II of this chapter with the view to obtain homologous           
nucleic acid probes to investigate the sites of natriuretic peptide and AVT rnRNA 
expression and their anatomical relationship in the brain of B. marinus. 
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MATERIALS AND METHODS 
 
Tissue Preparation 
 
Toads, B. marinus, were housed according to Deakin University institutional 
guidelines. The animals had free access to water but did not feed in captivity; however, 
they were used within four weeks of capture. For immunohistochemistry, a total of 
twenty animals were anaesthetised with an overdose (0.6 - 0.8 ml) of 5% MS 222             
(ethyl-m-amino benzoate, Sigma) in 0.9% phosphate buffered saline (PBS, pH 7.4). 
Anaesthetised animals were either intracardially perfused with 0.1 M PBS (pH 7.4, 4           
°C) followed by 50-100 ml of 4% paraformaldehyde (pH 7.4, 4 °C) and subsequently 
decapitated, or were immediately decapitated. Following this procedure, the braincases 
were split open and the brains were dissected out with the pituitary gland intact and 
subsequently immersed in 4% paraformaldehyde (4 °C) for either 2 h or overnight. The 
brains were washed in 0.1 M PBS (pH 7.4), and cryoprotected overnight in a solution of 
PBS containing 30% sucrose. The cryoprotected brains were mounted in an OCT            
Tissue-Tek (Bayer Diagnostics) mould and frozen in liquid nitrogen. Serial sections            
were cut at 20 µm on a Reichardt-Jung cryostat and thaw mounted onto gelatin-chrome- 
alum coated slides. The sections were surrounded with a wax coating to prevent loss of 
antibody solutions during incubation and were stored in sealed slide boxes at -20 °C           
until required. 
 
Primary antisera 
 
The primary antisera used in these experiments were rabbit anti-porcine brain 
natriuretic peptide (anti-NP; kindly donated by Dr. P. Needleman) and guinea pig anti- 
vasopressin (anti-AVP). The anti-NP has been previously shown to cross-react with  
ANP, BNP and CNP (Donald et al 1992). One day prior to the experiment, absorption 
controls were prepared, to demonstrate the specificity of the antibody. The controls 
consisted of anti-NP diluted 1:800 in antibody diluent (1.7 mM NaCl in 10 mM 
phosphate buffer, 0.3% Triton, 0.1% sodium azide, pH 7.1), plus an excess (1 µM) of 
either rat ANP (rANP), porcine CNP (pCNP) or frog ANP (fANP). Antibodies raised 
against AVP have previously been shown to recognise AVT in the amphibian brain 
(Boyd  1994;  Boyd  et  al  1992).   In  the present study a commercial preparation of anti- 
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AVP (Peninsula Laboratories, Belmont, Calif., USA) was used to demonstrate the 
distribution of AVT-like immunoreactivity in the brain of B. marinus. This antibody            
was different to that described by Boyd et al. (1992, 1994) and as such, absorption 
controls were prepared one day prior to the experiment to determine antibody            
specificity. The controls consisted of anti-AVP diluted 1:800 in antibody diluent with            
an excess (1 µM) of AVT or mesotocin. 
 
Single- and Double-Labelling Immunohistochemistry 
 
For single-labelling, sections were allowed to equilibrate to room temperature, 
and were washed with PBS, drained, and placed flat in a humid box. One hundred 
microlitres of either anti-NP (1:800) or anti-AVT (1:800), the antibody/peptide  
absorption control, or antibody diluent alone, was applied to separate slides and  
incubated overnight. The following day, sections were washed in PBS (3 x 10 mm) to 
remove excess antibody. NP-like immunoreactivity (NP-IR) was visualised with Texas 
Red-labelled anti-rabbit IgG (1:200)(Jackson Immunoresearch Labs, Pennsylvania) and 
AVT-like immunoreactivity (AVT-IR) was visualised with fluorescein isothiocyanate 
(FITC)-labelled anti-guinea pig IgG (1 :200) (Jackson Immunoresearch Labs, 
Pennsylvania). Sections were incubated with secondary antibody in a humid box for 3-              
4 h. The sections were then washed in PBS (3 x 10 mm), mounted in buffered glycerol 
(0.5 M Na2CO3 added dropwise to 0.5 M NaHCO3 to pH 8.6 combined 1:1 with                    
glycerol) and observed on a Leitz Dialux 22 microscope fitted with Texas Red and                
FITC filters. The brain anatomy of B. marinus was described according to Northcutt        
and Kicliter (1980) for the telencephalon; Neary and Northcutt (1983) for the 
diencephalon; and Wada et al. (1980) for the mesencephalon. 
For double-labelling, sections were incubated with a mixture of guinea pig anti- 
AVT (1:800) and rabbit anti-NP (1:800) overnight in a humid box. The sections were 
then washed in PBS (3 x 1 0 mm) and incubated with a mixture of Texas Red anti-rabbit 
IgG and F1TC anti-guinea pig IgG (1:200) for 3-4 h. The sections were washed in PBS              
(3 x 1 0 mm) and mounted in buffered glycerol. Any co-localisation of AVT-IR and              
NP-IR was observed by switching between Texas Red and FITC filter sets on a Leitz 
Dialux 22 microscope. The specificity of double-labelling was determined by a series              
of  control  sections  incubated  in  parallel.   The  controls  consisted  of  all  the  possible 
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combinations of primary and secondary antibodies to ensure no cross-reactivity             
occurred (see Table 2.1). 
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Table 2.1 Table of 3 X 3 matrices used for controls in the double-labelling             
experiments. 
 42
 
 
 
 
 
 
 
 
 
 
  
Texas Red Donkey 
anti-rabbit IgG 
 
FITC Goat anti- 
Guinea peg IgG 
 
Texas Red Donkey 
anti-rabbit IgG plus 
FITC Goat anti-
guinea pig IgG 
 
 
Rabbit anti-NP 
 
 
Slide 1 
 
Slide 2 
 
Slide 3 
 
Guinea pig anti-
vasopressin 
 
 
Slide 4 
 
Slide 5 
 
Slide 6 
 
Rabbit anti-NP plus 
Guinea pig anti-
vasopressin 
 
 
Slide 7 
 
Slide 8 
 
Slide 9 
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RESULTS 
 
Natriuretic peptide-like immunoreactivity 
 
The same pattern of distribution of natriuretic peptide-like immunoreactive (NP- 
IR) structures was observed in both perfusion-and immersion-fixed brains; however, a 
notable difference was observed in the number NP-IR cell bodies between fixation              
times, with more cell bodies visible in brains that were only fixed for 2 h. Therefore,            
the descriptions below are for brains that were fixed for 2 h. A schematic             
representation of the distribution of NP-IR in the brain of B. marinus is illustrated in 
Figures 2.1 and 2.2. 
In the telencephalon, a few NP-IR fibres and cell bodies were observed in the 
olfactory region. More caudally, NP-IR cell bodies were present in the lateral and          
medial pallium amongst dense networks of NP-IR fibres (Figure 2.3.A). Natriuretic 
peptide-like immunoreactive cell bodies were also observed in the lateral amygdala. In 
addition, a zone of NP-IR fibres ran dorsoventrally in the region of the medial septum 
(Figure 2.3.B). 
In the diencephalon, a distinct band of NP-IR fibres was observed to run dorso- 
ventrally adjacent to the ventricle through the region of the preoptic nucleus (Figures 
2.3.C and 2.3.D); NP-IR cell bodies were observed in the dorsal region of the nucleus 
(Figures 2.3.E and 2.3.F). A small number of cell bodies were observed amongst the   
NP-IR plexus in the medial section of the ventromedial nucleus (Figure 2.3.G) and 
occasional NP-IR fibres were observed in other regions of the diencephalon (Figure 
2.3.H). NP-IR fibres were also present in the dorsal and ventral hypothalamic nucleus 
(Figures 2.3.1 and 2.3.H). A few scattered NP-IR fibres were present in the median 
eminence, but no NP-IR was observed in the pituitary gland. 
In the mesencephalon, a plexus of NP-IR fibres was present in the optic tectum 
(see Figure 2.3.K). A tract of NP-IR fibres was observed to run laterally from the            
region of the interpeduncular nucleus towards the nucleus reticularis isthmi (Figure 
2.3.L). NP-IR cell bodies were also observed in the nucleus posterodorsalis tegmenti 
mesencephali, lying close to the ventricle (Figure 2.3.M). Many NP-IR cell bodies              
were also distributed amongst a dense zone of NP-IR varicose fibres in the 
interpeduncular nucleus (Figure 2.3.N). 
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In the rhombencephalon, only a few scattered NP-IR fibres were observed. In            
the spinal cord, a few varicose NP-IR fibres were observed in the grey matter. The   
pattern of NP-IR staining was not seen when the antibody was preabsorbed with either 
rANP, pCNP, fANP or when antibody diluent alone was applied to the sections. 
 
Arginine vasotocin-like immunoreactivity 
 
In contrast to the NP-IR structures, the distribution of AVT-IR structures was 
confined to distinct areas of the brain. In the telencephalon, a few AVT-IR cell bodies 
were observed amongst small patches of AVT-IR fibres in the medial amygdala and 
lateral pallium (Figure 2.5.A), and in the nucleus accumbens (Figure 2.5.B). The            
densest distribution of AVT-IR was observed in the diencephalon. In the preoptic 
nucleus, many brilliantly, fluorescent AVT-IR cell bodies were observed at the edge of 
the ventricle (Figure 2.5.C). Most of these cell bodies had processes extending              
laterally. Distinctive bands of AVT-IR fibres were seen in the ventral thalamic nucleus 
(Figure 2.5.D) dorsal and ventral hypothalamus (Figure 2.5.E). The bands of AVT-IR 
appeared to fuse to a single fibre plexus in the median eminence (Figure 2.5.F). A 
densely-staining distribution of AVT-IR fibres was observed in the posterior pituitary 
gland (Figure 2.5.G). No AVT-IR cell bodies were observed in this region. 
The pattern of AVT-IR staining was still visible when the antibody was 
preabsorbed with 1 µM mesotocin, but was absent when the antibody was preabsorbed 
with AVT or when antibody diluent alone was applied to the sections. 
 
Co-localisation ofnatriuretic peptide-like immunoreactivity and arginine vasotocin-like 
immunoreactivity 
 
The distribution of AVT-IR and NP-IR in the brain was similar to that seen in             
the single-labelling experiments. No cross reactivity of the antisera was observed. Co- 
localisation of AVT-IR and NP-IR in neuronal structures was not seen in any part of the 
brain. In the nuclei of the diencephalon, in which both NP-IR and AVT-IR were 
identified in the single labelling experiments, the peptide immunoreactivity appeared 
intermingled but was in separate neuronal structures. In the preoptic nucleus, NP-IR cell 
bodies were distinct from AVT-IR cell bodies although NP-IR fibres were seen               
running  dorsoventrally  amongst  large  AVT-IR cell bodies with their lateral projections. 
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It was not possible to determine the association between NP-IR fibres and the AVT-IR 
cell bodies. 
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Figure 2.1.A-F Schematic illustration of natriuretic peptide- and arginine vasotocin -            
like immunoreactivity (NP-IR and AVT-IR respectively) in frontal brain sections of B. 
marinus. The small dots represent the distribution of NP-IR and AVT-IR fibres. The 
larger dots represent the location of immunoreactive cell bodies. NP-IR is represented            
on the right side of the illustrations whilst AVT-IR is on the left. DP dorsal pallium;              
MP medial pallium; LP lateral pallium; OA olfactory area; MS medial septal nucleus;             
LS lateral septal nucleus; ACC nucleus accumbens; LPV lateral pallium, pars ventralis; 
APM amygdala, pars medialis, APL amygdala, par lateralis; POA anterior preoptic area; 
H habenular region; VTN ventral thalamic nucleus; VH ventral hypothalamic nucleus;  
VM ventromedial thalamic nucleus; LH lateral hypothalamic nucleus. 
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Figure 2.1(continued).G-J TeO optic tectum; TP posterior tuberculum; DH dorsal 
hypothalamic nucleus; VH ventral hypothalamic nucleus; ME median eminence; TS   
torus semicircularis; NIP nucleus interpeduncularis; NPD nucleus posterodorsalis 
tegmenti mesencephali; NRIS nucleus reticularis isthmi; PN pars nervosa; PD pars 
distalis. 
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Figure 2.2 Diagrammatic sagittal section of the brain of B. marinus, indicating the 
location of the schematic frontal sections. 
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Figure 2.3 Natriuretic peptide-like immunoreactivity in frontal brain sections of B. 
marinus. 
A. NP-IR cell bodies and fibres in the medial pallium of the telencephalon. 
B. NP-IR fibres in the medial septum of the telencephalon. 
C. NP-IR fibre tracts running dorso-ventrally in the preoptic region of the diencephalon. 
D. NP-IR fibre tracts descending ventrally in the preoptic region of the diencephalon. 
E. Clustered NP-IR cell bodies in the dorsal part of the preoptic region. 
F. NP-IR cell bodies in the preoptic region. 
G. NP-IR cell bodies in the ventromedial thalamic region. 
H. NP-IR fibre in the diencephalon. 
Scale bar = l00µm. 
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Figure 2.3 (continued) 
I. NP-IR fibres and terminals in the dorsal hypothalamic region. 
J. NP-IR fibre pathways in the ventral hypothalamic region. 
K. NP-IR fibre tracts in the optic tectum of the mesencephalon. 
L. NP-IR fibres and terminals in the nucleus reticularis isthmi of the mesencephalon. 
M. NP-IR cell bodies in the nucleus posterodorsalis tegmenti mesencephali. 
N. NP-IR fibres and terminals in the interpeduncular nucleus of the mesencephalon. 
Scale bar = 100µm.
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Figure 2.4 Colour photograph of NP-IR fibre tracts labelled with Texas Red in a             
frontal section of the preoptic region in the brain of B. marinus. Scale bar = 100µm. 
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Figure 2.5 Arginine vasotocin-like-immunoreactivity in frontal brain section of B. 
marinus. 
A. AVT-IR cell bodies and fibres in the lateral pallium of the telencephalon. 
B. AVT-IR fibres in the nucleus accumbens of the telencephalon. 
C. AVT-IR cell bodies and fibres in the preoptic region of the diencephalon  
     surrounding the ventricle. 
D. AVT-IR fibres in the ventral thalamic region of the diencephalon. 
E. AVT-IR fibre pathways in the ventral hypothalamic region. 
F. AVT-IR fibres in the median eminence. 
G. AVT-IR neuronal structures in the posterior pituitary gland. 
Scale bar = 100µm. 
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Figure 2.6 Colour photograph of AVT-IR cell bodies and fibres labelled with FITC in 
a frontal section of the preoptic region in the brain of B. marinus. Scale bar = 100µm. 
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DISCUSSION 
 
In this study, the antibody used to determine the location of NP-IR in the brain 
recognised two structural forms of natriuretic peptides since preabsorption of the  
antibody with excess rANP, fANP or pCNP quenched specific immunofluorescence in 
cell bodies and axons. Thus, it is very likely that the distribution of NP-IR structures,              
as shown immunohistochemically, is representative for the brain of B. marinus. 
Furthermore, previous studies have used the same antibody to demonstrate the 
distribution of NP-IR in the hearts and brains of Opsanus tau (Teleostei), Squalus 
acanthias (elasmobranchii), and Myxine glutinosa (cyclostomata) (Donald & Evans  
1992; Donald et al 1992). In these studies, the distribution of NP-IR in the brain of M. 
glutinosa was more extensive than previously reported (Reinecke et al 1987) and, in 
Squalus it was similar to another study of NP-IR in the elasmobranch brain (Vallarino            
et al 1990). Clearly, the antibody shows broad recognition of lower vertebrate            
natriuretic peptides. The distribution of AVT in the brain of B. marinus was  
demonstrated with a commercial antibody raised against AVP. Antibodies against AVP 
have previously been used to demonstrate the distribution of AVT in the brain of the 
bullfrog Rana catesbeiana (Boyd 1994; Boyd et al 1992), and the specificity of the 
antibody used in the present study was demonstrated using absorption controls with            
AVT and mesotocin. 
The present study demonstrated the existence of an extensive AVT-IR 
hypothalamo-pituitary pathway in B. marinus, as has been described for a number of 
amphibian species (Carr & Norris 1990; Conway & Gainer 1987; Gonzalez et al 
1992a,b). This study also confirmed the presence of AVT-IR in extrahypothalamic             
brain regions such as the medial amygdala and nucleus accumbens; AVP and AVT             
have been demonstrated in these brain regions in several vertebrate classes (Berecek 
1992). The function of AVT in the extrahypothalamic regions is not presently known            
but the variable distribution might reflect different functions of AVT as a 
neurotransmitter andlor neuromodulator in the brain (Gonzalez & Smeets 1992a). For 
example, brain AVT has been linked with sexual behaviour in amphibians such as   
mating calls and egg laying behaviour (Boyd et al 1992). 
The primary goal of this study was to identify the presence of a natriuretic  
peptide system in the brain of B. marinus and provide a general topographical          
description  of  this  system.   Natriuretic peptides and/or NP-IR have been reported in the 
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brains of a number of the lower vertebrates including cyclostomes, elasmobranchs 
(Donald et al 1992; Suzuki et al 1992; Vallarino et al 1990), teleosts (Donald & Evans 
1992) and amphibians (Netchitailo et al 1987) (see Chapter 1). These studies have  shown 
that, in many species, the preoptic area, circumventricular region and the             
hypothalamo-pituitary pathway are common areas of the brain in which NP-IR is found 
(Donald & Evans 1992; Donald et al 1992; Feuilloley et al 1993). Based on analogy   
with brain function in mammals, this suggests that brain natriuretic peptides may be 
involved in lower vertebrate cardiovascular control and osmoregulation. However, 
evidence for such a role is still forthcoming. 
The distribution of NP-IR in the brain of B. marinus shares many similarities  
with that described for other amphibians (Feuilloley et al 1993; Netchitailo et al 1987). 
Common regions for NP-IR include the olfactory region, pallium, medial septum, 
amygdala, preoptic region, hypothalamus, optic tectum and interpeduncular nucleus. 
However, some differences exist in distribution of NP-IR in other regions of the brain, 
particularly in the pituitary gland (see below). In the diencephalon, Feuilloley et al. 
(1993) reported the presence of NP-IR cell bodies in the preoptic nucleus of the green 
frog Rana ridibunda and the tree frog Hyla japonica; a similar distribution was also 
present in B. marinus. Interestingly, large NP-IR fibre tracts were also observed in the 
preoptic region in B. marinus. Although the hypothalamic distribution of NP-IR in 
amphibians shows strong similarities between species, there is inter-specific variation in 
the distribution of NP-IR in the pituitary gland. NP-IR is present in the neural lobe of          
the pituitary gland of R. ridibunda (Netchitailo et al 1986), but is absent in the same  
tissue of H. japonica and B. marinus, although NP-IR was present in the median 
eminence of each species. 
The arrangement of natriuretic peptides in the hypothalamo-pituitary system of 
amphibians implies possible variations in the method of natriuretic peptide release and 
site of action, according to the species studied. In R. ridibunda, there are NP-IR cell 
bodies in the hypothalamus and NP-IR fibres in the hypothalamo-pituitary tract and the 
neural lobe of the pituitary gland. Thus, the natriuretic peptide system may function in           
a similar manner to the AVT system, with natriuretic peptides being synthesised in the 
hypothalamus and transported axonally to the posterior pituitary gland for storage and 
putative release. In H. japonica, however, NP-IR cell bodies are present in the preoptic 
region and the median eminence, but there was no NP-IR in any lobe of the pituitary 
gland.  This  suggests  that  either  NP-IR  axons from the cell bodies do not project to the 
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pituitary gland or that the levels of natriuretic peptides in the pituitary gland are too low 
to be visualised by immunohistochemistry. The NP-IR pattern in the hypothalamo- 
pituitary system of B. marinus demonstrates similarities to that of H. japonica in which 
NP-IR is present in the preoptic region and median eminence but not the pituitary            
gland. The presence of NP-IR in the median eminence of all amphibian species            
examined to date demonstrates the potential for central natriuretic peptides to be            
released in to the hypophysial portal circulation to modulate anterior and posterior 
pituitary gland function and peripheral effector systems. 
In mammals, the level at which natriuretic peptides influence the synthesis and 
secretion of AVP has not been fully identified, although much of the literature tends to 
support the hypothesis that natriuretic peptides inhibit AVP release at the level of the 
hypothalamus (Crandall & Gregg 1986; Haskins et al 1986; litake et al 1986; Samson 
1985a; Samson 1985b; Standaert et al 1987), rather than the pituitary gland (Obana et al 
1985). Indeed, Samson et al. (1987) suggested that the level of AVP synthesis and  
release in the hypothalamus is inhibited by ANP-ergic neurons originating from the 
circumventricular region. The present study examined the relationship between the 
distribution of AVT-IR and NP-IR in the brain of B. marinus in an attempt to determine 
ifnatriuretic peptides could influence the AVT system of the amphibian brain. Double- 
labelling immunohistochemistry revealed no co-localisation of AVT-IR and NP-IR in  
any region of the brain; however NP-IR fibres were present near AVT-IR cell bodies in 
the preoptic area. The possibility therefore arises that natriuretic peptides released from 
these fibres may influence the activity of AVT neurons by modulating synthesis of          
AVT or neuronal activity that directs AVT release in the pituitary gland. However, 
studies on the distribution of NP-binding sites in the brain of B. marinus (see Chapter 3) 
and Xenopus laevis (Kloas & Hanke 1992a) have shown minimal binding sites in the 
preoptic area of the brain and, in particular, no specific natriuretic peptide binding was 
observed in the region of the AVT neurons. A second site for natriuretic peptide 
modulation of AVT release could be the posterior pituitary gland. The posterior           
pituitary gland of B. marinus is richly invested with natriuretic peptide binding sites          
(see Chapter 3) and is, therefore, clearly a target for natriuretic peptide action.                
However, NP-IR was not observed in the pituitary gland of B. marinus, although NP-IR 
was present in the median eminence. Therefore, natriuretic peptides originating from 
either  the  portal  circulation  of the pituitary gland which drains the median eminence, or 
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from the heart and the central circulation could influence AVT secretion; this           
mechanism remains to be determined. 
Using immunohistochemistry, the present study demonstrated the distribution of 
natriuretic peptides and their relationship with AVT in the brain of B. marinus. In order  
to identify the sites of natriuretic peptide mRNA expression in the brain of B. marinus 
and to correlate this distribution with that of AVT mRNA, cDNAs for the B. marinus 
natriuretic peptides and AVT would need to be cloned. Once obtained, these cDNAs 
could be used as nucleic acid probes for in situ hybridisation studies to compare the 
anatomical location of the sites of synthesis of natriuretic peptides and AVT in the brain 
of this species. Obtaining homologous nucleic acid probes for natriuretic peptides and 
AVT in the brain of B. marinus was therefore the focus of part II of this chapter. 
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II. Molecular Characterisation of Natriuretic Peptides and Arginine 
Vasotocin from the Brain of Bufo marinus 
 
INTRODUCTION 
 
In mammals, the potential for natriuretic peptides to be involved in the central 
regulation of fluid and electrolyte balance was first suggested when ANP was           
indentified in regions such as the hypothalamus, OVLT and supraoptic nucleus using 
immunohistochemistry (Kawata et al 1985; Saper et al 1985). These studies enabled           
the distribution of ANP in the brain to be described, but, with the discovery of BNP and 
CNP, it was likely that the early studies used antibodies that could cross-react with 
natriuretic peptides other than ANP. The subsequent cloning of ANP, BNP and CNP 
cDNAs provided a powerful tool to identify the precise anatomical location of the 
specific mRNA for each of the natriuretic peptides in the brain using in situ             
hybridisation techniques. 
In non-mammalian vertebrates, the distribution of natriuretic peptides in the            
brain has been shown using immunohistochemistry (Donald et al 1992; Feuilloley et al 
1993; Netchitailo et al 1986; Netchitailo et al 1987) (see Part I, this Chapter).              
Although, natriuretic peptides have been isolated from the tissues of a number of non- 
mammalian vertebrates, ANP and CNP cDNAs have only been cloned from a few 
species. In the periphery, ANP has been cloned from the heart of the eel Anguilla 
japonica (Takei et al 1997a) and CNP has been cloned from the heart of the shark 
Squalus acanthias (Schofield et al 1991). In the amphibian, Rana catesbeiana, two            
CNPs (CNP I and II) have been cloned from the brain (Kojima et al 1994). However,             
the precise anatomical location of the natriuretic peptide mRNAs, their relationship             
with other brain hormones and their response to physiological challenges using in situ 
hybridisation methods in the non-mammalian brain has not yet been investigated. 
The immunohistochemistry studies in Part I of this chapter have shown  
natriuretic peptide-like immunoreactivity is present in the brain of the amphibian B. 
marinus. However, the antibody used in this study recognises ANP, BNP and CNP 
(Donald et al 1992), and subsequently, the distribution of individual natriuretic peptides 
could not be determined. Thus, partial cloning of brain natriuretic peptides was 
undertaken  in  an  attempt  to  generate  homologous ANP and CNP cDNAs that could be 
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used in situ hybridisation studies of natriuretic peptide mRNA expression. In addition, 
partial cloning of a brain AVT cDNA was performed. The generation of homologous 
natriuretic peptide and AVT probes could be used in future studies to determine the 
effects of dehydration and volume loading on natriuretic peptide and AVT mRNA 
expression. Such information would provide a further understanding of the role of             
these peptides in the control of fluid and electrolyte balance. 
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MATERIALS AND METHODS 
 
RNA Isolation and cDNA synthesis 
 
Total RNA from the brain of B.marinus was isolated by the acid-phenol       
technique following the modified methods of Chomczynski and Sacchi (1987) 
(Chomczynski & Sacchi 1987). Brains were homogenised in guanidium thiocyanate  
(GT) buffer (4 M guanidium thiocyanate, 25 mM sodium citrate pH 7.0, 0.5% sarcosyl,  
0.1 M 2-β mercaptoethanol). For each ml of homogenate, 0.1 ml of 2 M sodium acetate 
(pH 4.0), 1 ml of water saturated acid phenol (pH 4.3) and 0.2 mls of chloroform 
isoamyalcohol (49:1) were added and mixed thoroughly by inversion. The sample was 
incubated on ice for 15 mm and centrifuged at 10,000 rpm at 4 °C for 10 min in a 
Beckman J2-21 M/E centrifuge. The upper aqueous phase was transferred to a fresh           
tube, and an equal volume of isopropanol was added, and the sample was incubated for           
1 h at -20 °C. The total RNA was pelleted by centrifugation, and the pellet was 
resuspended in 700 µl of GT buffer (minus the β-mercaptoethanol) and transferred to a 
microfuge tube. An equal volume of chloroform was added and the sample was 
centrifuged at 5000 rpm for 15 mm. The upper aqueous layer was transferred to a            
sterile microfuge tube arid the RNA was precipitated by the addition of 70 µl of 2 M 
sodium acetate and 700 µl of isopropanol and incubation for 1 h at -70 °C. The RNA          
was pelleted by centrifugation at 14,000 rpm for 20 min, washed with 75% ethanol,  
dried, and resuspended in 200-500 µl of sterile water. The quantity and quality of the  
total RNA was determined by spectrophotometry and agarose gel electrophoresis. 
First strand cDNA synthesis was performed using an oligo (dT) primer and 
Superscript II reverse transcriptase (Gibco BRL) according to the manufacturers 
protocols. All cloning was work was performed using Polymerase Chain Reaction        
(PCR)-based approaches and Taq DNA polymerase. 
 
AVT Cloning 
 
The primers used to generate a B. marinus AVT cDNA were designed by 
alignment of known AVT sequences from the chicken, Gallus gallus (Hunt et al 1990) 
and  an  amphibian,  Bufo  japonicus  (Nojiri  et al 1987) (Figure 2.7). The forward primer 
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coded for the amino acid sequence ACYIQNCP and was 5’ 
GC(N)TG(C/T)TA(C/T)AT(AIC/T)CA(AIG)AA(C/T)TG(C/T)CC 3’ . The reverse 
primer was the reverse complement of the amino acid sequence HMANRQQQ and was           
5’ TG(T/C)TG(T/C)TG(N)C(G/T)(G/A)TT(N)GCCAT(A/G)TG 3’. The estimated  
length of the amplified cDNA fragment using these primers was 41 1 base pairs. 
Polymerase chain reaction was performed by denaturation at 94 °C for 60 sec,              
annealing at 45 °C for 60 sec and an extension at 75 °C for 120 sec for 34 cycles; a final 
extension for 5 min was performed on the last cycle. The reaction product was            
analysed by agarose gel electrophoresis, and the amplified product was recovered from 
the gel using a QlAquick gel extraction kit (QIAGEN). The cDNA was cloned into a 
pMOS vector (Amersham) following standard transformation protocols provided by the 
manufacturer. The cDNA insert was sequenced on an Applied Biosystems automated 
sequencer (Westmead Hospital, Sydney), and the sequence was analysed using the            
Basic Local Aligmnent Search Tool (BLAST) (Altschul et al 1990). 
 
Natriuretic Peptide Cloning 
 
The N-terminal of known ANP and CNP sequences shows very little sequence 
homology between species (Figures 2.8 and 2.9), and subsequently the design of two 
gene-specific primers is problematic. As an alternative, the technique of 3’ RACE            
(Rapid Amplification of cDNA Ends) was used in an attempt to amplify sequences at            
the 3’ end (C-terminal) of the ANP and CNP mRNA. 3’ RACE PCR amplifies a    
sequence of mRNA from the 3’ end to a defined internal site, and this method has 
successfully been used to isolate the CNP cDNA sequence in the shark, Squalus 
acanthias (Schofield et al 1991). Brain RNA was isolated as above, and first strand 
cDNA synthesis was initiated using an adapter primer (5’             
GGATCCGCGGCCTCGA(T) 3’) and Superscript II reverse transcriptase. The            
mRNA template was degraded with RNase H (Gibco BRL). Polymerase Chain            
Reaction was performed using degenerate gene specific forward primers for ANP or    
CNP based on the conserved sequences DRIGAQ and KLDRTG respectively (Figures. 
2.9 and 2.10), and a generic 3’ RACE reverse primer (5’ GGATCCGCGGCCT CGA 3’). 
The DRIGAQ primer was 5’ GA(T/C)(MC)G(N)AT(A/C/T)GG(N)GC(N)GA 3’. The 
KLDRIG    primer   was   5’  AA(A/ G)(T/C)T(N)GA(T/C)(AIC)G(N)AT(A1CIT)GG 3’. 
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Polymerase chain reaction was performed as above using a range of annealing 
temperatures from 42 to 60 °C. The PCR products were analysed by agarose gel 
electrophoresis and precipitated prior to cloning into either a pCR script vector 
(Stratagene) or a pMOS vector (Amersham) using standard transformation protocols 
provided by the manufacturer. Insert cDNA was sequenced and analysed as above. 
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RESULTS 
 
AVT Cloning 
 
Polymerase chain reaction of B. marinus brain cDNA using the AVT forward  
and reverse primers generated an approximate 410 base pair product as predicted. The 
product was cloned and sequenced; the nucleotide (41 1 base pairs) and deduced amino 
acid sequences are shown in Figure 2.10. The nucleotide sequence was 95% and 67% 
homologous to B. japonicus and chicken AVT mRNA respectively. The deduced          
amino acid sequence of the PCR product showed 97% and 70% homology with prepro- 
AVT of B. japonicus and chicken respectively (Figure 2.7). In comparison with the  
amino acid sequence of B. japonicus preproAVT, B. marinus preproAVT differed by  
only three amino acids. 
 
Natriuretic Peptide Cloning 
 
3’ RACE PCR using the ANP gene specific primer DRIGAQ revealed only a 
smearing of bands between approximately 450 and 800 base pairs (Figure 2.11). 
Changing the stringency of the PCR conditions including MgC12 concentration,                
annealing and extension temperatures and times, failed to produce any cleaner bands.             
A more specific PCR product was not generated using a nested forward primer. No 
attempt was made to clone any of the ANP 3’ RACE products. 
3’ RACE PCR using the CNP gene specific primer KLDRIG and the RACE 
universal primer was more successful and revealed two strong bands of approximately 
650 and 520 base pairs in length, and a weaker band at approximately 460 base pairs          
(Figure 2.12). The bands were recovered from the gel using the same protocols as 
described for the AVT partial cDNA, and cloned and sequenced. Analysis of the 
nucleotide sequence and the deduced amino acid sequence of the three products showed 
no homology with any known natriuretic peptide sequence. 
To determine that the 3’RACE PCR method was viable, the AVT forward           
primer and the RACE universal primer were used to amplify the AVT mRNA sequence. 
An approximate 475 base pair product was generated and cloned, and interestingly was 
found to have minimal homology with B. japonicus AVT. However, the cDNA            
deduced   amino  acid  sequence  showed  97%  homology  with  B.  japonicus  mesotocin 
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(Figure 2.13). It was subsequently determined that the region where the AVT forward 
primer was designed had 100% sequence homology with the mesotocin sequence for 
those particular amino acids (Figure 2.13). The amplification of the mesotocin cDNA 
confirmed that the 3’RACE PCR method was viable. 
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Figure 2.7 Amino acid sequence alignment of arginine vasotocin from the chicken,           
Bufo japonicus and Bufo marinus showing positions of sequence homology. The          
forward and reverse primers are underlined. The stars indicate where amino acids differ 
between the chicken and B. japonicus; bold type shows the differences between B. 
marinus and chicken and B. japonicus. 
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Figure 2.8 Amino acid sequence alignment of ANP from monkey, rat, frog and           
chicken. The conserved region of the seventeen amino acid ring used as a gene specific 
primer for 3’ RACE PCR is underlined. The stars indicate positions where amino acids 
differ between species. 
 76
 
 
 
 
 
 
 
 
 
 
 
 77
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9 Amino acid sequence alignment of CNP from the shark (T scyllia), rat, eel  
and frog (CNP I and CNP II). The conserved region of the seventeen amino acid ring 
used as a gene specific primer for 3’ RACE PCR is underlined. The stars indicate 
positions where amino acids differ between species. 
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Figure 2.10 Nucleotide sequence and deduced amino acid sequence of the 411 base           
pair PCR product from B. marinus brain cDNA generated using AVT specific primers. 
The forward and reverse primers used are underlined. 
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Figure 2.11 Agarose gel analysis of 3’ RACE PCR using the gene specific primer 
DRIGAQ and the RACE reverse primer 5’ GGATCCGCGGCCTCGA 3’. A smearing          
of bands between approximately 450 and 800 base pairs in size (Lane 2) was amplified 
from B. marinus brain cDNA. Lane 1 = DNA molecular weight markers 1000 - 100 base 
pairs. 
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Figure 2.12 Agarose gel analysis of 3’ RACE PCR using the gene specific primer 
KLDRIG and the RACE reverse primer 5’ GGATCCGCGGCCTCGA 3’. Three bands           
of approximately 650, 520 and 460 base pairs were amplified from B. marinus brain 
cDNA (Lanes 2, 3 and 4). Lane 1 = DNA molecular weight markers 3147 - 50 base           
pairs. 
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Figure 2.13 Alignment of 107 amino acid sequence of B. japonicus mesotocin with the 
deduced amino acid sequence of B. marinus 3’ RACE PCR fragment. The gene           
specific primer used in 3’ RACE PCR is underlined. The stars indicate positions where 
amino acids differ between B. japonicus mesotocin and B. marinus 3’ RACE fragment. 
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DISCUSSION 
 
The aim of this study was to clone fragments of the natriuretic peptides and           
AVT cDNAs from the brain of B. marinus, in order to generate homologous nucleic           
acid probes for use in future in situ hybridisation studies. Immunohistochemical            
evidence in Part I of this chapter indicated that natriuretic peptides are present in the    
brain of B. marinus; however, the types of natriuretic peptides in the brain could not be 
determined. The generation of homologous natriuretic peptide cDNAs would allow the 
specific distribution of the peptide mRNAs in the brain of B. marinus to be determined.   
In addition, these probes could then be utilized in conjunction with an AVT probe to 
examine any changes in the expression of the peptides in response to osmotic         
challenges. 
The use of nucleic acid probes to study the expression of natriuretic peptide 
mRNAs has been performed mainly in mammals. In the rat brain, preproANP mRNA 
positive cells have been detected in the AV3V region, medial habenula, hippocampus  
and arcuate nucleus (Gundlach & Knobe 1992). A more recent study has also identified 
ANP mRNA in cells of the olfactory region, limbic cortices, preoptic region and 
mammillary nuclei (Langub et al 1 995b). The distribution of ANP mRNA is similar to 
the distribution of ANP detected immunohistochemically, with the exception of the 
pyramidal cells of the hippocampus in which ANP immunoreactivity was not detected   
but the mRNA was present (Gundlach & Knobe 1992). In contrast to ANP mRNA,              
BNP mRNA was not present in rat brain tissue (Langub et al 1995b). However, C-type 
natriuretic peptide mRNA is present in brain tissue, and shares a similar distribution to 
ANP mRNA. C-type natriuretic peptide mRNA is present in cells in the olfactory           
region, circumventricular/AV3V organs, preoptic region, limbic cortices and             
mammillary nuclei (Herman et al 1993; Langub et al 1995b). In addition, CNP mRNA          
is also present in the supraoptic and paraventricular nuclei, in which ANP mRNA is 
absent (Langub et al 1995b). 
Earlier physiological manipulations such as lesions and injection of hypertonic 
saline in to the AV3V region (Baldissera et al 1989; Bealer et al 1983), were observed            
to alter plasma ANP concentrations, which implied an important role for natriuretic 
peptides in this area of the brain. The advancement of molecular cloning and in situ 
hybridisation techniques made it possible to further investigate not only the relationship 
of  natriuretic  peptides  with  other  brain  hormones  such  as  AVP,  but  their role in the 
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AV3V, by examining the expression of the peptides in response to physiological 
challenges such as salt and volume loading. Indeed, preproANP and preproCNP              
mRNA expression following sodium loading and adrenalectomy have been investigated 
in rat brain (Ryan & Gundlach 1997; Ryan et al 1997). Interestingly, no change in 
preproANP and preproCNP mRNA was observed in response to adrenalectomy and           
only a small increase in preproCNP mRNA in the hippocampus was observed in  
response to sodium loading (Ryan & Gundlach 1997; Ryan et al 1997). The           
observation that only a small increase in preproCNP mRNA expression occurred in 
response to osmotic challenge is quite surprising considering the peptides are believed         
to be involved in osmotic homeostasis; however, it may be due to the experimental 
technique. The levels of expression were only examined between 7 and 14 days of 
sodium loading and the authors suggested that any early changes that may have            
occurred would be missed (Ryan & Gundlach 1997). Alternatively, the level of  
natriuretic peptide mRNA turnover may have been equal with the levels of natriuretic 
mRNA transcription. 
In the present study, the attempted cloning of partial ANP and CNP cDNAs            
from the brain of B. marinus was unsuccessful. It is probable that the inability to             
generate the partial cDNAs is due to inherent properties of the natriuretic peptide  
mRNAs rather than technical shortcomings, since a mesotocin cDNA was cloned using 
the same 3’ RACE approach. The presence of an ANP mRNA in the B. marinus brain         
is problematic since the inmiunohistochemical studies used an antibody that cross- 
reacted with ANP, BNP and CNP. In addition, northern blot analysis of brain total         
RNA using a Rana catesbeiana ANP cDNA did not produce any hybridisation signal in 
contrast to a very strong signal in the heart (Minerds, K. and Donald, J. unpublished). 
Interestingly, the transcript size of the putative cardiac ANP mRNA is 3.50 kilobases 
(Minerds, K. and Donald, J. unpublished), which is significantly larger than the average 
transcript size of ANP mRNA of about 0.9 kilobases that has been reported for  
mammals. Since it is probable that the size of the open reading frame of B. marinus          
ANP is similar to other species, the large transcript size is most likely due to extensive             
3’ and 5’ untranslated regions. Therefore, if an ANP mRNA transcript of similar size is 
present in the brain, the viability of the RACE procedure may be compromised by a           
large 3’ untranslated region. 
In contrast to ANP, it is likely that a CNP molecule is present in the brain of B. 
marinus,  since  CNP  has  been  isolated  from  the  brain of a number of non-mammalian 
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vertebrates (Kojima et al 1994; Price et al 1990; Suzuki et al 1992). However, a CNP 
cDNA could not be amplified from the brain using a gene-specific sequence, KLDRJG, 
which is conserved in all CNP molecules; the same 3’ RACE technique was used to    
clone a CNP cDNA from the heart of the spiny dogfish, Squalus acanthias (Schofield et  
al 1991). Interestingly, two CNP cDNAs, called CNP I and and CNP II, have been    
cloned from the brain of the amphibian, R. catesbeiena (Kojima et al 1994). However,            
it is important to note that the amino acid sequence of R. catesbeiana CNP was known          
to assist in the design of oligonucleotides. Northern analysis of B. marinus RNA using           
R. catesbeiana CNP I and CNP II cDNA probes failed to produce a hybridisation signal 
(J. Donald, unpublished), which probably reflects the extensive sequence divergence of 
CNP mRNA outside the coding region for the highly conserved CNP-22 molecule.   
Future PCR-based approaches with a variety of primer designs may yield a B. marinus 
CNP clone 
The use of homologous nucleic acid probes for in situ hybridisation studies have 
been used to investigate the distribution of the AVP transcript within the mammalian 
brain. In sheep, brain cells expressing high levels of AVP mRNA were present in the 
paraventricular, supraoptic and suprachiasmatic nucleus of the hypothalamus             
(Matthews et al 1993a). Extrahypothalamic cells expressing AVP mRNA were also 
observed in the bhoroid plexus, accessory magnocellular nuclei and pineal gland 
(Matthews et al 1993a). The response of AVP-producing cells following physiological 
changes has also been observed. In sheep, dehydration resulted in no change in AVP 
mRNA expression in either the paraventricular or supraoptic nuclei of the                  
hypothalamus (Matthews et al 1993b). In contrast, sodium loading in rats and mice         
was observed to evoke an eight-fold increase in AVP RNA from control levels in the 
posterior pituitary (Murphy et al 1989), which indicated the potential for local            
production of AVP in the pituitary, in addition to that produced by the hypothalamus. 
In contrast to the natriuretic peptides, the anatomical location of cells expressing 
AVT mRNA in the non-mammalian vertebrate brain has been investigated in some 
species. In situ hybridisation studies using a 260 base pair nucleic acid probe generated 
towards the 3’ end of the chicken AVT gene has been used to investigate the          
distribution of AVT mRNA in the brain of the Japanese quail Coturnix japonica and the 
chicken Gallus domesticus (Aste et al 1996). Intense expression of AVT mRNA is 
present in the hypothalamic region and cells expressing low levels of AVT mRNA were 
observed   in   extrahypothalamic   regions   such  as  the  optic  lobe,  lateral  septum  and 
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anterior commissure (Aste et al 1996). This distribution was consistent with the 
distribution of AVT identified immunohistochemically in the chicken brain (Chaturvedi 
et al 1994). The extrahypothalamic distribution of AVT has also been identified 
immunohistochemically in the brain of other non-mammalian vertebrates (Gonzalez & 
Smeets 1992a; Gonzalez et al 1992b; Zoeller & Moore 1986). 
In the present study, a 411 base pair partial AVT cDNA showed 97% homology 
to the amino acid sequence of B. japonicus AVT. The deduced amino acid sequence of 
the partial cDNA of B. marinus AVT differed by three amino acids to the AVT             
sequence in B. japonicus. The differences were in very conserved regions of the 
AVT/AVP sequence of other species, but, the B. marinus clone was only sequenced   
once, since the cloning was performed as a control for the molecular approaches used in 
this study. In addition a B. marinus mesotocin cDNA was amplified using 3’ RACE 
protocols, which confirmed the presence of this molecule in the toad brain. The cloning  
of AVT and mesotocin cDNAs confirmed the viability of the PCR and cloning          
protocols used in this study and generated homologous probes that could be used in                       
future studies on the control of osmoregulation in the brain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER THREE 
 
Atrial Natriuretic Peptide Binding Sited in the Brain of Bufo 
marinus 
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INTRODUCTION 
The natriuretic, diuretic and vasodilatory properties of the natriuretic peptides in 
mammals are mediated by two distinct guanylate cyclase receptors, NPR-A and NPR-B 
(Maack 1992). As discussed in Chapter 1, a third natriuretic peptide receptor that lacks              
a guanylate cyclase, NPR-C, has also been identified. The three natriuretic peptide 
receptors NPR-A, NPR-B and NPR-C are present in the mammalian brain and there is 
evidence to suggest that natriuretic peptide receptors are present in the hypothalamus 
(Brown & Zuo 1993; Langub et al 1995a). This observation is consistent with the view 
that natriuretic peptides play a neuromodulatory role in the central control of fluid 
homeostasis and demonstrate the potential to modulate other fluid and electrolyte 
regulating hormones in the brain. 
Most of the investigations on the natriuretic peptide receptors in the mammalian 
brain have been performed using ANP as the ligand (see Chapter 1 for details). In 
contrast, there is little information regarding the types of natriuretic peptide receptors in 
the lower vertebrate brain. Studies in the peripheral tissues of a number of non- 
mammalian vertebrates have shown that both NPR-GC and NPR-C populations are 
present. For example, in fish there is evidence to suggest that two natriuretic peptide 
receptors are present in the shark rectal gland (Gunning et al 1993) and a mixed 
population of GC-linked and NPR-C receptors are present in the gills of the toadfish 
Opsanus beta (Donald et al 1994). In addition, more recent studies have indicated that             
an NPR-A-like receptor population is present in the dorsal and ventral aorta in the 
aganathan Myxine glutinosa (Toop et al 1995), and NPR-B and NPR-C like receptors 
have been identified in the heart of the eel Anguilla anguilla (Cerra et al 1996). In 
amphibians, ANP binding sites have been observed on the renal glomeruli and adrenal 
tissue of the anuran Rana temporaria (Kloas & Hanke 1992b) and the urodele Abystoma 
mexicanum (Kloas & Hanke 1993). However, in these two studies, the types of ANP 
binding sites present (ie. NPR-GC and NPR-C), was not examined. 
Immunohistochemical studies in lower vertebrates have shown that natriuretic 
peptides have a broad distribution in the brain (see Chapter 2). In amphibians, these 
studies have indicated natriuretic peptides are present in the preoptic area of the brain  
that is believed to be analogous to the AV3V/hypothalamic region in (Netchitailo et al 
1987; Wada et al 1980). In addition, natriuretic peptide-like immunoreactive (NP-IR) 
terminals  have  been  observed in the preoptic region in the vicinity of arginine vasotocin 
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(AVT) immunoreactive neurons in the brain of B. marinus (see Chapter 2), which 
suggests that the potential exists for natriuretic peptides to modulate AVT synthesis and 
release. However, binding sites for natriuretic peptides in the lower vertebrate brain             
have only been shown in one dipnoan species (Vallarino et al 1996) one agnathan 
(Donald et al in press) and amphibians (Kloas & Hanke 1992a; Tong et al 1989). The 
distribution of ANP binding sites in the amphibian brain has been demonstrated in two 
species, Xenopus laevis (Kloas & Hanke 1992a) and Rana ridibunda (Tong et al 1989). 
These studies showed conflicting data on the distribution of ANP binding sites in the 
preoptic region since no specific binding was found in this region in X. laevis, but,               
dense binding was observed in R. ridibunda. In addition, the ANP binding sites in the 
brain of these two species were not characterised. Therefore, the nature of the               
natriuretic peptide receptors in the amphibian brain is at present unclear. 
The use of heterologous antibodies and ligands to demonstrate both natriuretic 
peptides and their binding sites in non-mammalian tissues has been demonstrated in a 
number of studies (Donald et al 1992; Netchitailo et al 1987; Tong et al 1989; Vallarino 
et al 1996). Moreover, other studies have shown that heterologous peptides bind to 
natriuretic peptide receptors with high affinity and can stimulate cGMP production to 
levels similar to those in mammalian tissues (Gunning et al 1993). The present study, 
therefore, used the ligand rat ANP to investigate the distribution of ANP binding sites in 
the brain of the toad, B. marinus. To investigate a potential role for natriuretic peptides             
in the central control of cardiovascular homeostasis and osmoregulation, the distribution 
of binding sites was correlated with that of NP-JR and AVT immunoreactive elements. 
To further characterise the types of natriuretic peptide binding sites in the brain of B. 
marinus, the NPR-C specific ligand C-ANF, was also used in displacement             
experiments. C-ANF is a ring delected natriuretic peptide designed to bind specifically            
to NPR-C (Maack 1992), and any natriuretic peptide binding observed in the presence                
of C-ANF would potentially indicate the presence of NPR-GC. 
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MATERIALS AND METHODS 
 
Toads, B. marinus, were housed according to Deakin University institutional 
guidelines. The animals had free access to water but did not feed in captivity; however, 
they were used within four weeks of capture. For autoradiography, a total of six            
animals were anaesthetised with an overdose (0.6 - 0.8 ml) of 5% MS 222 (ethyl-m-
amino benzoate, Sigma) in 0.9% phosphate buffered saline (PBS, pH 7.4) and 
subsequently decapitated. Following this, the braincases were split open and the brains 
were dissected out with the pituitary gland intact. The pituitary gland was either left in 
place for whole brain studies or removed, to be sectioned separately. 
The brains and isolated pituitaries were frozen in a mould of OCT Tissue Tek 
(Bayer Diagnostics) in liquid nitrogen and 20 µm serial sections were cut and mounted   
on gelatin-chrome-alum coated slides. The sections were stored in sealed slide boxes at          
-20°C until required. The sections were processed for autoradiography using rat (3-          
[125I]iodotyrosoll28) atrial natriuretic peptide (termed 125I-rANP) (Amersham,                  
Australia) as a ligand, following the method of Donald et al. 1994. Briefly, sections were 
preincubated at room temperature (20-22°C) for 15 min in 50 mM tris- 
(hydroxymethyl)aminomethane (Tris).HC1 buffer (pH 7.4), 50 mM NaCl, 5 mM             
MgCl2 0.1% bovine serum albumin (BSA) and 0.05% bacitracin (Sigma). This was 
followed by incubation for 90 min in the same buffer supplemented with of 4 µg/ml 
leupeptin, 2 µg/ml chymostatin, 2 µg/ml pepstatin, 10-6 M phenymethylsulfonylfluoride 
(PMSF) (Sigma) and 125I-rat ANP. 
The specificity of binding was determined in consecutive sections in the           
presence of either 1 µM rat ANP (rANP) or 1 µM C-ANF (Auspep, Australia). After 
incubation, the sections were washed (2 x 10 mm, 4°C) in wash buffer (50 mM      
Tris.HC1, 100 mM NaCl, pH 7.4), fixed for 20 mm in 4% formaldehyde in phosphate 
buffer (0. 1 M, pH 7.4, 4°C), rinsed in 0.1 M phosphate buffer (pH 7.4, 4°C), followed  
by distilled water (dH2O), and then dehydrated in an alcohol series and dried overnight            
at 60°C. The dried sections were exposed to Hyperfilm-βmax (Amersham, Australia)             
for 4-7 days at room temperature. The films were developed using Ilford Phenisol X-ray 
developer (4 min), rinsed in water (1 min) and then fixed in Ilford Hypam (4 min). X-          
ray films were photographed with Techpan film on a white light-box using a Zeiss 
dissecting microscope and a Zeiss MC 80 camera. 
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Quantitative analysis of autoradiographs was performed using the computer 
imaging analysis program NIH image (National Institute of Health, Public Domain 
Software, Version 1.62) to determine the density of binding sites in the various brain 
regions. Images of the autoradiographs were recorded on video tape and then captured 
using Apple Video Player software, version 1.4, on a Power Macintosh 7500/700. The 
optical density of the autoradiography images was calibrated using 125I optical density 
standards and converted to fmol/mm2 using the specific activity of the ligand. 
For higher resolution autoradiography, brain sections were dipped in nuclear            
track emulsion (Amersham) melted at 43°C, dried, and stored at 4°C for 14 days. The 
slides were then developed and fixed as above. Following fixation, the sections were 
stained with haematoxylin and eosin using standard protocols. The sections were then 
viewed under a Zeiss Axioskop and photographed using Techpan film and a MC 80 
camera. 
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RESULTS 
 
Specific binding was determined as the difference in binding between sections 
incubated with either 200 pM 125I-rANP alone and adjacent sections incubated with 
radiolabelled ligand and 1 µM of unlabelled rANP. A schematic representation of the 
distribution of 125I-rANP specific binding in the brain of B. marinus is illustrated in                   
Figures 3.1 and 3.2. 125I-rANP binding densities (fmol/mm2) as determined by NIH                       
Image analysis, are shown in Table 3.1. 
125I-rANP binding sites were broadly distributed in the brain, being found in the 
telencephalon, diencephalon and mesencephalon (Table 3.1). In the telencephalon,              
strong binding was observed in the olfactory region and the dorsal and medial pallium 
(Figures 3.3.A.1 and 3.3.B.l). No significant binding was present in the lateral pallium             
or the medial and lateral septum. 
In the diencephalon, dense 125I-rANP binding was observed on the choroid               
plexus and the paraphysis regions (density not measured) (Figures 3.3.C.1 and 3.3.D.1). 
No specific 125I-rANP binding was seen in the preoptic region (Figure 3.3.D.1) or the                
median eminence. Dense binding was observed in the habenular nuclei (2.65                  
(fmol/mm2) (Figures 3.3.E.1 and 3.6.A) and moderate 125I-rANP binding was found in                    
the thalamic region. Lower levels of specific binding were present in the dorsal and 
ventral regions of the hypothalamus (Figure 3.3.E.1). 
In the mesencephalon, moderately dense 125I-rANP binding were observed in the                  
torus semicircularis, and moderate binding was found in the optic tectum (1.78               
fmol/mm2) (Figure 3.3.F.1). Very low levels of 125I-rANP binding were observed in the 
interpeduncular nucleus and little, if any, specific binding was found in the remaining 
regions of the mesencephalon. The densest 125I-rANP binding in the brain was observed                          
in the pituitary gland (5.67 fmol/mm2) (Figure 3.3.G.1). Examination of pituitary gland 
sections dipped in X-ray sensitive emulsion showed a dense distribution of silver grains 
in both the anterior and posterior pituitary gland (Figures 3.4.A and 3.5.A), although the 
125I-rANP binding in the anterior lobe was confined to distinct regions. However, the                 
type of pituicytes on which 125I-rANP was present, were not identified. The distribution                      
of 125I-rANP binding sites was similar in the isolated pituitary gland (Figure 3.7.A).                      
Some 125I-rANP binding was also present in the intermediate lobe at the interface                      
between the anterior and posterior lobes. 
 97
In all brain regions, rANP displaced 125I-rANP binding, but, in some brain 
regions, significant binding was observed following incubation of sections with 125I- 
rANP and 1 µM of the NPR-C specific ligand C-ANF (Table 3.1). In the telencephalon, 
residual binding was observed in the olfactory region (Figure 3.3.A.3). In the 
diencephalon, the dense 125I-rANP binding observed in the habenular nucleus (Figure 
3.3.E.3 and 3.6.C) and the pituitary gland in both the anterior and posterior lobes, was 
only partially displaced by C-ANF (Figures 3.3.G and 3.7.C). 
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Table 3.1 The density of 125I-rANP binding sites in the brain of B. marinus determined 
using NIH image (n = 6). The 125I-rANP binding column shows the density of specific 
ANP binding (total minus control). The 125I-rANP and C-ANF binding column shows             
the density of specific ANP binding in the presence of C-ANF (total 125I-rANP binding 
minus the control). The average density of binding is given with the standard error of            
the mean. The (-) indicates regions in which no binding was detected with either 125I-
rANP alone or 125I-rANP in the presence of C-ANF. The density of binding is given in 
fmol/mm2. 
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Figure 3.1.A-F Schematic illustration of the distribution of 125I-rANP binding sites in 
frontal brain sections of B. marinus. Total 125I-rANP binding is represented on the right 
side of the illustrations and 125I-rANP binding in the presence of C-ANF is shown on             
the left. DP dorsal pallium; MP medial pallium; LP lateral pallium; OA olfactory area; 
MS medial septal nucleus; LS lateral septal nucleus; ACC nucleus accumbens; LPV  
lateral pallium, pars ventralis; APM amygdala, pars medialis, APL amygdala, par        
lateralis; ChP choroid plexus; POA anterior preoptic area; H habenular region; VTN 
ventral thalamic nucleus; VH ventral hypothalamic nucleus; VM ventromedial thalamic 
nucleus; LH lateral hypothalamic nucleus. 
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Figure 3.1(continued).G-J TeO optic tectum; TP posterior tuberculum; DH dorsal 
hypothalamic nucleus; VH ventral hypothalamic nucleus; ME median eminence; TS           
torus semicircularis; NIP nucleus interpeduncularis; NPD nucleus posterodorsalis 
tegmenti mesencephali; NRIS nucleus reticularis isthmi; PN pars nervosa; PD pars 
distalis. 
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Figure 3.2 Diagrammatic sagittal section of the brain of B. marinus, indicating the 
location of the schematic frontal sections. 
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Figure 3.3.A-D Photomicrographs of 125I-rANP binding in frontal sections of the brain    
of B. marinus. Each row (A-D) contains three photographs showing (from left to right) 
total 125I-rANP binding, non specific 125I-rANP binding in the presence of 1 µM                  
unlabelled rANP and  125I-rANP binding in the presence of 1 µM C-ANF. Specific 
binding can be determined by the comparison of total 125 binding (Figures Al,                  
B1, Cl, D1) and non-specific 125I-rANP binding (Figures A2, B2, C2, D2). Residual             
125I-rANP binding is observed in some brain regions in the presence of the NPR-C 
specific ligand C-ANF (Figures A3, B3, C3, D3). The figures are arranged from rostral 
(row A) to caudal (row D). 
 
A. 125I-rANP binding in the olfactory region of the telencephalon (OA olfactory area).  
B. 125I-rANP binding in the dorsal and medial pallium of the telencephalon (DP dorsal 
    pallium; MP medial pallium). 
C. 125I-rANP binding in the caudal region of the dorsal and medial pallium. 
     Dense binding is also present in the choroid plexus (ChP choroid plexus). 
D. Absence of demonstrable 125I-rANP binding in the preoptic region and choroid  
    plexus of the diencephalon (POA anterior preoptic area). 
Scale bar = 2 mm 
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Figure 3.3(continued).E-G Photomicrographs of 125I-rANP binding in frontal brain 
sections of B. marinus. Bach row contains three photographs showing (from left to                 
right) total 125I-rANP binding, non-specific 125I-rANP binding in the presence of 1 µM 
unlabelled rANP and 125I-rANP binding in the presence of 1 µM C-ANF. The figures             
are arranged from rostral (row B) to caudal (row G). 
E. 125I-rANP binding in the habenular region and hypothalamic nuclei of the 
     diencephalon (H habenular region; VTN ventral thalamic nucleus; DH dorsal  
     hhypothalamus; VH ventral hypothalamus).                                                 
F. 125I-rANP binding in the optic tectum and torus semicircularis of the mesencephalon         
    (TeO optic tectum; TS torus semicircularis). 
G. 125I-rANP binding in the interpeduncular nucleus and pituitary gland of the 
      mesencephalon (NIP nucleus interpeduncularis; PN pars nervosa; PD pars distalis). 
Scale bar =2 mm 
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Figure 3.4 Digital images of 125I-rANP binding in frontal brain sections of B. marinus 
dipped in X-ray sensitive emulsion and processed for haematoxylin and eosin 
histochemistry. 
A. Total 125I-rANP binding in the anterior pituitary gland. 
B. 125I-rANP binding in the presence of 1 µM unlabelled rANP in the  
     anterior pituitary gland. 
C. 125I-rANP binding in the presence of 1 µM unlabelled C-ANF in the  
     anterior pituitary gland. 
Scale bar = 500 µm. 
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Figure 3.5 Digital images of 125I-rANP binding in frontal brain sections of B.marinus 
dipped in X-ray sensitive emulsion and processed for haematoxylin and eosin 
histochemistry. 
A. Total 125I-rANP binding in the posterior pituitary gland. 
B. 125I-rANP binding in the presence of 1 µM unlabelled rANP in the  
     posterior pituitary gland. 
C. 125I-rANP binding in the presence of 1 µM unlabelled C-ANF in the  
     posterior pituitary gland. 
Scale bar = 500  µm. 
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Figure 3.6 Dark field digital images of 125I-rANP binding in frontal brain sections of B. 
marinus dipped in X-ray sensitive emulsion and processed for haematoxylin and eosin 
histochemistry. 
A. Total 125I-rANP binding in the habenular region. 
B. 125I-rANP binding in the presence of 1 µM unlabelled rANP in the  
     habenular region. 
C. 125I-rANP binding in the presence of 1 µM unlabelled C-ANF in the  
     habenular region. 
Scale bar = 250 µm. 
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Figure 3.7 Photomicrographs of 125I-rANP binding in sections of pituitary glands 
isolated from the brain of B. marinus (PD pars distalis; PN pars nervosa). 
A. Total 125I-rANP binding in the anterior and posterior lobes. 
B. 125I-rANP binding in the presence of 1 µM unlabelled rANP. 
C. 125I-rANP binding in the presence of 1 µM C-ANF. 
Scale bar =2 mm 
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DISCUSSION 
 
In the present study, the distribution of ANP binding sites was examined in the 
brain of the toad, B. marinus, using the heterologous ligand, 125I-rANP The same ligand 
has been used to describe the distribution of ANP binding sites in the brain of the                      
frogs R.. ridibunda (Tong et al 1989) and X. laevis (Kloas & Hanke 1992a).                
Comparison of the pattern of 125I-rANP binding between the species reveals that there                     
are some similarities, but that there are also some interesting differences in the 
distribution. In each species, a similar level of 125I-rANP binding was observed in the                 
pituitary gland, the optic tectum, and the habenular nucleus, but only low levels of 
binding were observed in the interpeduncular nucleus of B. marinus, compared to the 
high levels observed in this region of R.. ridibunda and X. laevis (see Table 1.1, Chapter 
1). In addition, the presence of 125I-rANP binding sites in the preoptic region shows                  
species variation. No specific binding is observed in the preoptic region of B. marinus     
and X. laevis, but dense binding is present in R. ridibunda; interestingly dense binding       
was found in the preoptic area of the lungfish P. annectens. Immunohistochemistry has 
shown NP-JR cell bodies and fibres in the preoptic nucleus of R. ridibunda (Netchitailo       
et al 1987), P. annectens (Vallarino et al 1996) and B. marinus (see Chapter 2). Since                
the preoptic region in the lower vertebrate brain is considered to be analogous to the 
mammalian AV3V region (Netchitailo et al 1987; Wada et al 1980), an area important                       
in central fluid and electrolyte regulation, the presence of natriuretic peptides in this 
region has led to the idea that the peptides play a role in central control of fluid 
homeostasis in lower vertebrates. However, it is clear that the distribution of binding          
sites (receptors) in the preoptic region is a variable feature between species. 
In the mammalian brain, autoradiography has shown that ANP receptor 
populations are present in the hypothalamic/preoptic region (Brown & Zuo 1993;  
Quirion et al 1984) and, as discussed above, the same ligand has demonstrated ANP 
binding sites in this region of R. ridibunda (Tong et al 1989) and P. annectens             
(Vallarino et al 1996). Therefore, it would not have been surprising to see evidence for 
ANP binding sites in the preoptic region in B. marinus. There are two explanations for    
the absence of 125I-rANP binding in the preoptic region of the brain of B. marinus. The                    
first is that ANP binding sites (receptors) may be present, but at levels beyond the 
detection limits of the autoradiography technique. Alternatively, the absence of 125I-                  
rANP   binding   in   the   preoptic   region   in   B.  marinus  may  reflect that there are no 
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receptors for ANP (NPR-A) in this area of the brain. Since CNP is thought to be the 
predominant natriuretic peptide in the brain it is not unreasonable to suggest that CNP 
receptors (NPR-B) are present in the preoptic region. For example, in rats there is 
evidence to suggest that the CNP specific receptor NPR-B is the predominant natriuretic 
peptide receptor in the hypothalamus and that the ANP specific receptor, NPR-A is  
found only in brain regions outside the hypothalamus (Langub et al 1995a). The 
distribution of CNP binding sites in the brain of B. marinus was investigated in Chapter 
Four. 
The absence of ANP binding sites in the preoptic region of B. marinus is 
interesting when comparing the distribution of ANP binding with that of the AVT- 
synthesising neurons. In chapter two, immunohistochemical studies in the brain of B. 
marinus showed natriuretic peptides and AVT were not co-localised in the same neural 
pathways although the presence of NP-JR fibre tracts in the vicinity of AVT-  
synthesising neurons in the preoptic region indicated that the potential exists for 
natriuretic peptides to influence the activity of the neurons. It was hypothesised that                 
this may occur via natriuretic peptide receptors on AVT neurons. Studies in the 
mammalian brain have shown that ANP can inhibit the firing activity of AVP neurons           
in the hypothalamus (see Chapter 1). However, in B. marinus, the absence of ANP 
binding sites in the preoptic region would suggest that in this species, ANP does not 
modulate the AVT neurons. However, an interesting observation from the ANP binding 
studies performed in the lower vertebrate brain is that high levels of 125I-rANP binding 
sites are found in the posterior pituitary gland of all species examined to date (see Table 
1.1, Chapter 1). This would suggest that the posterior pituitary gland rather than the 
preoptic region, particularly in amphibians, is a potential target site for ANP regulation  
of AVT release into the circulation. Indeed, ANP has been observed to inhibit AVP 
release from isolated rat posterior pituitary glands (Obana et al 1985). 
The high level of 125I-rANP binding in the pituitary gland of B. marinus is 
consistent with that observed in all three lower vertebrate species examined to date, 
although some differences appear in the levels of binding between the anterior and 
posterior lobes (see Table 1.1, Chapter 1). The presence of 125I-rANP binding in the 
anterior pituitary gland indicates that the pituitary gland is an important target for the 
actions of ANP and provides evidence for a potential role for ANP in modulating  
anterior pituitary gland hormones such as those involved in growth and reproduction. 
Indeed,  in  mammals  ANP  inhibits  the release of adrenocorticotropin hormone (ACTH) 
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from the anterior pituitary gland (Antoni et al 1992). Moreover, studies in the interrenal 
gland of the amphibian R. ridibunda have shown that ANP-immunoreactive nerve fibres 
are present near interrenal cells (Lihnnann et al 1988), and that ANP inhibited AII- 
stimulated corticosteroid production. This provides evidence that ANP modulates the 
release of other hormones in amphibians, and that the presence of 125I-rANP binding                  
sites in the anterior pituitary of B. marinus suggests that ANP may also modulate 
amphibian anterior pituitary function. 
The present study also attempted to partially characterise the distribution of 125I-
rANP binding sites using C-ANF, a ligand specific for NPR-C in mammals (Maack et al 
1987). C-ANF has been used to demonstrate the presence of NPR-C-like receptors in a 
number of lower vertebrates including the toadfish O. beta (Donald et al 1994), the 
hagfish M. glutinosa (Toop et al 1995) and the dogfish T. scyllia (Sakaguchi & Takei 
1998). The NPR-C receptor has been cloned and characterised in the eel (Takashima et             
al 1995) and partial sequences have also been obtained from the gill of the lamprey, 
Geotria australia (Toop et al 1998), and the kidney of B. marinus (Donald and Toop 
unpublished, accession number AF006821). In addition, binding studies have shown             
that eel NPR-C has a high affinity for C-ANF. These studies provide strong evidence            
that C-ANF can be used as an NPR-C specific ligand in lower vertebrates. 
In B. marinus, 125I-rANP binding in most regions of the brain was displaced by      
C-ANF, which suggests that a large population of NPR-C is present in the brain. Based 
on our knowledge of the function of mammalian NPR-C, it would be reasonable to 
conclude that there is a large population of receptors in the brain that may be involved            
in the removal of natriuretic peptides from the circulation and/or extracellular fluid; 
however, this role for NPR-C in amphibians is yet to be established. Alternatively, in              
the amphibian brain, the NPR-C may mediate the actions of natriuretic peptides via  
signal transduction pathways not linked to guanylate cyclase. Indeed, in mammals it             
has been suggested that the NPR-C provide not only a clearance role, but activate 
intracellular signalling via the adenylate cyclase and IP3 pathways (Anand-Srivastava 
1997; Anand-Srivastava et al 1996; Anand-Srivastava & Trachte 1993). 
In the anterior olfactory area, habenular nucleus and pituitary gland residual 125I-
rANP binding was observed in the presence of C-ANF demonstrating not only the 
presence of C-ANF binding sites (NPR-C?), but another population of binding sites 
potentially linked to guanylate cyclase (NPR-GC?). The presence of NPR-GC in the  
brain  of  B.  marinus  was  demonstrated in Chapter Five and it is therefore likely that the 
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residual 125I-rANP binding observed in the presence of C-ANF in the olfactory and 
habenular regions and pituitary gland are representative of the NPR-GC in the brain of          
B. marinus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER FOUR 
 
C-Type Natriuretic Peptide Binding Sites in the Brain of Bufo 
Marinus 
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INTRODUCTION 
 
The presence of ANP and BNP in the brain and the potential role of the peptides 
in fluid and electrolyte regulation led to the subsequent discovery of CNP in the porcine 
brain (Sudoh et al 1990). The distribution of CNP was originally thought to be confined 
to the brain (Kojima et al 1990), but it has since been found in a number of peripheral 
tissues including the endothelium, vascular smooth muscle, heart, gastrointestinal tract 
and kidney (Komatsu et al 1991 ; Stingo et al 1992b) (see Chapter 1). Two mature             
forms of CNP have been identified in the central nervous system of several mammals; 
CNP-53 and CNP-22 (Barr et al 1996; Espiner et al 1995). C-type natriuretic peptide-           
22 and CNP-53 arise from the same precursor molecule, and are believed to be the            
result of differential processing (Levin et al 1998). However, most of what is known 
about the function and distribution of CNP has been obtained through investigations of 
CNP-22 (Barr et al 1996; Espiner et al 1995) and it will therefore be the focus of 
discussion in this chapter. 
In the mammalian brain, CNP shows a similar distribution between species, and  
is highly concentrated in AV3V region and pituitary gland which indicates that CNP           
may be involved in central fluid and electrolyte regulation. However, it has been            
observed that some of the biological actions of CNP differ from that of ANP and BNP. 
For example, the intracerebroventricular application of ANP in sheep decreases water 
intake, whilst intracerebroventricular application of CNP in sheep stimulates water            
intake (Charles et al 1992) (see Chapter 1). 
In the periphery, initial radioinimunoassay studies suggested controversy over         
the presence of CNP-IR in the heart (Komatsu et al 1991; Ueda et al 1991), and 
observations of CNP-IR in the heart were thought to be due to antibody cross reactivity 
with ANP and BNP. However, in situ hybridisation studies have subsequently shown          
that CNP mRNA is expressed in both the rat atria and ventricles (Gardner 1994;            
Vollmar et al 1993). C-type natriuretic peptide is also expressed in the endothelium of 
blood vessels (Barr et al 1996) and reverse transcription-polymerase chain reaction (RT- 
PCR) has shown CNP mRNA is present in the glomerulus, vasa recta bundle and             
arcuate artery in the rat kidney (Terada et al 1994). C-type natriuretic peptide is a             
potent dilator of the vasculature and has also been linked with the regulation of vascular 
smooth  muscle  and  cellular  growth  (Barr et al 1996). Therefore, it appears that CNP in 
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the periphery is predominantly located in the blood vessels which suggests an important 
role for CNP in the vascular natriuretic peptide system (Inagami et al 1995). 
As discussed in Chapter 1, the actions of natriuretic peptides are mediated  
through the NPR-GC, which catalyses the conversion of GTP to cGMP. The NPR-B 
receptor was originally cloned in 1 989 from a human placental cDNA library (Chang et 
al 1989), prior to the discovery of CNP (Sudoh et al 1990). Initially BNP was thought             
to be the specific ligand for NPR-B; however, following the discovery of CNP, ligand 
binding affinity studies have shown CNP binds to NPR-B with the greatest affinity            
(Suga et al 1992). This is also supported by the observation that in cells expressing only 
NPR-A, CNP does not stimulate cGMP production (Koller et al 1991). 
In the mammalian brain, most of the investigations of CNP binding sites have 
been performed in rats (Brown & Zuo 1993; Himeno et al 1992; Konrad et al 1991).              
All discernable CNP binding was displaced by the NPR-C specific ligand, C-ANF,   
which suggests that the CNP was binding only to NPR-C. However, the expression of 
NPR-B mRNA transcripts has been shown in the rat brain, and it appears that the NPR-  
B is the predominant NPR-GC in the hypothalamic nuclei when compared with the            
levels of NPR-A mRNA in these regions (Langub et al 1 995a). In the pituitary gland, 
RT-PCR indicated the presence of both NPR-A and NPR-B transcripts in the mouse, 
although northern blot analysis could only detect NPR-B mRNA in the rat (McArdle et           
al 1994). Thus, although the CNP binding studies in the mammalian brain suggested             
that CNP binds only to NPR-C, and not its specific guanylate cyclase linked receptor 
NPR-B, in situ hybridisation techniques have confirmed NPR-B mRNA is present in 
brain tissue. Interestingly, a recent study has suggested that the iodination of CNP,           
which requires addition of a tyrosine residue to the molecule, can reduce the affinity of 
the peptide for NPR-B (Thibault et al 1 995), and that this may account for the limited 
distribution of CNP binding sites observed with autoradiography. However, what is 
apparent from the current literature is that it appears that the interaction of CNP and its 
receptors (NPR-B and NPR-C) in the brain is at present not completely clear. 
In the lower vertebrates, CNP has mainly been identified in the peripheral            
tissues. High concentrations of CNP have been observed in the plasma and heart of 
elasmobranch fish (Takano et al 1 994) and the peptide has strong vasodilatory actions              
on shark vascular smooth muscle (Evans et al 1993). The high levels of CNP in the             
heart and plasma of elasmobranch fish is in contrast to that found in mammals, and 
suggests  that  CNP  may  be a circulating natriuretic peptide in elasmobranchs rather than 
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an endothelial and neural peptide as observed in mammals. There is no data at present             
on circulating CNP levels in amphibians although there is evidence to suggest that CNP 
does have biological effects. For example, in the amphibian Rana catesbeiana, CNP              
was observed to relax both preconstricted and untreated aortic smooth muscle             
(Uchiyama et al 1997), as well as decrease the rate of contraction of R. catesbeiana 
isolated atria and ventricles (Uchiyama et al 1997). 
There is limited information regarding the distribution of CNP and the NPR-B 
receptor in the non-mammalian brain. In the lower vertebrates, CNP has been purified 
from the brain of several fish species including the killifish F. heteroclitus (Price et al 
1990), the eel A. japonica (Takei et al 1990) and the elasmobranch T. scyllia (Suzuki et al 
1992) (see Chapter 1). In amphibians, CNP was originally purified from the brain of                
R. catesbeiana (Yoshihara et al 1990). More recently, two CNP cDNAs have been             
cloned from R. catesbeiana brain (Kojima et al 1994) and their deduced amino acid 
sequences have shown that they are two different CNPs (CNP I and II). Both CNP I              
and CNP II stimulated cGMP production in cultured cells; however, the two peptides 
demonstrated differences in structure in the N-terminal region and different tissue 
distributions (Kojima et al 1994). Northern blot analysis showed that the distribution of 
CNP I was limited to the brain of R. catesbeiana whilst CNP II mRNA was detected in 
the brain, lung and stomach (Kojima et al 1994). Little is known about the receptors for 
CNP in the non-mammalian brain. To date, CNP binding studies have only been 
performed in the agnathan M. glutinosa (Donald et al, in press), and the expression of 
NPR-B mRNA has been shown in the brain of A. japonica (Katafuchi et al 1994). 
Consequently, the distribution of NPR-B and its relationship with CNP in the lower 
vertebrate brain is virtually unknown. 
As CNP is the only natriuretic peptide that has been isolated and cloned from the 
lower vertebrate brain to date, the present study investigated the distribution of CNP 
binding sites in the brain of B. marinus to determine if CNP is an important ligand in the 
brain. To further characterise the types of CNP binding sites present, displacement  
studies using the NPR-C specific ligand C-ANF were also performed. 
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MATERIALS AND METHODS 
 
The distribution of CNP binding sites in the brain of B. marinus was           
investigated as previously described for ANP binding studies, with the following      
changes. In the incubation medium, 125I-rANP was replaced with porcine 125I-[Tyr0]-C-                                
type natriuretic peptide-22 (termed 125I-pCNP) (Amersham, Australia). As the labelled                  
CNP contained an attached tyrosine molecule, unlabelled Tyr0-CNP-22 (tCNP) was             
used to determine specificity of binding (Peninsula Laboratories, California). 125I-pCNP 
binding was also examined in the presence of rANP and the NPR-C specific ligand C- 
ANF. Since it has been suggested that iodination of CNP can alter the affinity of CNP           
for NPR-B (Thibault et al 1995), the present study was performed to provide a             
qualitative description of 125I-pCNP binding sites in the amphibian brain, and quantitative 
analysis was not performed. 
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RESULTS 
 
Specific binding was determined as the difference in binding between sections 
incubated with either 200 pM 125I-pCNP alone and adjacent sections incubated with                  
either radiolabelled ligand and 1 µM  tCNP or 1µM C-ANF. A schematic             
representation of the distribution of 125I-pCNP binding sites in the brain of B. marinus is 
illustrated in Figure 4.1. 125I-pCNP binding sites were observed throughout the brain in 
the telencephalon, diencephalon and mesencephalon; however, unlike 125I-rANP             
binding, the distribution of 125I-pCNP in each region was far more limited. In the 
telencephalon, medium levels of specific binding were only observed in the medial 
pallium (Figures 4.3.A.1 and 4.3.B.1). Dense 125I-pCNP binding in the diencephalon            
was observed in the choroid plexus (Figure 4.3.C.1). The preoptic and hypothalamic 
regions contained no visible 125I-pCNP binding sites (Figure 4.3.D.1). In the 
mesencephalon, the highest level of binding seen throughout the brain was in the 
posterior pituitary gland (Figure 4.3.E.1). No 125I-pCNP binding was observed in the 
anterior pituitary gland or regions such as the optic tectum and interpeduncular nucleus. 
The distribution of 125I-pCNP binding was similar in isolated pituitaries (Figure 4.4). 
Examination of pituitary sections dipped in X-ray sensitive emulsion showed a             
moderate distribution of silver grains in the posterior pituitary gland (Figure 4.5.A). In          
all brain regions 1 µM tCNP, 1 µM rANP and 1 µM C-ANF completely displaced all  
125I-pCNP binding. 
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Figure 4.1.A-F Schematic illustration of the distribution of 125I-pCNP binding sites in 
frontal brain sections of B. marinus. Total 125I-pCNP binding is represented on the right 
side of the illustrations and 125I-pCNP binding in the presence of C-ANF is shown on            
the left. DP dorsal pallium; MP medial pallium; LP lateral pallium; OA olfactory area; 
MS medial septal nucleus; LS lateral septal nucleus; ACC nucleus accumbens; LPV  
lateral pallium, pars ventralis; APM amygdala, pars medialis, APL amygdala, par  
lateralis; ChP choroid plexus; FOA anterior preoptic area; H habenular region; VTN 
ventral thalamic nucleus; VH ventral hypothalamic nucleus; VM ventromedial thalamic 
nucleus; LH lateral hypothalamic nucleus. 
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Figure 4.1(continued).G-J TeO optic tectum; TP posterior tuberculum; DH dorsal 
hypothalamic nucleus; VH ventral hypothalamic nucleus; ME median eminence; TS            
torus semicircularis; NIP nucleus interpeduncularis; NPD nucleus posterodorsalis 
tegmenti mesencephali; NRIS nucleus reticularis isthmi; PN pars nervosa; PD pars 
distalis. 
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Figure 4.2 Diagrammatic sagittal section of the brain of B. marinus, indicating the 
location of the schematic frontal sections. 
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Figure 4.3.A-D Photomicrographs of 125I-pCNP binding in frontal sections of the brain  
of B. marinus. Each row (A-E) contains three photographs showing (from left to right) 
total 125I-pCNP binding, non-specific 125I-pCNP binding in the presence of 1 µM                  
unlabelled tCNP and 125I-pCNP binding in the presence of 1 µM C-ANF. Specific            
binding can be determined by comparison of the total 125I-pCNP binding (Figures Al,             
B1, Cl, Dl, El) with non-specific binding (Figures A2, B2, C2, D2, E2). The figures               
are arranged from rostral (row A) to caudal (row E). 
 
A. 125I-pCNP binding in the olfactory region of the telencephalon (OA olfactory area). 
B. 125I-pCNP binding in the dorsal, medial and lateral pallium of the telencephalon (LP   
     lateral pallium; DP dorsal pallium; MP medial pallium). 
C. 125I-pCNP binding in the caudal region of the dorsal and medial pallium.  
     Dense binding is also present in the choroid plexus (ChP choroid plexus). 
D. 125I-pCNP binding in the hypothalamus and optic tectum (TeO optic tectum;  
     DH dorsal hypothalamus; VH ventral hypothalamus). 
E. 125I-pCNP binding in the posterior pituitary gland (PN pars nervosa; PD pars  
     distalis). 
Scale bar = 1 mm 
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Figure 4.4 Photomicrographs of 125I-pCNP binding in sections of pituitaries isolated  
from the brain of B. marinus (PN pars nervosa; PD pars distalis). 
 
A. Total 125I-pCNP binding in the anterior and posterior lobes. 
B. 125I-pCNP binding in the presence of 1 µM unlabelled tCNP. 
C. 125I-pCNP binding in the presence of 1 µM C-ANF. 
Scale bar = 1 mm 
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Figure 4.5 Digital images of 125I-pCNP binding in sections isolated pituitaries of B. 
marinus dipped in X-ray sensitive emulsion and processed for haematoxylin and eosin 
histochemistry. 
 
A. Total 125I-pCNP binding in the pituitary gland. 
B. 125I-pCNP binding in the presence of 1 µM unlabelled tCNP in the  
    pituitary gland. 
C. 125I-pCNP binding in the presence of 1 µM unlabelled C-ANF in the  
    pituitary gland. 
Scale bar = 20 µm. 
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DISCUSSION 
 
There is substantial evidence to show that natriuretic peptide receptors are  
present in the mammalian brain (see Chapter 1). Most of the studies carried out have 
investigated the nature and distribution of the ANP receptor sites within the central 
nervous system. However, due to its higher concentration than ANP and BNP    
(Minamino et al 1988; Ueda et al 1991), CNP is thought to be the predominant  
natriuretic peptide in the brain. Interestingly, the majority of binding and expression 
studies examining the distribution of the CNP receptor have only been performed in the 
rat (Brown & Zuo 1993; Himeno et al 1992; Langub et al 1995a). As discussed in 
Chapter 1, CNPs have been isolated from a number of non-mammalian vertebrates. 
However, the distribution of CNP binding sites in the non-mammalian brain has only 
been examined in one species of fish, the hagfish M. glutinosa (Donald et al, in press). 
This is the first study to investigate the distribution of 125I-pCNP binding sites in                
the amphibian brain. The same ligand has been used to demonstrate the distribution of 
CNP binding sites in the brain of rats and M. glutinosa (Brown & Zuo 1993; Donald et           
al in press; Himeno et al 1992). In B. marinus, 125I-pCNP binding sites showed a                       
limited distribution throughout the brain and were only observed in the medial pallium, 
choroid plexus and posterior pituitary gland. A limited distribution of CNP binding             
sites, when compared to that of ANP, was also observed in the rat brain. In rat, CNP 
binding sites were confined to the olfactory bulb, choroid plexus, arachnoid matter, 
frontal cortex and lateral septal nucleus (Brown & Zuo 1993). C-type natriuretic              
peptide binding sites in the brain of M. glutinosa were observed in the olfactory bulb               
and pallial layers of the telencephalon and the thalamus and hypothalamus of the 
diencephalon (Donald et al, in press). In both B. marinus and rat, no 125I-pCNP binding                   
was observed in the hypothalamic/preoptic region of the brain. It is possible receptors             
for CNP are present in this region, although they may be at levels too low to be detected 
by autoradiography. Indeed, NPR-B mRNA expression has been observed in the 
hypothalamus in the rat brain (Langub et al 1995a) which suggests that the NPR-B 
protein is also present. 
This study also investigated the presence of natriuretic peptide receptor 
subpopulations in B. marinus, using the NPR-C specific ligand C-ANF. As C-ANF 
competes with 125I-pCNP for NPR-C receptor sites, any residual binding observed in the 
presence  of  C-ANF  would  indicate  the  presence  of  NPR-B,  the  specific receptor for  
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CNP. 125I-pCNP binding was totally displaced by C-ANF in all regions of the brain of                           
B. marinus. There are two possible explanations for these observations. The first is that 
all 125I-pCNP binding was to NPR-C implying the absence of NPR-B in the brain.                      
Second, in addition to binding to NPR-C, C-ANF may also recognise and bind to NPR-  
B in the brain of B.marinus, and hence, displace CNP from both of its potential binding 
sites. However, this is unlikely as there is growing evidence to indicate C-ANF is a 
specific ligand for NPR-C in lower vertebrates (Takashima et al 1995; Toop et al 1995; 
Toop et al 1998). Brown and Zuo (1993) also observed the total displacement of 125I-
pCNP binding by C-ANF in the rat brain. To confirm if CNP was binding only to NPR- 
C, Brown and Zuo (1993) conducted displacement experiments on 125I-pCNP binding                    
using ANP as the competing ligand. Atrial natriuretic peptide preferentially binds to 
NPR-A and NPR-C but not to NPR-B and, therefore, would compete with 125I-pCNP for                    
NPR-C. This would leave 125I-pCNP free to bind to NPR-B and, thus, any binding                     
observed in the presence of ANP would therefore be indicative of NPR-B. Atrial 
natriuretic peptide also totally displaced 125I-pCNP binding in rat brain and the                           
conclusion was that all binding of CNP was to NPR-C and that NPR-B in the rat brain 
could not be detected by autoradiography (Brown & Zuo 1993). The total displacement  
of 125I-pCNP by rANP was also observed in B. marinus. Thus in two vertebrate species,                 
CNP has only been shown to bind to NPR-C. The absence of demonstrable NPR-B in             
the brain is surprising considering CNP is present in the brain at higher levels than ANP 
and BNP. A study in mammals has suggested that the addition of a tyrosine molecule to 
CNP to allow iodination can reduce the affinity of the peptide for NPR-B (Thibault et al 
1995) and this may account for the pattern of 125I-pCNP binding in the rat brain                        
observed by Brown and Zuo (1993). However, a recent study of CNP binding sites in                 
the gills of the dogfish have shown that addition of a tyrosine molecule to dogfish CNP  
to allow iodination did not affect the affinity of dogfish CNP for its receptors              
(Sakaguchi & Takei 1998). Therefore, it is likely that the pattern of 125I-pCNP binding               
observed in the brain of B. marinus is indicative of the absence of NPR-B. 
In contrast to autoradiography, in situ hybridisation and guanylate cyclase             
studies in rat brain have shown that NPR-B mRNA is present in the brain and is 
expressed in the hypothalamic nuclei (Langub et al 1995a), and CNP stimulates cGMP 
production in hypothalamic brain slices (Gonçalves et al 1995). Thus, there is 
contradiction between the different techniques used to determine the distribution of 
natriuretic peptide receptors in the brain. Clearly, studies of natriuretic peptide receptor 
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mRNA expression are probably more sensitive than autoradiography, but further work             
is required to clarify the types of natriuretic peptide receptors in the mammalian brain.             
A similar situation may also exist in the brain of B. marinus. For example, ANP              
binding studies in the heart of B. marinus showed no specific binding sites (receptors) 
using autoradiography; however, RT-.PCR techniques showed that natriuretic peptide 
receptor mRNA (NPR-GC and NPR-C) is present in the heart (Minerds & Donald              
1997). Therefore, it is also possible that low levels of NPR-B receptors are present in              
the brain of B. marinus, particularly in the preoptic region, but their levels are beyond             
the detection limits of the autoradiography technique. 
The distinct pattern of 125I-pCNP binding in the posterior pituitary gland of B.              
marinus is also an interesting finding. In mammals, the highest levels of CNP 
immunoreactivity are found in the anterior pituitary gland (Komatsu et al 1991; Ueda et         
al 1991) and CNP mRNA has been detected in total pituitary gland RNA from mouse          
and rat (McArdle et al 1994). In the CNP binding studies in the rat brain (Brown & Zuo 
1993), the presence of CNP binding sites in the pituitary gland was not discussed. 
However, RT-PCR has shown that both NPR-A and NPR-B transcripts are present in           
the mouse pituitary gland whilst only NPR-B mRNA was detected by northern analysis      
in the rat (McArdle et al 1994). It is assumed that the authors used whole pituitary              
gland RNA as a template for RT-PCR in these experiments and did not investigate the 
individual lobes. Expression studies by Langub and colleagues (1995a) have confirmed 
the presence of NPR-B mRNA in the rat pituitary gland and have suggested that it is 
localised in the posterior lobe. Since there is homology between the hypothalamo- 
pituitary pathway between mammals and amphibians, it is possible that NPR-B would            
be present in the posterior pituitary gland of B. marinus. However, 125I-pCNP binding                            
in the pituitary gland of B. marinus was totally displaced by C-ANF which suggests that 
CNP bound only to NPR-C. If CNP could signal via NPR-C, then the presence of 125I-
pCNP binding in the posterior pituitary gland gives rise to the potential for CNP, in 
addition to ANP, to modulate the release of AVT. 
The 125I-pCNP binding studies in Chapter 3 have also indicated that a population                  
of NPR-C-like receptors is present in the posterior pituitary gland of B. marinus. The 
interesting feature of this binding pattern is that studies with 125I-rANP indicated that a 
population of NPR-C is also present in the anterior pituitary gland of B. marinus (see 
Chapter 3). However, no 125I-pCNP binding was observed in this region and                    
displacement  studies  with  C-ANF  suggest  that this ligand is only binding to NPR-C. In 
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the rat brain, Brown and Zuo (1993) observed differences in the affinities of NPR-C for 
ANP and CNP suggesting that more than one population of NPR-C was present; one  
with a stronger preference for ANP binding. It is possible, therefore, that more than one 
population of NPR-C is present in the pituitary gland of B. marinus and that an NPR-C 
that shows preferential binding for ANP rather than CNP is localised in the anterior 
pituitary gland. This hypothesis is further strengthened when comparing the                
distribution of 125I-rANP binding sites and 125I-pCNP binding sites in other brain                            
regions in B.marinus. The displacement of 125I-rANP binding by C-ANF in a number                               
of regions of the brain of B. marinus suggested that a large population of NPR-C is 
present. In contrast, the 125I-pCNP binding pattern that was displaced by C-ANF       
indicated that a population of NPR-C is present in the brain of B. marinus            
demonstrating a more limited distribution. For example, 125I-rANP binding in the 
posterior hypothalamus, interpeduncular nucleus and torus semicircularis was displaced 
in the presence of C-ANF, suggesting that only NPR-C is present in these regions (see 
Chapter 3). However, no 125I-pCNP binding was observed in these regions suggesting  
that no receptors for CNP are present. It is therefore possible that in addition to the 
pituitary gland, there are heterogenous populations of NPR-C throughout the brain of B. 
marinus in regions such as the interpeduncular nucleus and torus semicircularis that 
demonstrate preferential binding of ANP over CNP. 
 
Overview of 125I-rANP and 125I-pCNP binding in the brain of B. marinus. 
 
In comparison with the distribution of 125I-rANP the pattern of 125I-pCNP          
binding in the brain of B. marinus was more limited. The absence of 125I-pCNP binding  
in the presence of C-ANF indicated that CNP in the brain binds only to NPR-C. In the 
olfactory and habenular regions and the pituitary gland, residual 125I-rANP binding was 
still observed in the presence of C-ANF. Based on our knowledge of mammalian 
natriuretic peptide receptors, if C-ANF is only binding to NPR-C, it is likely a         
population of guanylate cyclase linked natriuretic peptide receptors is present in these 
regions. In addition, if CNP is binding only to NPR-C, it is likely the 125I-rANP              
binding observed in the presence of C-ANF, in the olfactory area, habenular region and 
pituitary gland, is to an NPR-A-like receptor. This observation would suggest ANP is a 
major ligand in the brain of B. marinus. The current study, therefore, identified the 
presence  of  at  least  two  natriuretic  peptide  receptors  in  the  brain of  B. marinus; one 
 144
representing a C-ANF binding site (NPR-C?) and the other potentially containing a 
guanylate cyclase. The molecular characteristics of these natriuretic peptide receptors 
were investigated in Chapter Five. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER FIVE 
 
Molecular Characterisation of the Natriuretic Peptide Receptors 
in the Brain of Bufo Marinus 
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INTRODUCTION 
  
The natriuretic peptide receptor family consists of two classes; those containing            
a guanylate cyclase catalytic domain (NPR-GC) and the clearance receptors which lack            
a guanylate cyclase domain. There are two members of the NPR-GC that are                          
recognised, as discussed in Chapters 1 and 3, by their affinity for ANP, BNP and CNP. 
Natriuretic peptide receptor-A preferentially binds ANP followed by BNP and to a               
much lesser extent CNP. Natriuretic peptide receptor-B, on the other hand, binds               
almost exclusively to CNP (Suga et al 1992). In the cell membrane, the NPR-GC exist             
as disulphide linked tetramers, which are reduced to 130-140 kDa by sodium dodecyl 
sulphate polyacrylamide electrophoresis (SDS-PAGE) under reducing conditions that 
rupture the disuiphide bonds (Wong & Garbers 1992). The NPR-GC structure consists              
of a large N-terminal extracellular domain, a hydrophobic transmembrane domain 
consisting of approximately 20 amino acids, and an intracellular protein kinase-like 
domain attached to a C-terminal guanlyate cyclase (Chang et al 1989; Koller & Goeddel 
1992; Maack et al 1996) (Figure 5.1). In humans, the extracellular ligand binding              
domain of NPR-A shares only 44% sequence homology with that of NPR-B (Chang et             
al 1989), and this is thought to account for the different ligand specificities              
demonstrated by the two receptors. In the intracellular domain, particularly in the 
guanylate cyclase region, NPR-A and NPR-B demonstrate a much higher sequence 
homology of approximately 88% that is conserved across several species (Wong & 
Garbers 1992). 
The physiological actions of natriuretic peptides mediated by the NPR-GC 
involve a number of processes and recent studies indicate that the intracellular protein 
kinase-like domain appears to have an important role in receptor activation. The protein 
kinase-like domain (PKLD) of the NPR-GC has been named because of its similar                        
amino acid sequence to other protein kinases such as the mouse platelet derived growth 
factor (PDGF) receptor and human c-fes tyrosine kinases (Singh et al 1988; Wong & 
Garbers 1992). However, the PKLD of the NPR-GC lacks an essential aspartic acid 
residue in its sixth subdomain, which is involved in the catalytic activity of known  
protein kinases (Chinkers 1996), and although the PKLD shares a structural homology 
with other protein kinases, it has not yet been determined that protein kinase activity is 
associated with NPR-GC (Chirikers 1996; Duda & Sharma 1995; Wong & Garbers 
1992).  However,  a  significant  role  for  the  PKLD  in NPR-GC has been established. It 
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has been suggested that the PKLD is involved in the regulation of the guanylate cyclase 
domain activity (Koller & Goeddel 1992) suppressing the enzyme until the binding of 
ligand (Maack et al 1996). The PKLD possesses an ATP regulatory module that also 
appears to be essential in the signal transduction process. The binding of ATP to the 
PKLD, in addition to ligand binding, is thought to be important in initiating a structural 
change, which allows the guanylate cyclase to be active and catalyse the production of 
cGMP (Duda & Sharma 1995; Maack et al 1996). Moreover, a dual role for ATP in 
regulation of the guanylate cyclase is apparent that is dependent on the presence of 
specific cofactors (Marala et al 1991). In the presence of the cofactor magnesium, ATP 
stimulates the natriuretic peptide-dependent guanylate cyclase whilst in the presence of 
manganese, ATP has an inhibitory effect (Marala et al 1991). A recent study has   
indicated yet another requirement of the PKLD is that it must be phosphorylated for 
efficient signal transduction (Potter & Hunter 1998). Therefore it appears that at least 
three processes are required for the natriuretic peptide signal transduction pathway via 
NPR-GC. For receptor activation, the PKLD must be phosphorylated, natriuretic              
peptide must bind to the extracellular domain and ATP must bind to the intracellular 
PKLD region, thereby allowing guanylate cyclase to be active and mediate the                  
generation of cGMP (Duda & Sharma 1995; Maack et al 1996; Potter & Hunter 1998). 
The second class of natriuretic peptide receptors has been referred to as the 
clearance receptors, which are recognised by their relatively equal affinity for ANP,            
BNP and CNP (Suga et al 1992). Two receptors make up this group; NPR-C and the  
more recently discovered NPR-D (Kashiwagi et al 1995). Natriuretic peptide receptor-            
C is the most abundant of the natriuretic peptide receptors and in some tissues, can 
comprise 95% of the natriuretic peptide receptor population (Maack 1992). The NPR-C 
are present in the cell membrane and exist mainly as 120 kDa homodimers which are 
reduced to 6OkDa band by SDS-PAGE under reducing conditions (Anand-Srivastava 
1997; Maack et al 1996). In addition, there is a small proportion of NPR-C present as 
6OkDa monomers in the cell membrane. The structure of the NPR-C differs from that            
of the NPR-GC in that the NPR-C lack the intracellular PKLD and guanylate cyclase 
domain found in the NPR-GC, and, instead, contain only a short cytoplasmic tail of 
approximately 37 amino acids (Fuller et al 1988) (Figure 5.1). The NPR-C also have a 
single membrane spanning domain and a large extracellular ligand binding domain. In 
humans the extracellular domain of NPR-C shares only a 30% sequence homology with 
that  of  NPR-A  (Chang  et  al  1989).  As  discussed  in  Chapter  1,  the most recognised 
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function of the NPR-C is the clearance of the natriuretic peptides from the circulation  
and tissues. However, in cultured cells there is evidence to suggest that NPR-C and 
natriuretic peptides are involved in signal transduction via pathways not linked to 
guanylate cyclase (Anand-Srivastava 1997; Anand-Srivastava & Trachte 1993) (see 
Chapter 1). 
Amongst the non-mammalian vertebrates, there is limited knowledge regarding 
the structure and characteristics of the natriuretic peptide receptors. To date, an NPR-C 
receptor has only been cloned from the gill of the eel (Takashima et al 1995). The 
structure of eel NPR-C is similar to that of mammalian NPR-C with a short cytoplasmic 
tail. Like mammalian NPR-C, eel NPR-C is present as a 135 kDa homodimer which is 
reduced to 65 kDa protein by SDS-PAGE (Takashima et al 1995). Messenger RNA for 
the eel NPR-C has been identified in the eel gill, atrium, ventricle and brain (Takashima 
et al 1995). Partial NPR-C-like sequences have also been cloned in the spiny dogfish 
(Donald et al 1 997), the toad Bufo marinus (Donald and Toop, unpublished) and  
lamprey (Toop et al 1 998), although the partial sequence obtained from the lamprey is 
more closely related to NPR-D (see below). The homology of the lower vertebrate           
NPR-C sequences to mammalian NPR-C ranges from 76% for B. marinus to 60% for           
the dogfish arid eel (Donald et al 1997; Takashima et al 1995). 
The second member of the non-GC linked natriuretic peptide receptors, NPR-D 
has only been cloned in the eel gill (Kashiwagi et al 1995). The structural features of               
the NPR-D are interesting in that it appears to exist in the cell membrane as a             
disulphide-linked tetramer, a characteristic of the NPR-GC; however, NPR-D contains a 
short cytoplasmic tail as observed for NPR-C. Similar to NPR-C, NPR-D demonstrates              
a broad ligand specificity but ligand binding to NPR-D is competitively inhibited by the 
NPR-GC specific antagonist HS-l42-1 (Kashiwagi et al 1995; Morishita et al 1991).             
The structure of NPR-D has provided some clues as to the mode of action of the HS-          
142-1 antagonism of the NPR-GC indicating HS-142-1 may target receptors with a 
tetrameric extracellular structure (Kashiwagi et al 1995). The partial natriuretic peptide 
receptor cDNA cloned from the gill of the lamprey shows 68% sequence homology to 
NPR-D, compared with 50% homology sequence homology with NPR-C which            
suggests that the sequence obtained from the lamprey is probably an NPR-D (Toop et al 
1998). 
Natriuretic peptide receptor-B has also been cloned from the gills of the eel A. 
japonica  (Katafuchi  et  al  1994).  Eel  NPR-B  is  structurally  similar to the mammalian 
 149
NPR-GC sharing 84% sequence homology in the guanylate cyclase domain. The strong 
guanylate cyclase activity following binding of CNP further confirmed this receptor is 
NPR-B (Katafuchi et al 1994). Eel NPR-B mRNA is expressed in the liver, atrium and 
gill, and a small amount has also been detected in the brain (Katafuchi et al 1994). 
The molecular characteristics of the natriuretic peptide receptors in lower 
vertebrates therefore, have only been identified in fish. It is also apparent that, although 
autoradiographical studies and northern blot analysis have indicated the presence of 
natriuretic peptide receptors in the non-mammalian brain, no studies have investigated          
the types of receptors using biochemical and molecular cloning analysis. 
Autoradiographical studies (see Chapter 3) have provided evidence for both NPR-C,            
and, a putative NPR-GC, in the brain of B. marinus through the observation of residual           
125I-rANP binding in the presence of the NPR-C specific ligand C-ANF in the olfactory                        
and habenular regions and pituitary gland. 
To further investigate the nature of these natriuretic peptide receptors in the               
brain of B. marinus, this study used affinity cross-linking SDS-polyacrylamide gel 
electrophoresis and molecular cloning techniques in order to identify some of the 
molecular features of the NPR-C and NPR-GC in this species. To further characterise             
the natriuretic peptide receptors in the brain of B. marinus, guanylate cyclase activity 
using ANP and CNP as ligands was also investigated. 
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Figure 5.1 Schematic illustration of the structure of the mammalian natriuretic peptide 
receptors. NPR-A and NPR-B are indicated showing the extracellular ligand binding 
domain and intracellular protein kinase-like domain and guanylate cyclase in which 
guanosine triphosphate (GTP) is converted to cyclic guanosine monophosphate             
(cGMP). NPR-C is depicted showing the extracellular ligand binding domain and short 
cytoplasmic tail. 
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MATERIALS AND METHODS 
 
Membrane Preparation and Guanylate Cyclase Assays 
 
Animals were decapitated and the brains without the pituitary gland, were 
homogenised in l0mls of ice cold Tris-HC1 buffer solution (50 mM Tris-HC1, 1 mM 
NaHCO3 pH 7.4). The homogenate was diluted 1:1 with a Tris-HC1 diluting buffer 
containing 1 mM EDTA and 1 mM MgCl2 (pH 7.4) and centrifuged for 15 min at 4°C  
and 4000 x g in a Beckman J2-21 M/E centrifuge. The supernatant was filtered through 
cheese-cloth and further centrifuged for 20 min at 4°C at 16000 x g to pellet the cell 
membranes. The membrane pellet was resuspended in 125 µl of 50 mM Tris-HC1 
containing 250 mM sucrose (pH 7.4), snap frozen in liquid nitrogen and stored at -80°C 
until use. An aliquot was assayed for protein concentration using a BCA protein assay          
kit (PIERCE Chemicals) and bovine serum albumin (BSA) as a standard. 
To determine the affect of ANP and CNP on guanylate cyclase activity, 50 µg of 
protein was incubated with 1 mM GTP, 4 mM MnCl2 10 mM creatine phosphate, 2           
mM isobutyl methylxanthine (IBMX), 100 U/µl creatinine phosphokinase (Sigma) and             
50 mM Tris-HC1, containing increasing concentrations (10-10 M to 10-6 M) of rat ANP 
(rANP) or porcine CNP (pCNP) (Auspep, Australia), for 15 min at room temperature. 
Basal levels of guanylate cyclase activity were determined in samples not treated with  
the ligands. The reaction was stopped with 4 mM EDTA and the tubes boiled for 3-4  
min. Samples were then centrifuged at 8000 x g for 10 mm and the supernatants frozen 
until cGMP concentration was determined by a cGMP [3H] assay system (Amersham, 
Australia), following protocols provided by the supplier. The data was analysed 
parametrically (analysis of variance) and non-parametrically using a Kruskal-Wallis           
non-parametric test. 
 
Affinity Cross Linking and Electrophoresis of Brain Membranes 
 
Brain membrane protein (100 µg) was incubated for 2 h at 4°C with either 0.25 
nM 125I-rANP alone, or in the presence of 1 µM rANP or C-ANF, in an incubation                   
medium which consisted of 50 mM Tris-HC1, 50 mM NaCl, 5 mM MgCl2 0.1% BSA, 
0.05%    bacitracin   supplemented   with   the   peptidase   inhibitors  pepstatin  2   µg/ml, 
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chymostatin 2 µg/m1, leupeptin 4 µg/mi and PMSF 1 µM. The incubation volume was   
250 µl.  Following this, the membranes were incubated at room temperature for a                 
further 20 min after the addition of the cross-linking agent, disuccinimidyl suberate  
(DSS) (PIERCE Chemicals) in dimethyl sulfoxide (DMSO) at a final concentration of 1 
mM. The reaction was stopped with 250 µ1 of cross-linking quench buffer (400 mM 
EDTA, 1M Tris-HC1, pH 6.8) and centrifuged at 13000 x g for 20 min to pellet the 
membranes and bound hormone. The supernatant was removed and the pellet 
resuspended in 24 µl of reducing buffer (0.5 M Tris-HC1, pH 6.8, 5% glycerol, 2% β- 
mercaptoethanol, 10% SDS and 0.05% bromophenol blue), or non-reducing buffer (as     
for reducing buffer, without β-mercaptoethanol). Samples were boiled for 3-4 min and  
the proteins separated on a 7.5% polyacrylamide gel for 2-3 h at 200V. To determine                
the approximate molecular weight of the proteins a molecular mass marker (30,000 - 
200,000 kDa) (Gibco BRL) was also run on the gel. Gels were stained with Coomassie 
Brilliant Blue (Bio Rad), dried overnight and exposed to Hyperfilm β-max (Amersham, 
Australia) for 1 -2 weeks at room temperature. A linear relationship between the relative 
mobility (Rf) and the log molecular mass of the standards was constructed, and the 
unknown values calculated. 
 
RNA Isolation and cDNA synthesis 
 
The total RNA from the brain of B. marinus was isolated by the acid-phenol 
technique following the modified methods of Chomczynski and Sacchi (1987) as 
previously described in Chapter 2, Part II. First strand synthesis was performed using             
an oligo (dT) primer and Superscript II reverse transcriptase (Gibco BRL) following 
protocols provided by the manufacturer. 
 
Partial Cloning of the NPR-C and NPR-GC cDNAs 
 
The primers used to amplify the NPR-GC cDNA were designed by alignment of 
known NPR-GC sequences from human, rat and eel. The forward primer coded for the 
amino acid sequence MEQYAN and was 5’ ATGGA(A/G)CA(A/G)TA(T/C)GC(N)AA 
3’. The reverse primer was the reverse complement of the amino acid sequence 
GDVEMKG    and    was    5’    (N)CC(T/C)TTCAT(T/C)TC(N)AC(AIG)TC(N)CC    3’. 
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Homologous primers were used for the NPR-C studies based on an NPR-C cloned from 
B. marinus kidney (Donald and Toop unpublished, accession number AF006821). The 
forward primer coded for the amino acid sequence VHMAFKE and was 5’ 
GGTCCACATGGCCTTCAAGGAG 3’. The reverse primer was the reverse  
complement of the amino acid sequence IEGFHD and was 5’ 
TCATGGAAGCCTTCGATGAAC 3’. The sequences of the forward and reverse  
primers are underlined in Figures 5.2 and 5.3. The estimated length of the amplified 
cDNA fragment was 669 base pairs for the NPR-GC primers and 432 base pairs for the 
NPR-C. Polymerase chain reaction (PCR) conditions for both sets of primers involved 
denaturation at 94°C (60 sec), an initial annealing temperature of 60°C which was 
lowered to 55°C following the first cycle (90 sec), and an extension temperature of             
75°C (90 sec) for 34 cycles, with a final extension time of 5 min on the last cycle. 
Polymerase chain reaction products were examined by agarose gel electrophoresis (1% 
agarose in 0.5 X TBE buffer, 45 mM Tris Borate, 1 mM EDTA) and the cDNA was 
precipitated following the method described in Chapter 2, Part II. The cDNA was 
reconstituted in sterile water and the concentration estimated against known standards. 
The cDNA was then cloned into a pCR 2.1 vector (Invitrogen) following standard 
transformation protocols provided by the manufacturer. Cloning was confirmed by 
digestion with the restriction enzyme Eco R1 and the inserts were sequenced 
commercially (Westmead Hospital, Sydney). The sequences were then identified using 
the Basic Local Alignment Search Tool (BLAST) (Altschul et al 1990). 
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RESULTS 
 
Guanylate Cyclase Assays 
 
The basal rate of cGMP production was 2.58 ± 0.46 pmol/mg protein. 0.1 µM 
rANP raised cGMP levels 50% (4.16 ± 0.49 pmol/mg protein) above basal and 1.0 µM 
rANP raised cGMP levels 90% (5.10 ± 0.52 pmol/mg protein) above basal production. 
Analysis of variance showed that 0.1 µM and 1.0 µM rANP significantly increased 
cGMP production above basal (p = 0.015) (Figure 5.4). 
1.0 µM CNP raised cGMP levels to approximately 50% (4.16 ± 0.42 pmol/mg 
protein) above basal production. Non-parametric analysis showed that 1.0 µM pCNP 
significantly increased cGMP production above basal (p = 0.0059) (Figure 5.4). 
 
Affinity Cross Linking and SDS-PAGE 
 
To identify the proteins that 125I-rANP binds to on the membranes in the brain of 
B. marinus, 125I-rANP was affinity cross-linked to the membranes either alone or in the 
presence of 1 µM rANP or 1 µM C-ANF. The affinity cross-linking of 125I-rANP to           
brain membranes was then examined by SDS-PAGE under reducing and non-reducing 
conditions. Two binding sites were observed under non-reducing conditions with an 
estimated apparent molecular weight of 126 kDa and 67 kDa (data not shown). These 
bands were displaced by both 1 µM rANP and I µM C-ANF. Under reducing conditions 
two bands were also visible and were estimated to be 136 kDa and 65 kDa in size           
(Figure 5.5). The lower band with an estimated molecular mass of 65 kDa was the most 
dominant band and was displaced with 1 µM rANP and 1 µM C-ANF. The 136 kDa  
band was less prominent than the 65 kDa band. In the presence of 1 µM C-ANF a faint 
band at 136 kDa was still visible. 
 
Molecular Cloning 
 
Polymerase chain reaction amplification of cDNA from the brain of B. marinus 
with the NPR-GC primers produced a 669 base pair product; the nucleotide and           
deduced   amino   acid   sequence   are   shown   in   Figure  5.6. Computer analysis of the 
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nucleotide sequence showed that it was homologous to natriuretic peptide particulate 
guanylate cyclase receptors NPR-A and NPR-B. Alignment of the six frame translation           
of the nucleotide sequence against a protein database generated an amino acid sequence 
that demonstrated 91% homology with human and rat NPR-A and 89% sequence 
homology with human, rat and eel NPR-B (Figure 5.2). 
Polymerase chain reaction amplification of cDNA from the brain of B. marinus 
using the homologous NPR-C primers yielded a 432 base pair product; the nucleotide  
and deduced amino acid sequence are shown in Figure 5.7. Computer analysis of the 
nucleotide sequence showed that it was homologous with bovine NPR-C. Alignment of 
the six frame translation of the nucleotide sequence against a protein database generated 
an amino acid sequence that demonstrated 64% homology with bovine NPR-C, 57% 
homology with eel NPR-C and 58% sequence homology with eel NPR-D. The putative        
B. marinus NPR-C amino acid sequence contained two cysteine (C) residues and an N- 
glycosylation site which are conserved in bovine and eel NPR-C and eel NPR-D, but 
lacked a third cysteine residue present at position 317 of the eel NPR-D (Figure 5.3). 
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Figure 5.2 Amino acid alignment of B. marinus NPR-GC cDNA (toad GC) fragment 
with human and rat NPR-A (hNPR-A and rNPR-A) and human, rat and eel NPR-B 
(hNPR-B, rNPR-B and eNPR-B) showing sequence homology. The forward and        
reverse primers are underlined. The stars indicate where amino acids differ between  
NPR-A and NPR-B. The bold type shows the differences between B. marinus NPR-GC 
and the NPR-GC sequences shown. The boxed amino acids indicate where the B.  
marinus NPR-GC cDNA shows sequence homology with NPR-B. The underlined            
amino acids indicate where the B. marinus NPR-GC cDNA shows sequence homology 
with NPR-A. 
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Figure 5.3 Amino acid alignment of B. marinus NPR-C cDNA (tNPR-C) with bovine 
and eel NPR-C (bNPR-C and eNPR-C) and eel NPR-D (eNPR-D). The forward and 
reverse primers are underlined. The stars indicate where amino acids differ between 
bovine and eel NPR-C and eel NPR-D. The bold type shows the differences between B. 
marinus NPR-C and bovine and eel NPR-C and NPR-D. The N-glycosylation site is 
boxed and the cysteine residue unique to NPR-D is indicated (   ). 
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Figure 5.4 The effects of ANP and CNP on stimulation of cGMP production in B. 
marinus brain membranes. The statistically significant increases in cGMP production 
above basal levels were observed at 0.1 and 1.0 µM ANP and 1.0 µM CNP and are 
indicated (*).  Each point is the mean ± SE of six experiments. 
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Figure 5.5 Autoradiograph of SDS-polyacrylamide gel electrophoresis of affinity                  
cross-linked 125I-rANP to brain membrane binding sites from B. marinus under reducing 
conditions. Specifically labelled bands show approximate molecular masses of 136 kDa 
and 65 kDa (lane 1). Binding of radio-labelled ligand to the 65 kDa band was inhibited          
in the presence of 1 µM rANP and 1 µM C-ANF (lanes 2 and 3). Binding of 125I-rANP          
to the 130 kDa band was inhibited in the presence of 1 µM rANP (lane 2) but was still 
visible in the presence of 1 µM C-ANF (lane 3). 
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Figure 5.6 Nucleotide sequence and deduced amino acid sequence of a PCR-amplified 
669 base pair cDNA fragment of NPR-GC from the brain of B. marinus. Primer sites            
are    underlined    and    numbers    to    the   right    indicate    the    base    pair    number. 
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Figure 5.7 Nucleotide sequence and deduced amino acid sequence of a PCR-amplified 
432 base pair cDNA fragment of NPR-C from the brain of B. marinus. Primer sites are 
underlined     and     numbers     to     the     right     indicate     the     base    pair    number. 
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DISCUSSION 
 
The presence of natriuretic peptide binding sites in the non-mammalian brain 
using autoradiographical techniques has previously been demonstrated in the hagfish M. 
glutinosa, (Donald et al in press), the African lungfish P. annectens (Vallarino et al         
1996) and two amphibians R. ridibunda (Tong et al 1989) and X. laevis (Kloas & Hanke 
1992a) (see Chapter 1). However, the molecular characteristics and types of natriuretic 
peptide receptors have only been identified in fish. For example, the CNP specific 
receptor, NPR-B, has been cloned from eel gills (Katafuchi et al 1994), in addition to 
NPR-C and NPR-D (Kashiwagi et al 1995; Takashima et al 1995); partial NPR-C and 
NPR-D cDNAs have been cloned in the spiny dogfish S. acanthias (Donald et al 1997) 
and the lamprey G. australis respectively (Toop et al 1998). 
The autoradiography studies in Chapters 3 and 4 have shown that natriuretic 
peptide binding sites are present in the brain of B. marinus. These studies used the            
NPR-C specific ligand, C-ANF, to show that the natriuretic peptide receptor population  
in the brain of B. marinus consisted of at least two types; a putative population 
demonstrating binding characteristics similar to the mammalian NPR-C, and a second 
population that does not bind C-ANF and may potentially be linked to guanylate            
cyclase. The purpose of the present investigation was to identify the molecular 
characteristics of these natriuretic peptide receptors in the brain of B. marinus. 
 
Guanylate Cyclase Studies 
 
Studies of the guanylate cyclase activity in the brain of B. marinus showed  
cGMP levels increased to approximately 50% above basal levels with 0.1 µM rANP and 
approximately 90% above basal with 1.0 µM rANP (Figure 5.4). This confirmed the 
presence of a guanylate cyclase-linked receptor in the brain of B. marinus. In rats,             
Grove and colleagues (1997) observed that 0.1 µM ANP increased cGMP production in 
hypothalamic brain slices (basal levels = 1.11 ± 0.24 pmol/mg protein; 0.1 µM ANP =           
7.13 ± 0.92 pmol/mg protein). The same concentration of ANP increased cGMP from 
2.58 ± 0.46 pmol/mg protein at basal rates to 4.16 ± 0.49 pmol/mg protein in the brain           
of B. marinus. In contrast, a ten-fold higher concentration (1 µM) of CNP was required             
to  significantly  increase  cGMP  levels  above  basal  in  B. marinus, which suggests that 
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CNP is less potent than ANP in activating guanylate cyclase receptors in the brain of B. 
marinus. A similar result was also seen in rat brain in which CNP only achieved minor 
stimulation, of cGMP, compared to ANP, even at a concentration of 1µM (Brown &            
Zuo 1993). 
The observation that ANP stimulated cGMP production at lower concentrations 
than CNP, and that all 125I-pCNP binding was totally displaced by C-ANF, in contrast to                  
125I-rANP binding (see Chapters 3 and 4), is an interesting result. Based on our                          
knowledge of the mammalian receptors, these observations would indicate that the 
predominant guanylate cyclase receptor in the brain of B. marinus is characteristic of an 
NPR-A, and would suggest that ANP is an important ligand in the brain of this species. 
However, as CNP was observed to stimulate guanylate cyclase activity at a               
concentration of 1 µM, it is possible that CNP is also a signalling molecule and that an 
NPR-B-like receptor is present in the brain of B. marinus. The weak stimulation of 
guanylate cyclase by CNP suggests that perhaps, in comparison to the levels of NPR-A, 
the levels of NPR-B in the brain of B. marinus may be quite small. Alternatively, it is 
possible that the increase in cGMP observed with the 1 µM CNP is due to its high 
concentration acting via the NPR-A as guanylate cyclase studies have shown that CNP 
weakly stimulates NPR-A at physiologically high concentrations (Suga et al 1 992) (see 
above). The results from the guanylate cyclase studies would suggest that ANP is a             
strong mediator of the guanylate cyclase linked actions of natriuretic peptides in the             
brain of B. marinus. It is possible that CNP in the brain of B. marinus has a more 
important signalling role through the NPR-C via a non-GC-linked pathway. In             
mammals, NPR-C has been linked with the inhibition of the adenylate cyclase/cAMP 
pathway via G inhibitory proteins (Anand-Srivastava & Trachte 1993). C-type             
natriuretic peptide acting via the NPR-C has also been observed to suppress dopamine 
release from PC12 cells (Trachte et al 1995), which suggests that this receptor mediates 
the neuromodulatory effects of natriuretic peptides. 
 
Affinity Cross-Linking and SDS-Polyacrylamide Gel Electrophoresis 
 
Affinity cross-linking studies using SDS-PAGE to investigate the apparent 
molecular weight of the natriuretic peptide receptors in the brain of B. marinus provided 
further  evidence  for  the  presence  of at least two types of receptors. SDS-PAGE of 125I- 
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rANP affinity cross-linked to brain membranes under non-reducing conditions indicated 
two proteins with an approximate molecular weight of 126 kDa and 67kDa (data not 
shown). Both ofthe bands were displaced with rANP and the NPR-C specific ligand C- 
ANF. The displacement of both bands by C-ANF would suggest that they were  
indicative of NPR-C. In mammals, the NPR-C exist in two forms under non-reducing 
conditions; a large population of homodimers of approximately 120 kDa and a smaller 
monomeric population of an apparent molecular mass of 60 kDa (Maack et al 1996).          
As analysis by SDS-PAGE provides only an approximate molecular mass, it is possible 
that the 126 kDa and 67 kDa bands observed in the brain of B. marinus are             
representative of these two populations of NPR-C. In reducing conditions, 125I-rANP             
affinity cross linked to B.marinus brain membranes was observed to bind to a protein of 
approximately 65 kDa that was displaced in the presence of C-ANF. The mammalian 
NPR-C in reducing conditions is present as a protein of approximately 60 kDa. The 
approximate molecular mass of the bands in reducing and non-reducing conditions and 
their similarity to the apparent molecular weight of the NPR-C in mammals, provides 
more evidence to suggest that NPR-C is present in the brain of B. marinus. Moreover,             
the observation that binding to the proteins was displaced with C-ANF further  
strengthens the hypothesis that C-ANF can be used as an NPR-C specific ligand in the 
lower vertebrates. It is also possible that the band identified under reducing conditions 
may be representative of an NPR-D in B. marinus as this receptor shows a similar  
affinity for C-ANF as NPR-C and is also reduced to an approximately 65 kDa band on           
an SDS polyacrylamide gel under reducing conditions (Kashiwagi et al 1995).             
Therefore, the potential exists for an NPR-C and/or NPR-D to be present in the brain of 
B. marinus (see below). 
The mammalian NPR-GC exist as tetramers of high molecular mass under non- 
reducing conditions (Wong & Garbers 1992). The molecular mass of these receptors in           
a non-reduced form is beyond the detection limits of the SDS-PAGE analysis used in            
this study, and therefore the potential presence of tetrameric NPR-GC in B. marinus   
brain membranes could not be determined. Like the mammalian NPR-GC, the NPR-D 
receptor exists in the membrane as a tetramer (approximately 240-280 kDa) under non- 
reducing conditions (Kashiwagi et al 1995), therefore, evidence for this receptor in B. 
marinus could not be shown. 
In reducing conditions, the mammalian disulphide-linked tetrameric NPR-GC           
are  reduced  to  a  molecular mass of 130-140 kDa (Wong & Garbers 1992). A protein of 
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a molecular mass of approximately 136 kDa was observed when 125I-rANP was cross- 
linked to B. marinus brain membranes and separated by SDS-PAGE. The molecular  
mass reported here is similar to the expected size of the mammalian NPR-GC and          
could, therefore, be representative of the NPR-GC in B. marinus. 125I-rANP binding to 
this 136 kDa band was still visible in the presence of C-ANF and this would therefore 
suggest that 125I-rANP has bound to a receptor other than NPR-C. The size of the band 
and the observation that it is still visible in the presence of C-ANF provides further 
evidence for the presence of NPR-GC in the brain of B. marinus. 
 
Molecular Cloning Studies 
 
Molecular cloning studies using NPR-GC primers generated from homologous 
regions of known sequences in the guanylate cyclase domain of natriuretic peptide 
receptors, resulted in a partial cDNA that demonstrated a significant homology with         
both NPR-A and NPR-B. The B. marinus partial cDNA sequence showed a 91% 
homology with human and rat NPR-A and an 89% homology with human, rat and eel 
NPR-B, which confirms that an NPR-GC-like receptor is present in this species. Within 
the guanylate cyclase domain of the NPR-GC there is considerable homology between 
NPR-A and NPR-B (Koller & Goeddel 1992) and, due to the similarity between the two 
receptors it is difficult to determine whether the sequence obtained from the brain of B. 
marinus is NPR-A-or NPR-B-like in nature. However, much of the evidence obtained 
from the autoradiography (see Chapters 3 and 4) and guanylate cyclase studies (this 
Chapter) indicate that an NPR-A-like receptor in the brain of B. marinus is more 
prevalent, and that ANP is a key natriuretic peptide in the brain of B. marinus. In  
contrast, all other studies in the lower vertebrate brain to date, with the exception of the 
eel brain in which mRNA for ANP has been shown by RT-PCR (Takei et al  1997a),  
have isolated or cloned only CNP and suggest that CNP is the key natriuretic peptide in 
the lower vertebrate brain. It is possible that both NPR-GC receptors are present in the 
brain of B. marinus, and that NPR-A may be the major NPR-GC in the brain of this 
species whilst NPR-B has only a minor role. However, 125I-pCNP binding studies could 
not provide evidence for the presence of NPR-B. To determine whether the cDNA 
fragment of the NPR-GC cloned from the brain of B. marinus is an NPR-A or NPR-B, a 
full sequence would need to be obtained. 
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The partial cDNA amplified using homologous NPR-C primers showed 
homology with other known sequences of NPR-C. The B. marinus brain cDNA amino 
acid sequence demonstrated a 64% homology with bovine NPR-C and 57% and 58% 
homology with eel NPR-C and NPR-D respectively, confirming a non-guanylate             
cyclase-linked natriuretic peptide receptor is also present in the brain of B. marinus.            
The observations from the cross-linking studies showed that under reducing conditions,           
a protein with an approximate molecular weight of 65 kDa was displaced using the          
NPR-C specific ligand C-ANF. In addition, it has been determined that the NPR-D 
receptor binds C-ANF with a similar affinity to NPR-C (Kashiwagi et al 1995) and is             
also present as a 65 kDa band on a reducing SDS-PAGE gel. This would suggest that             
the 65 kDa band observed in the cross-linking studies in the brain of B. marinus could 
potentially represent an NPR-C and/or NPR-D. However, molecular cloning studies 
showed that the putative B. marinus NPR-C partial cDNA showed 58% homology with 
eel NPR-D, but did not contain a third cysteine residue that is unique to eel NPR-D 
(Kashiwagi et al 1995). Therefore, it is likely that the non-guanylate cyclase linked 
natriuretic peptide receptor in the brain of B. marinus is more closely related to the 
mammalian NPR-C. 
In summary, this study has confirmed previous observations using 
autoradiography techniques that at least two types of natriuretic peptide receptors are 
present in the brain of B. marinus. SDS-PAGB analysis and molecular cloning have 
shown that a receptor characteristic of the mammalian NPR-C is present in the brain of  
B. marinus. In addition, guanylate cyclase assays have confirmed that a natriuretic 
peptide receptor with guanylate cyclase activity is present in the brain of B. marinus. 
Furthermore, these studies have also strengthened the hypothesis that ANP is an 
important natriuretic peptide in the brain of B. marinus and that an NPR-A -like         
receptor may be the major guanylate cyclase linked natriuretic peptide receptor in the 
brain of this species, although this remains to be confirmed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER SIX 
 
General Discussion 
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GENERAL DISCUSSION 
 
It is now clear that natriuretic peptides and their receptors are present in the 
vertebrate brain. In mammals, the natriuretic peptides are distributed throughout the          
brain although they are particularly concentrated in the AV3V/hypothalamic region in 
which a significant role for natriuretic peptides in central fluid and electrolyte 
homeostasis has been established (Gutkowska et al 1997a). The natriuretic peptides          
have also been identified in the non-mammalian vertebrate brain and are broadly 
distributed throughout the brain, as has been observed in mammals (Donald & Evans 
1992; Feuilloley et al 1993; Netchitailo et al 1986). In the non-mammalian vertebrates, 
natriuretic peptides are also concentrated in the hypothalamic/preoptic region which 
implies that natriuretic peptides may be involved in central fluid and electrolyte 
regulation, although this has yet to be determined. 
The presence of natriuretic peptides in the lower vertebrate brain has previously 
been identified by immunohistochemistry, however, to date, CNP is the only member of 
the natriuretic peptide family that has been isolated from the brain. Moreover, 
autoradiographical studies of the natriuretic peptide receptors in the lower vertebrate 
brain, with the exception of the hagfish M. glutinosa, have only been performed using 
ANP as the ligand (Kloas & Hanke 1992a; Tong et al 1989). In addition, the types of 
ANP binding sites (receptors) have not been characterised. Molecular evidence for the 
presence of the CNP specific receptor, NPR-B, has only been shown in the brain of the 
eel, Anguilla japonica, using northern blot analysis (Katafuchi et al 1994). 
The present study, therefore, investigated the distribution of natriuretic peptides  
in the brain of Bufo marinus, and compared this distribution with that of AVT to           
identify a potential role for natriuretic peptides in central fluid and electrolyte 
homeostasis. In addition, the distribution of both ANP and CNP binding sites was 
investigated in the brain of B. marinus. Although ANP binding sites have previously             
been identified in the lower vertebrate brain (see Chapter 1), CNP binding sites have          
only been demonstrated in one fish species, in spite of the fact that CNP is the only 
natriuretic peptide that has been isolated from the brain in non-mammalian vertebrates. 
This study further characterised the ANP and CNP binding sites with the use of the           
NPR-C specific ligand, C-ANF, since any residual ANP or CNP binding in the presence 
of C-ANF would potentially indicate NPR-GC. Furthermore, this study used molecular 
cloning   and   guanylate   cyclase  assays   to   identify   the  types  of  natriuretic  peptide 
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receptors in the brain of B. marinus. The natriuretic peptide receptors have not yet been 
cloned from the brain of any lower vertebrate species. 
Immunohistochemical studies using a heterologous antibody that recognised 
ANP, BNP and CNP, established that natriuretic peptides were broadly distributed           
across the brain of B. marinus. Although this distribution showed similarities to that 
described for other amphibians (Donald et al 1992; Feuilloley et al 1993; Netchitailo et         
al 1987), some differences in distribution were observed with the most marked            
difference being that in the pituitary gland. Natriuretic peptide-like immunoreactivity 
(NP-IR) has previously been identified in the hypothalamo-pituitary pathway in the 
amphibian Rana ridibunda (Feuilloley et al 1993; Netchitailo et al 1987), which             
suggests that natriuretic peptide synthesis, storage and release may occur in a manner 
similar to that of AVT, being synthesised in the preoptic/hypothalamic region and 
axonally transported to the posterior pituitary gland for storage and potential release into 
the circulation (Netchitailo et al 1987). In contrast no NP-IR was found in the pituitary 
gland of B. marinus. This strongly suggests that the hypothalamo-pituitary mechanism           
of release of natriuretic peptides as proposed in R. ridibunda, is not the same for B. 
marinus. 
As the antibody used in the immunohistochemical studies showed cross- 
reactivity with ANP and CNP, molecular cloning techniques were used in an attempt to 
clone partial cDNAs to determine if ANP and CNP are present in the brain of B.                   
marinus, but, this was unsuccessful. The cloning of ANP and/or CNP cDNAs would  
have provided evidence as to which members of the natriuretic peptide family are           
present in the brain of B. marinus. Moreover, the partial cDNAs would have provided 
nucleic acid probes for in situ hybridisation studies to indicate the sites of individual 
natriuretic peptide mRNA expression in the brain of B. marinus. A partial AVT cDNA 
was successfully cloned, and, had the natriuretic peptide cloning also been successful,           
the relationship between the sites of AVT and natriuretic peptide mRNA expression  
could have been investigated. 
In order to investigate the role of natriuretic peptides in fluid and electrolyte 
homeostasis in the brain, the topographical relationship between natriuretic peptides and 
AVT was examined. In mammals, an antagonistic relationship between natriuretic 
peptides and AVP has previously been established (Lee et al 1987; Samson et al 1987; 
Wong et al 1986) (see Chapter 1). A similar antagonistic relationship between AVT             
and   natriuretic  peptides   has  also  been   established   in  amphibians   (see  Chapter  2) 
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although these studies have only examined an antagonistic role for AVT and natriuretic 
peptides in the periphery. Therefore, the topographical relationship of natriuretic           
peptides and AVT in the brain of B. marinus was investigated to determine if the      
peptides are located in the same neural pathways in the hypothalamo-pituitary tract. If 
natriuretic peptides and AVT were synthesised in the same cells, the potential exists for 
natriuretic peptides to influence AVT synthesis through autocrine regulatory     
mechanisms. Co-localisation studies revealed that while natriuretic peptides and AVT          
are both found in the preoptic region, they occur in separate cells. This suggested that 
natriuretic peptides do not influence the synthesis of AVT in an autocrine manner and 
may, therefore, act in a paracrine manner via cell surface receptors. Therefore, the 
distribution of ANP and CNP binding sites in the brain of B. marinus was examined. 
125I-rANP binding studies demonstrated that ANP binding sites are broadly                 
distributed throughout the brain of B. marinus. The distribution of 125I-rANP binding                   
sites generally matched the distribution of natriuretic peptides as observed with 
immunohistochemistry, with two interesting exceptions. High levels of NP-IR were 
observed in the preoptic region whilst 125I-rANP binding was absent from this area. In             
contrast, no NP-IR was observed in the pituitary gland, but, the pituitary gland                 
contained the highest density of 125I-rANP binding sites in the brain of B. marinus. It                             
was suggested from the immunohistochemical studies that natriuretic peptides may 
potentially modulate AVT in the brain of B. marinus in a paracrine fashion via cell 
surface receptors. In the preoptic region, in which the AVT synthesising neurons are 
located, no 125I-rANP binding was detected. It is possible that ANP receptors are                      
present in this region but at levels too low to be detected by autoradiography, but this is 
unlikely. Alternatively, AINP receptors may not be present in this region, and therefore, 
natriuretic peptides may not influence AVT synthesis in the brain of B. marinus. In rats, 
NPR-A mRNA is absent from the hypothalamic/AV3V region (Langub et al 1995a),            
and it is possible therefore, that receptors for ANP are also absent from the preoptic 
region in B. marinus as indicated by the observations from the autoradiography studies. 
The high density of binding sites in the posterior pituitary gland of B. marinus suggests 
that natriuretic peptides may modulate AVT storage and release rather than AVT 
synthesis in this species. This has been observed in rats in which natriuretic peptides 
inhibited AVP release from the isolated posterior pituitary glands (Obana et al 1985).              
In addition, high levels of 125I-rANP binding sites are located in the anterior pituitary                   
gland  in  B.  marinus,  which  implies  that  a  role  for  natriuretic  peptides  exists  in the 
 178
 
modulation of other pituitary gland hormones such as those involved in growth and 
reproduction. In the rat anterior pituitary gland, natriuretic peptide receptor mRNA is 
expressed in corticotrophic, lactotrophic and gonadotrophic cells (Grandclement et al 
1995), further enhancing the suggestion that natriuretic peptides may be involved in the 
regulation of anterior pituitary gland function. 
The specificity of 125I-rANP binding was also determined in the presence of the                   
NPR-C specific ligand C-ANF. Residual binding was observed in the presence of C- 
ANF, implying at least two types of natriuretic peptide receptors are present in the brain 
of B. marinus; one that shows binding characteristics similar to that of the mammalian 
clearance receptor, NPR-C, and one potentially linked to guanylate cyclase. In                      
mammals, two types of NPR-GC have been identified; NPR-A, which has a high                
affinity for ANP, and NPR-B, which has the greatest affinity for CNP (Suga et al 1992). 
C-type natriuretic peptide is thought to be one of the major natriuretic peptides in the 
mammalian brain (Komatsu et al 1991 ; Ueda et al 1991) and the CNP receptor, NPR-B, 
is also found in brain tissue (Langub et al 1995a). Similarly, CNP has been isolated            
from the brain of a number of non-mammalian vertebrates (Arimura et al 1991; Price et             
al 1990; Suzuki et al 1992); however, the distribution of CNP binding sites in the lower 
vertebrate brain has only been investigated in one fish species (Donald et al in press).              
As CNP has been cloned from the brain of the frog, Rana catesbeiana (Kojima et al 
1994), and immunohistochemical studies using an antibody that cross-reacts with CNP 
indicated CNP may be present in the brain of B. marinus, the distribution of 125I-pCNP                     
binding sites was investigated. 
When compared with the distribution of 125I-rANP the distribution of 125I-pCNP                     
binding sites in the brain of B. marinus was far more limited. Moreover, all 125I-pCNP              
binding was displaced by C-ANF indicating that CNP only binds to NPR-C in the brain. 
In contrast to 125I-pCNP binding in the brain of B. marinus, residual 125I-rANP binding                               
in the presence of C-ANF was observed in the olfactory, habenular and pituitary gland.              
If CNP binds only to NPR-C and ANP binds to both NPR-C and NPR-GC it would               
seem, that for B. marinus at least, ANP may be the key natriuretic peptide in the brain that 
mediates the fluid and electrolyte regulatory effects of the natriuretic peptides via                     
the production of cGMP. In B. marinus, guanylate cyclase assays using ANP and CNP             
as ligands further enhance this hypothesis, because low concentrations of ANP 
significantly increased cGMP levels, whilst a ten-fold higher concentration of CNP was 
required  to  stimulate  guanylate  cyclase  activity. Similarly in mammals, the application 
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of ANP to guinea pig cerebellar slices resulted in an increase in cGMP levels that 
required a ten-fold higher concentration of CNP to produce a similar response  
(Hernandez et al 1994). In rats, ANP was also observed to stimulate cGMP production            
in hypothalamic brain slices to higher levels than the same concentration of CNP              
(Grove et al 1997). Moreover, in diencephalic rat brain slices, greater cGMP levels             
were observed when stimulated by ANP than that observed with CNP (Gonçalves et al 
1995). The above studies all suggested that ANP is the more potent natriuretic peptide            
in the manmialian brain supporting the observations made in the brain of B. marinus.             
As the 125I-pCNP binding studies in B. marinus showed no evidence for the presence of            
NPR-B, it is possible that the increase in cGMP levels stimulated by high                
concentrations of CNP, may be the result of CNP acting via the NPR-A, which in 
mammals is activated by CNP at physiologically high concentrations (Suga et al 1992). 
The molecular cloning studies confirmed the autoradiography, SDS-PAGE 
analysis and guanylate cyclase assays that a guanylate cyclase linked natriuretic peptide 
receptor is present in the brain of B. marinus. However, due to the high sequence 
homology between NPR-A and NPR-B in the intracellular guanylate cyclase domain, it 
could not be determined whether the cloned fragment was an NPR-A or NPR-B. The 
observations from the autoradiography which suggested that 125I-rANP bound to both an             
NPR-C and NPR-GC and 125I-pCNP bound only to NPR-C, and from the guanylate                        
cyclase studies which showed that ANP was more potent than CNP in stimulating 
guanylate cyclase, would suggest that the main guanylate cyclase receptor in the brain             
of B. marinus is NPR-A like in nature. As CNP was observed to stimulate guanylate 
cyclase activity it is possible that both NPR-A and NPR-B are present in the brain of B. 
marinus, but, based on these observations it would seem that NPR-A is the predominant 
receptor. This conclusion is supported by the observations made in the 125I-pCNP                      
binding studies which strongly indicated that NPR-B is absent. In order to confirm 
whether the cDNA fragment cloned was from a NPR-A or NPR-B, a full sequence              
would need to be obtained. 
An interesting finding of this study is the distribution of natriuretic peptide 
binding sites in the pituitary gland of B. marinus. 125I-rANP binding studies across the 
vertebrates indicate that this tissue is a key target organ for natriuretic peptide action, as 
high numbers of binding sites for natriuretic peptides have been identified in the             
pituitary gland of most species examined to date. 125I-pCNP binding in the pituitary                     
gland was distinctly confined to the posterior lobe  in  B.  marinus  whilst  125I-rANP  was 
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present in all three lobes. The total displacement of 125I-pCNP binding by C-ANF in the             
posterior pituitary gland suggests that this lobe contains only NPR-C. However, in the 
presence of C-ANF, residual 125I-rANP binding was still observed in both the anterior                  
and posterior parts of the pituitary gland (Figure 6.1). This suggests that both NPR-GC 
and NPR-C are present in the anterior and posterior pituitary gland of B. marinus. This 
observation is interesting because if NPR-C is present in the anterior pituitary gland and 
CNP binds only to NPR-C, this begs the question, why was no 125I-pCNP binding                     
observed in this lobe? Brown and Zuo (1993) reported differences in affinities of the 
NPR-C for ANP and CNP in rat brain, and suggested the possibility of heterogeneous 
populations of NPR-C, with one type of NPR-C showing preferential binding of ANP 
over CNP. The presence of heterogeneous NPR-C populations may provide an 
explanation for the pattern of 125I-rANP and 125I-pCNP binding observed in the pituitary                         
gland of B. marinus. An alternative explanation to this pattern of binding observed in              
the pituitary gland of B. marinus is that it may also be indicative of an NPR-D     
population. At present NPR-D has only been cloned from the eel (Kashiwagi et al               
1995) and a partial sequence has been obtained from lamprey gills (Toop et al 1998). 
Messenger RNA for NPR-D has been identified in the eel brain by northern analysis.                 
The NPR-D, like NPR-C, shows a broad recognition for all members of the natriuretic 
peptides, but, it demonstrates a lesser affinity for CNP than NPR-C (Kashiwagi et al 
1995). If NPR-D does bind CNP with a lesser affinity, it is possible that the presence of 
125I-rANP binding in the anterior pituitary and the absence of 125I-pCNP in this region                           
could represent a population of NPR-D (see Figure 6.1). However, this possibility is 
unlikely as NPR-D binds C-ANF and, therefore, if an NPR-D population was present, it 
would be expected that some CNP binding would be observed. 
Cloning studies using the toad NPR-C specific primers in the brain of B.              
marinus indicated that the amplified cDNA sequence had 64% amino acid sequence 
homology with bovine NPR-C, and a lesser sequence homology with eel NPR-D. 
Moreover, the B. marinus NPR-C cDNA contained two cysteine residues and a N- 
glycosylation site which are conserved in both bovine and eel NPR-C, and lacked a              
third cysteine residue unique to NPR-D. Therefore, it is likely that the non-guanylate 
cyclase linked receptor in the brain of B. marinus is more closely related to the 
mammalian NPR-C. To fully determine the specific natriuretic peptide-C and/or D 
receptors in the brain of B. marinus, the full sequence would need to be cloned. In 
addition,  to  further  investigate  if  NPR-D  is  present  in B. marinus, several approaches 
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could be undertaken. Firstly, as the NPR-D exists as a tetrameric structure in the 
membrane (Kashiwagi et al 1995), analysis using SDS-PAGB conditions that detect 
proteins of high molecular weight under non-reducing conditions could be performed. 
Secondly, binding studies using the antagonist, HS-142-1, which competitively inhibits 
natriuretic peptides from binding to their tetrameric receptors (NPR-GC and NPR-D) 
could also be performed. In addition, cloning strategies could be developed that would 
isolate a putative NPR-D rather than an NPR-C. 
There are some interesting considerations arising from the CNP binding studies 
performed to date. It has been reported that the addition of a tyrosine molecule to CNP         
to allow iodination can reduce the affinity of the peptide for NPR-B (Thibault et al   
1995), and it is therefore possible that the NPR-B receptor may not be recognising 125I- 
pCNP in the tissue examined. However, a recent study of CNP binding sites in the gills  
of the dogfish have shown that addition of a tyrosine molecule to dogfish CNP (dfCNP) 
to allow iodination, did not affect the affinity of dfCNP for its receptors (Sakaguchi & 
Takei 1998). In the studies of 125I-pCNP binding sites in the rat brain, Brown and Zuo              
(1993) observed no evidence for 125I-pCNP binding to NPR-B. These observations                
suggested that NPR-B was not present in rat brain, but, in situ hybridisation studies             
have shown that NPR-B mRNA, and potentially an NPR-B protein, is indeed present in 
rat brain tissue (Langub et al 1995a). There are several possible explanations for these 
observations. Firstly, the addition of a tyrosine molecule to CNP for iodination does             
alter the affinity of the ligand for its receptor, although based on the studies of           
Sakaguchi and Takei (1998), this may be unlikely. Secondly, it appears that there are 
different relative amounts of ANP and CNP in the brain between different mammalian 
species. For example, CNP is more abundant than ANP in the human and porcine brain, 
whilst ANP is in higher concentrations than CNP in the rat brain (Ryan et al 1997).              
This is an interesting observation considering much of the work investigating the 
natriuretic peptide receptors in the brain have been performed in rats, in which it seems 
ANP and presumably its receptor NPR-A are in greater abundance. Therefore, the lack           
of CNP binding observed in the autoradiographical studies of Brown and Zuo (1993), 
may be due to a down-regulated CNP peptide and receptor system that can only be 
detected by the more sensitive in situ hybridisation technique (Langub et al 1995a). 
At present, with the exception of the eel (Takei et al 1997a), CNP is the only 
member of the natriuretic peptide family that has been identified in the non-mammalian 
brain.   Indeed,  CNP  is   the  only   natriuretic  peptide   that  has  been  cloned  from  the 
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amphibian brain (Kojima et al 1994). The lack of evidence for NPR-B in B. marinus is 
therefore an interesting result. The results obtained from both the ANP and CNP             
binding studies and guanylate cyclase assays would suggest that ANP is an important 
natriuretic peptide in the brain of B. marinus. It is possible that, as observed in rat, ANP     
is in greater abundance than CNP in the brain of B. marinus and, therefore, there are             
low levels of NPR-B. Alternatively, CNP may be in greater abundance than ANP in the 
brain, but ANP may be the key natriuretic peptide mediating the guanylate cyclase-  
linked actions of the natriuretic peptides and, in contrast, CNP may have other effects          
via the NPR-C. This could be investigated in the future using radioimmunoassay 
techniques with homologous antibodies for B. marinus ANP and CNP to determine   
which natriuretic peptide is in greater abundance. 
In summary, the present study investigated the natriuretic peptides and their 
receptors in the brain of B. marinus using a number of approaches in order to provide a 
greater understanding of the natriuretic peptide system in the lower vertebrate brain.          
This study builds on the observations of several previous studies that have indicated 
natriuretic peptides are present in the brain of lower vertebrates. However, only a few 
studies have shown the presence of natriuretic peptide receptors in the lower vertebrate 
brain. These earlier studies investigated the distribution of natriuretic peptide binding 
sites using ANP as the ligand, although, CNP is the natriuretic peptide that has been 
isolated from the brain of a number of non-mammalian species. This study              
demonstrated that natriuretic peptides are distributed throughout the brain of B.            
marinus, and showed natriuretic peptide neural elements in the vicinity of AVT 
synthesising neurons in the preoptic region. The high concentration of natriuretic   
peptides in the preoptic/hypothalamic region and their close proximity to AVT neurons 
provides further evidence to suggest that natriuretic peptides are involved in the central 
control of amphibian fluid and electrolyte homeostasis. This study established the 
presence of at least two natriuretic peptide receptor populations in the brain of B. 
marinus, one linked to guanylate cyclase and the other demonstrating characteristics 
similar to the mammalian NPR-C. This study also provided evidence to suggest that  
ANP may be the key natriuretic peptide in stimulating the guanylate cyclase linked 
actions of natriuretic peptides in the brain of B. marinus and identified the pituitary            
gland as an important target for natriuretic peptide action. 
 183
Future Work 
 
The presence of natriuretic peptides in the preoptic/hypothalamic region in the 
lower vertebrate brain implies the potential for natriuretic peptides to be involved in 
central fluid and electrolyte regulation. However, to date, this role has not been 
established. The present study in the brain of B. marinus provides a basis for this 
hypothesis to be investigated. One approach to investigating this role is through the use      
of the immediate early gene product, fos, as a marker for cellular activation. Fos is   
rapidly expressed following neuronal activation and regulates the expression of other 
genes (Badoer 1996; Hamamura et al 1992). Immunohisochemical studies using fos as            
a tool for indicating neuronal activity in response to physiological stimuli have  
previously been reported (Sharp et al 1991; Ubink et al 1997). To gain an               
understanding of the role of natriuretic peptides in fluid and electrolyte homeostasis in            
B. marinus, the pattern of fos-like immunoreactivity in response to physiological              
stimuli, for example, volume loading, could be investigated. The co-localisation of fos 
immunoreactivity with natriuretic peptide immunoreactivity could be examined to 
determine if cells synthesising the natriuretic peptides are activated during osmotic 
challenge. 
To identify whether the partial NPR-GC cloned from the brain of B. marinus           
was from an NPR-A or NPR-B, the full sequence would need to be obtained. Once this 
receptor is identified, and using the knowledge of the mammalian natriuretic peptide 
receptors, the potential ligand (ie ANP or CNP) for that receptor could then be the focus 
of cloning studies. Obtaining homologous nucleic acid probes for the particular      
natriuretic peptides in the brain of B. marinus would provide probes that could be           
utilized for in situ hybridisation studies to investigate the anatomical location of the 
expression sites for the peptides in the brain. Once this distribution is established, the            
role of the natriuretic peptides in fluid and electrolyte homeostasis could then be 
investigated by examining any changes in natriuretic peptide mRNA expression during 
osmotic challenges such as salt and volume loading. In addition, with the partial             
cloning of the AVT sequence, the expression of both AVT and natriuretic peptides 
mRNAs could be investigated in response to a number of physiological challenges to 
identify any relationship between natriuretic peptide and AVT expression during          
osmotic challenge such as volume and/or salt loading. 
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This study has provided the basis for future investigations into the role of 
natriuretic peptides in the non-mammalian brain. It is evident that some parallels            
between the amphibian and higher vertebrate natriuretic peptide system in the brain           
exist, and therefore, investigations performed in the amphibian brain contribute to the 
knowledge of the natriuretic peptide system in the vertebrate brain in general. 
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Figure 6.1 Schematic representation illustrating 125I-rANP binding and 125I-pCNP 
binding in the pituitary gland of B. marinus. Illustrations A and B show the distribution  
of 125I-rANP binding alone and in the presence of the NPR-C specific ligand C-ANF. 
Residual 125I-rANP binding is still visible in both the anterior and posterior lobes in the 
presence of C-ANF, which suggests that a population of both NPR-GC and NPR-C are 
located in these regions. Illustrations C and D show the distribution of 125I-pCNP          
binding in the posterior lobe alone and in the presence of C-ANF, which suggests that a 
population of NPR-C are only present in the posterior lobe and not the anterior region. 
This is in contrast to that observed with the 125I-rANP binding studies and indicates that 
perhaps a heterogeneous population of NPR-C which show a preference for ANP are 
present in the anterior pituitary gland or that the binding pattern may be indicative of a 
population of NPR-D-like receptors. 
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